5th Global Uro-Oncology Meeting
Under the auspices of
The World Urologic Oncology Federation
Oct. 15–16, 2011 - Berlin, Germany

Saturday, October 15

0800–0815
Chairman’s Welcome and Introduction
Laurence Klotz, Canada

0815–1000
SESSION ONE
Prostate Cancer Prevention
Moderator: Hideyuki Akaza, Japan

0820–0835
5ARIs and Prostate Cancer Prevention
Following the FDA Decision
Neil Fleshner, Canada

0835–0850
Diet, Statins, Cholesterol
Hanjong Ahn, South Korea

0850–0905
Curcumin and Other Micronutrients
Shigeo Horie, Japan

0905–0920
Discussion

0920–0935
Exercise in Prostate Cancer
Arturo Mendoza-Valdés, Mexico

0935–0950
Pre-Clinical Models of Prostate Cancer Prevention
Hirotugu Uemura, Japan

0950–1000
Discussion

1000–1015
Break

1015–1125
SESSION TWO
Town Hall Forum
Moderator: Laurence Klotz

1020–1025
Screening in Men Over Age 65: Introduction
Laurence Klotz

1025–1035
Overdiagnosis and How To Avoid This
Monique Roobol, The Netherlands

1035–1045
An Epidemiologic Perspective
Peter Albertsen, USA
1045–1105
Pros and Cons of Screening Over Age 65
Franz Recker, Switzerland

1105–1125
Group Debate: Healthy Men: The Case for Continuing to Screen Over Age 65
Peter Albertsen
Monique Roobol
Franz Recker
Christopher Evans, USA

1125–1245
SESSION THREE
Update on Biomarkers
Moderator: Peter Albers, Germany

1130–1140
PCA3
Inge Van Oort, The Netherlands

1140–1150
Seminal Fluid Markers
Frank Gardiner, Australia

1150–1200
Serum Biomarkers
John Davis, USA

1200–1215
Discussion

1215–1225
Angiogenesis and Lymphangiogenesis in Prostate Cancer
Derya Tilki, Germany

1225–1235
MRI as a Prostate Cancer Detection Tool: Where Are We Right Now?
Mark Emberton, UK

1235–1245
Discussion

1245–1330
40-Minute Lunch Break
(lunch available for purchase on site)

1330–1520
SESSION FOUR
Mechanisms of Castrate Resistance
Moderator: David Gillatt, UK

1335–1350
Intermittent vs Continuous Androgen Deprivation Therapy: Biological Implications
Laurence Klotz

1350–1405
Autophagy and Prostate Cancer
Christopher Evans, USA

1405–1420
Immune Escape and Prostate Cancer
Rob Siemens, Canada

1420–1435
Discussion
1435-1450
Adapting Treatment Strategies for CRPCa in the Elderly
Fred Saad, Canada

1450-1505
Focal MR-Guided Thermotherapy: An Update
John Trachtenberg, Canada

1505-1520
Discussion

1520-1530
Break

1530-1720
SESSION FIVE

Kidney
Moderator: Marcelo Bendhack, Brazil

1535-1550
Small Renal Masses: Indications for Intervention in Elderly Patients
Antonio Finelli, Canada

1550-1605
Partial Nephrectomy in the Elderly
Thomas Schwaab, USA

1605-1620
Role of Biopsy in Management of Renal Masses
Michael Jewett, Canada

1620-1635
Case Discussion

1635-1650
Incorporation of TKIs into Surgical Management
Anil Kapoor, Canada

1650-1705
Lessons Learned from Partial vs Radical Nephrectomy Studies
Hendrik van Poppel, Belgium

1705-1720
Case Discussion

1720
Conclude
### Sunday, October 16

**0800–0950**  
**SESSION SIX**

**Bladder Cancer Biology**  
Moderator: Michael Droller, USA

**0805–0820**  
Update on New Diagnostic Methods  
Fred Witjes, The Netherlands

**0820–0835**  
Tissue Markers  
Peter Black, Canada

**0835–0845**  
Discussion

**0845–0900**  
Management of Invasive Bladder Cancer in the Elderly  
Shahrokh Shariat, USA

**0900–0915**  
Management of Non-Muscle Invasive Bladder Cancer in China  
Ningchen Li, China

**0915–0930**  
Considerations for Treatment Decisions in Bladder Cancer  
Michael Droller

**0930–0945**  
Discussion

**0945–1005**  
Break

**1005–1125**  
**SESSION SEVEN**

Surgical Management of Invasive Bladder Cancer  
Moderator: Urs E. Studer, Switzerland

**1010–1025**  
Role of Extended Node Dissection  
Wassim Kassouf, Canada

**1025–1040**  
Quality of Care in the Management of Bladder Cancer  
Badrinath Konety, USA

**1040–1055**  
Orthotopic Bladder in Elderly Patients: Limits and Results  
Richard Hautmann, Germany

**1055–1110**  
Discussion
1110-1220

SESSION EIGHT

Moderator: Christopher Cheng, Singapore

1115-1130
Why and How To Do a Nerve-Sparing Cystectomy
Urs E. Studer

1130-1145
Upper Tract TCC: Role of Neoadjuvant Therapy
Surena Matin, USA

1145-1200
Neoadjuvant vs. Adjuvant Chemotherapy: Which is Preferable?
Peter Albers, Germany

1200-1215
Discussion

1220
Wrap-up
Laurence Klotz

1220
Adjourn
0800–1230

WUOF CONFERENCE

Room: ICC Lounge

(see programme on page 38)

0800–1215

DEUTSCHE GESELLSCHAFT FÜR UROLOGIE (DGU) (GERMAN SOCIETY OF UROLOGY)

Chairs: Maurice Stephan Michel, Germany
        Bernd Wullich, Germany

Room: Hall 3

Introduction to the DGU

0800–0810
Structure and Boards of the DGU
Stefan Müller, DGU President

0810–0830
Organization of Structured Urological Education in Germany
Maurice Stephan Michel

High-Ranked German Guidelines and Development of Excellence Centres

0830–0850
S-3 Guideline: Prostate Cancer
Manfred P. Wirth

0850–0910
S-3 Guideline: Urinary Tract Infection
Florian Wagenlehner

0800–1720

WUOF CONFERENCE

Room: ICC Lounge

(see programme on page 35)

0800–1700

SIU BOARD OF CHAIRMEN MEETING

Room: Salon Esperanto, Grand Hotel Esplanade

The Best of German Urology in 2011 in Clinical Practice and Research

The Akademie der Deutschen Urologen (Academy of German Urologists)

0810–0830
Organization of Structured Urological Education in Germany
Maurice Stephan Michel

High-Ranked German Guidelines and Development of Excellence Centres

0830–0850
S-3 Guideline: Prostate Cancer
Manfred P. Wirth

0850–0910
S-3 Guideline: Urinary Tract Infection
Florian Wagenlehner
0800–1215

DEUTSCHE GESELLSCHAFT FÜR UROLOGIE (DGU) (GERMAN SOCIETY OF UROLOGY)

0910–0930
S-3 Guideline: Prophylaxis of Deep Vein Thrombosis
Peter Walz

0930–0950
Certified Prostate Cancer Centres and Testicular Cancer Second Opinion Centre
Axel Heidenreich

Research in Urology

0950–1000
Structural Concepts of Research Promotion by the German Society of Urology
Bernd Wullich

Highest-Ranking Urological Research in Germany
DGU Award Recipients Present Their Studies

1000–1020
Recipient of the Nitze Award 2011
Jens Bedke

1020–1040
Recipient of the “Science Around Thirty” Award 2011
Edwin Herrmann

1040–1050
Recipient of the AuF Award 2010 (I)
Natalie Sampson

1050–1100
Recipient of the AuF Award 2010 (II)
Friedemann Zengerling

Top-Level Research by Network Concepts

1100–1115
Comprehensive Clinical and Molecular Characterization of Selective Renal Tumor Entities
Kerstin Junker, on behalf of the German Network for Renal Cell Tumors

1115–1130
The Relevance of National Communication Platforms for Realization of Multicentre Research Projects
Peter Olbert, on behalf of the German Bladder Cancer Research Network

1130–1145
Training and Quality Control: Indispensable Tools for Outstanding Research
Gerd Unteregger, on behalf of the German Prostate Cancer Consortium

1145–1200
Male Infertility Through Infectious and Inflammatory Diseases of the Urogenital Tract
Florian Wagenlehner, on behalf of the Network for Urogenital Infection

1200–1215
Network for Infertility: Today and Tomorrow
Wolfgang Weidner, on behalf of the Network for Infertility
0900–1200

SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS) SYMPOSIUM

Room: Stockholm

Treatment of Complications After the Treatment of Prostatic Disease: “How I Do It”

Session 1: Urethral Stricture and Bladder Neck Contracture After TURP
Discussant: Ronald Kodama, Canada

0900–0925
Incidence, Causes, Endoscopic and Open Treatments
Christopher Gonzalez, USA

0925–0930
Discussion and Questions

Session 2: Anastomotic Stricture After RRP
Discussant: Kurt McCammon, USA

0930–0955
Incidence, Causes, and Treatment (Radical Resection, Botox, Urolume and Open Repair)
Richard Santucci, USA

0955–1000
Discussion and Questions

Session 3: Artificial Urinary Sphincter
Discussant: Frank Burks, USA

1000–1025
Primary and Secondary Applications of AUS
Allen Morey, USA

1025–1030
Discussion and Questions

Session 4: Rectourethral Fistula
Discussant: Joel Gelman, USA

1030–1055
Transperineal Repair of Complex Rectourethral Fistulas
Kenneth Angermeier, USA

1055–1100
Discussion and Questions

Session 5: The Devastated Outlet “I and II”
Discussants: Joel Gelman, USA
Kurt McCammon, USA

1100–1125
Complete Reconstruction vs Suprapubic Diversion (Outlet I)
Margit Fisch, Germany

1125–1150
Complete Reconstruction vs Suprapubic Diversion (Outlet II)
Steven Brandes, USA

1150–1200
Discussion and Questions
0900–1200

INTERNATIONAL SOCIETY FOR SEXUAL MEDICINE (ISSM) SYMPOSIUM

Chair: John Dean, UK
Room: Hall 7

Peyronie’s Disease and Men’s Sexual Well-Being
Claudio Teloken, Brazil
The Impact of Chronic Diseases on Men’s Sexual Health
Ekaterina Kulchvenya, Russia
Assessment and Management of Low Sexual Desire in Men
John Dean, UK

0900–1200

THE MIDDLE EAST SOCIETY FOR ORGAN TRANSPLANTATION (MESOT) SYMPOSIUM

Chairs: Adib Rizvi, Pakistan
Nasser Simforoosh, Iran
Room: Hall 10

0900-0935
Technical Aspects of Kidney Transplantation: Experience with 3400 Cases
Nasser Simforoosh

0935-1010
Transplantation Complications and Infections
Adib Rizvi

1010-1045
Pediatric Kidney Transplantation
Bassam Saeed, Syria

1045-1120
Transplantation in MESOT Countries
Marwan Masri, Lebanon

1120-1155
Transplantation in Abnormal Lower Urinary Tract Patients
Altaf Hashemi, Pakistan

0900–1200

PAN-AFRICAN UROLOGICAL SURGEONS ASSOCIATION (PAUSA) SYMPOSIUM

Chairs: Khaled Dabees, Egypt
Serigne Gueye, Senegal
Room: Hall 9

0900–0915
Introduction and Welcome
Serigne Gueye, Programme Coordinator
Mohamed Eissa, PAUSA President

0915–0940
Management of Penile Curvature
Hisham Badawi, Egypt

0940–1005
West African Lymphatic Filariasis Morbidity Management Project: History and Outcome
Sunny D. Mante, Ghana
1005–1015
Questions and Answers

1015–1040
New Approaches to Prostate Cancer Management in the Native African
E. Oluwabunmi Olapade-Olaopa, Nigeria

1040–1105
Metastatic Castrate-Resistant Prostate Cancer: What Are the Options?
Jean McDonald, UK

1105–1115
Questions and Answers

1115–1140
Robots, Laparoscopy and Lasers: Is High Tech Possible in Low-Resource Countries?
Catherine deVries, USA

1140–1150
Questions and Answers

1150–1200
Conclusion: The Way Forward
Khaled Dabees
Serigne Gueye

1000–1200
SIU NATIONAL DELEGATES’ MEETING

Room: Hall 6

1200–1300
BREAK

1300–1600
EUROPEAN ASSOCIATION OF UROLOGY (EAU) SYMPOSIUM
Chair: Per-Anders Abrahamsson, Sweden

Room: Hall 7

1300–1320
Screening for Prostate Cancer: An Update
Fritz Schröder, The Netherlands

1320–1340
Robotics in Surgery: A Real Advance?
Walter Artibani, Italy

1340–1400
Optimal Treatment of High Risk Prostate Cancer
Hein van Poppel, Belgium

1400–1420
What’s New in the Treatment of Castration-Resistant Prostate Cancer?
Bertrand Tombal, Belgium

1420–1440
Break

1440–1500
Surgery for Stress Incontinence: Current Concepts and Future Directions
Walter Artibani, Italy

1500–1520
What’s New in Andrology?
Wolfgang Weidner, Germany
1300–1600
EUROPEAN ASSOCIATION OF UROLOGY (EAU) SYMPOSIUM

1520–1540
Management of Small Renal Masses
Didier Jacqmin, France

1540–1600
What Is the Role of Lasers in Management of Benign Prostate Disease?
Rolf Muschter, Germany

1300–1700
JOINT EDUCATIONAL COURSE: INTERNATIONAL CONTINENCE SOCIETY (ICS) AND SOCIETY FOR URODYNAMICS & FEMALE UROLOGY (SUFU)
Chairs: Eric Rovner, USA
Werner Schaefer, USA
Room: ICC Lounge

1300–1330
Urodynamics and Biomechanics of Female Incontinence
Werner Schaefer, USA

1330–1400
Sonography in the Diagnoses of Pre- and Post-Operative Bladder Dysfunction
Ralf Tunn, Germany

1400–1430
SUI Surgery in 2011: Does One Operation Fit All?
Eric Rovner, USA

1430–1500
Break

1500–1530
Current Concepts of Prolapse Surgery
Heinz Koelbl, Germany

1530–1600
Mesh Complications in SUI/POP Surgery
Sandip Vasavada, USA

1600–1630
Evaluation of Patients with Neurogenic Bladder: Indications and Implications
Gary Lemack, USA

1630–1700
Panel Discussion

1300–1600
EUROPEAN SOCIETY FOR PAEDIATRIC UROLOGY (ESPU)
Moderator: Rien Nijman, The Netherlands
Room: Hall 10

1300–1320
European Reflux Guidelines
Rien Nijman

1320–1340
The Long-Term Results of Endoscopic Treatment of Reflux
Göran Lackgren, Sweden
1340–1415
Debate: What Are My Indications for Endoscopic Treatment of Reflux?
Moderator: Rien Nijman

1340–1345
Göran Läckgren, Sweden

1345–1350
Antoine Khoury, USA

1350–1355
Paolo Caione, Italy

1355–1400
Raimund Stein, Germany

1400–1415
Debate

1415–1445
Laparoscopy for Paediatric Renal Pathologies: An Update
Alaa el Ghoneimi, France

1445–1500
Break

1500–1530
Current Management of PUV
Raimund Stein, Germany

1530–1600
Update on the Management of Cryptorchidism
Christian Radmayr, Austria

1600–1700
Panel on Distal Hypospadias
Moderator: Barry Kogan, USA
Panelists: Alaa el Ghoneimi, Margit Fisch,
Marc David Leclair, Emilio Merlini

1300–1700

SYMPOSIUM ON UROLOGICAL STENTS (SUS)
Chair: Daniel Yachia, Israel
Room: Oslo

1300–1310
Opening
Daniel Yachia

1310–1340
Updates
Identification of Conditioning Film Components on Indwelling Ureteral Stents and Their Role in Bacterial Adhesion
Dirk Lange, Canada
Update on Metallic Stents in the Urinary Tract
Ravi Kulkarni, UK

1340–1410
Biodegradable Materials in Urinary Tract Stenting
Biodegradable Urethral Stents: What’s New?
Taina Isotalo, Finland
Degradable Ureteral Stents
Ben Chew, Canada
Panel on Post-Surgical Bladder Neck Stenosis

Moderator: Gerald H. Jordan, USA

Palliation or Definitive Surgery? Is There Another Approach?
Gerald H. Jordan

Memokath 045TW Stent in Intractable Bladder Neck Stricture: Preliminary Experience
Carlo Luigi Augusto Negro, UK

Allium RPS in Recurrent Bladder Neck Stenoses: Preliminary Experience
Ofer Nativ, Israel

New and Upcoming Stent Designs for the Urinary Tract

Stenting Blood Vessels or the Urinary Tract: What Makes It Different?
Taina Isotalo

A Novel 3.0F Ureteral Stent with Drainage Characteristics of a 4.75 F JJ Stent
Dirk Lange

Is There a Need for New Materials or New Stent Designs in the Urinary Tract?
Daniel Yachia

BREAK AND POSTER VIEWING

POSTER SESSION

Group A: Ask the Author

Utilization of Allium Ureteral Stent in the Endoscopic Treatment of Ureteral Stenosis: Our Experience and Preliminary Results
Mariarita Salvitti, Italy

The Dilemma of Infected Hydronephrosis Treatment Due To Ureteric Calculi: To Stent or To Perc?
Michael Nomikos, Greece

Rate of Inaccessible Ureter and Effect of Passive Dilation by Pre-Stenting at Ureteroscopic Laser Lithotripsy
Yuji Kato, Japan

Retrograde-Anterograde Combined Catheterization in Ureteral Injuries
Omar Bilal Halawa González, Spain

Urological Complications After Renal Transplantation
Mihai Christian Harza, Romania

Short-Term Success Rates of Ureteral De-Obstruction in Patients with Primary Retroperitoneal Fibrosis Undergoing Medical or Surgical Treatment
Hannes Cash, Germany
1600–1700

POSTER SESSION
➤ Group B: Podium Posters

Pressure Transmission Through Ureteric Stents: A Novel In-Vivo Human Study
Wael Sameh, Egypt

New Management of Upper Urinary Tract Obstruction by Using Allium® Stents
Joachim Alefelder, Germany

Open Label, Randomized Clinical Trial To Evaluate the Safety and Efficacy of “Herbmed Plus” for Ureteral Stent Discomfort Against Tolterodine
Suresh Patankar, India

Outcome of Dual Flange Metallic Sphincteric Urethral Stents in the Treatment of Neuropathic Bladder Dysfunction After Spinal Cord Injury
Andre Van Der Merwe, South Africa

Characterization of Morbidity of Double-J Ureteral Stents
Khaled Mursi Hammoud, Egypt

1800–1930

OPENING CEREMONIES

Hall 1

1930–2100

WELCOME RECEPTION

Exhibit Hall
Halls 15.1 and 16
0630–0800

INSTRUCTIONAL COURSES IC01–IC04

► IC01: Transforming Urology in Africa: Designing Clinical and Research Collaborations

Chair: Catherine deVries, USA

Room: Salon 11/12

0630–0650
Why Initiatives Fail: Analysis of Success and Failure in Global Urology
Catherine deVries

0650–0710
How to Develop Clinical and Research Collaborations to Build Capacity in Sub-Saharan Africa
Serigne Gueye, Senegal

0710–0730
Male Circumcision for Prevention of HIV Transmission in Africa
Ira Sharlip, USA

0730–0750
The Concept of Periodic Modular Training in Improving Urology Care in Africa
Stephen Watya, Uganda

0750–0800
Discussion

► IC02: Management of Post-Prostatectomy Incontinence

Chair: Ajay Singla, USA

Room: Salon 13/14

0630–0635
Introduction
Ajay Singla

0635–0650
Non-Surgical Management
Stavros Charalampous, Greece

0650–0700
Adjustable Male Slings
Rodrigo Leyton, Chile

0700–0710
Non-Adjustable Male Sling: AdVance
Kurt McCammon, USA

0710–0735
Non-Adjustable Male Sling: InVance
Ajay Singla

0735–0750
Artificial Urinary Sphincter: The Gold Standard
Dirk De Ridder, Belgium

0750–0800
Round Table Discussion and Conclusion
Ajay Singla
IC03: Prostate Cancer Diagnosis and Screening: New Methods To Approach an Old Problem

Chair: Badrinath Konety, USA

Room: Salon 15/16

0630–0635
Introduction
Badrinath Konety

0635–0655
New Markers
Badrinath Konety

0655–0715
New Biopsy and Other Diagnostic Techniques: Practical Pointers
Stephen Jones, USA

0715–0735
Experience with ERSPC
Monique Roobol, The Netherlands

0735–0755
Meta-analysis and Evidence Synthesis on Prostate Cancer Screening
Phil Dahm, USA

0755–0800
Conclusion
Badrinath Konety

IC04: Robotic-Radical Retropubic Prostatectomy

Chair: Ashutosh Tewari, USA

Room: Salon 17/18

0630–0635
Introduction and Welcome
Ashutosh Tewari

0635–0700
Technical Tips To Optimize Oncologic and Functional Outcomes
Ashutosh Tewari

0700–0725
The Role of Pelvic Lymphadenectomy and How It Is Done in Robotic Prostatectomy
Francesco Montorsi, Italy

0725–0750
Management of Complications and Improving Quality of Life After Robotic Prostatectomy
Peter Wiklund, Sweden

0750–0800
Discussion and Concluding Remarks
Ashutosh Tewari
PLENARY 1

Prostate Cancer

Chairs: Margit Fisch, Germany
Gerald H. Jordan, USA
Joachim W. Thüroff, Germany

Room: Hall 1

0745–0755
Welcome Address
Joachim W. Thüroff, SIU President
Margit Fisch, Chair, Local Organizing Committee
Gerald H. Jordan, Chair, SIU 2011 Scientific Programme

0755–0805
Pharmacology of Adrenoceptor Subtypes Creates New Drugs Treating LUTS/BPH and OAB
Toichi Takenaka, Japan

0805–0810
Presentation of SIU-Astellas Lecture
Toichi Takenaka

0810–0830
SIU-Astellas Lecture: Early Versus Delayed Endocrine Treatment of Locally Advanced Prostate Cancer: 40 Years of Progress Through International Cooperation
Fritz Schröder, The Netherlands

1000–1200
PARALLEL PLENARIES 1–3

PARALLEL PLENARY 1

Focal Therapy of Prostate Cancer

Chairs: Peter Hammerer, Germany
William Lynch, Australia

Room: Hall 3

1000–1015
Does Clinical Unifocal PCA Translate into Prostatectomy pT2a Stage?
Thomas Polascik, USA

1015–1030
Transrectal MRI Imaging
Arnauld Villers, France

1030–1045
What Biopsy Strategy Does Focal Therapy Demand?
Mark Emberton, UK
1000–1200

PARALLEL PLENARY 1

Focal Therapy of Prostate Cancer

1045–1100
Robot-Assisted Image Guided Focal Therapy of Prostate Cancer: Initial Results
John Trachtenberg, Canada

1100–1115
Trans-Urethral Ultrasound Thermotherapy with MR Thermometry and Control
Laurence Klotz, Canada

1115–1130
Real-Time Ultrasound Monitoring of Tissue Changes
Michael Marberger, Austria

1130–1200
Focal Therapy of Low-Risk Prostate Cancer Using MR Guided Focus Ultrasound: Initial Clinical Experience
Christopher Cheng, Singapore

PARALLEL PLENARY 2

Pediatric Urology

Chairs: Mohamed Eissa, Egypt
Margit Fisch, Germany

1000–1015
Has Injection Therapy Changed Indications/Timing for Antireflux Surgery?
Antoine E. Khoury, USA

1015–1030
Is There Still a Role for Long-Term Antibiotic Prophylaxis?
Jean Hollowell, USA

1030–1045
Indications and Timing of Surgical Correction of UPJ Obstruction
Barry Kogan, USA

1045–1125
Pro–Con Debate: Open vs. Laparoscopic vs. Robotic Surgery in Toddlers: Advantages and Limitations
Open Surgery: Margit Fisch, Germany
Laparoscopy: Marc David Leclair, France
Robotic: Sarah Lambert, USA

1125–1140
Non-Neurogenic Voiding Disorders in Children
Paolo Caione, Italy

1140–1155
Strategies for Treating Neurogenic Detrusor Overactivity in Myelomeningocele
Raimund Stein, Germany

PARALLEL PLENARY 3

Testis Cancer

Chairs: Peter Albers, Germany
Michael Jewett, Canada

1000–1030
Pro–Con Debate: The Contralateral Testis Should Always Be Biopsied
Pro: Niels Skakkebaek, Denmark
Con: Harry Herr, USA

1030–1110
Pro–Con Debate: Active Surveillance vs. Chemotherapy vs. RPLND in Stage I–IIa NSGCTT
Active Surveillance: Alan Horwich, UK
Prophylactic Chemotherapy: Peter Albers, Germany
RPLND: Paul Lange, USA
1110–1125
When Should You Do Retroperitoneal Dissection After Chemotherapy of Stage IIb-III NSGCTT?
Axel Heidenreich, Germany
1125–1140
Fertility and Testis Cancer
JWA Ramsay, UK
1140–1155
Testis-Sparing Surgery
Stephen Riggs, USA

1200–1315
BREAK

SPONSORED SYMPOSIA

Astellas Pharma Inc.

► Trust Me, I’m a Doctor: Clinical Decisions in OAB
Chair: Eric Rovner, USA

1200–1205
Chairman’s Introduction
Eric Rovner
1205–1225
Trust Me, I Know the Patient
Elise De, USA
1225–1245
Trust Me, I Know the Latest Developments and Data
Karl-Dietrich Sievert, Germany

1245–1305
Trust Me, I Know the Role of Guidelines
Hidehiro Kakizaki, Japan
1305–1315
Discussion
Summary and Close
Eric Rovner

Sanofi

► Optimizing Patient Care in mCRPC: Who, When and How To Treat
Chair: John Fitzpatrick, Ireland

1200–1220
Changing Management Strategies in mCRPC
John Fitzpatrick
1220–1305
Optimising Patient Care in mCRPC: A Case Study
Participants: Amit Bahl, UK
Nicolas Mottet, France
John Fitzpatrick
Risk Stratification to Guide Multidisciplinary Team Treatment Decisions in mCRPC
Nicolas Mottet
When and How To Use Chemotherapy in mCRPC
Amit Bahl
1305–1310
Interactive Discussion
All
1310–1315
Summary and Meeting Close
John Fitzpatrick
PARALLEL PLENARIES 4–5

PARALLEL PLENARY 4
► Male Incontinence

Chairs: Dirk De Ridder, Belgium
Osamu Ogawa, Japan

Room: Hall 7

1315–1330
Pathophysiology of Incontinence in Males
Paul Abrams, UK

1330–1345
Physiotherapy and Electrical/Magnetic Stimulation—Do They Change Natural History of Post-Prostatectomy Incontinence?
Christian Hampel, Germany

1345–1400
Do Drugs in Post-Prostatectomy Incontinence Do Any Good?
Karl-Erik Andersson, USA

1400–1440
Panel Presentations and Discussion: Which Surgical Therapy for Which Patient?

1400–1410
Injectables and Balloons
Christian Hampel, Germany

1410–1420
Slings, Slings, Slings
Klaus Höfner, Germany

1420–1430
Hydraulic Controllable Sphincters
Anthony Mundy, UK

1430–1440
Discussion
All

PARALLEL PLENARY 5
► Potentially Lethal Infections

Chairs: Mete Cek, Turkey
Chris F. Heyns, South Africa

Room: Hall 6

1315–1330
Fournier’s Gangrene
Amir Zarrabi, South Africa

1330–1345
Emphysematous Pyelonephritis
Dick Barnes, South Africa

1345–1400
Retroperitoneal Abscess
Redouane Rabii, Morocco

1400–1430
Panel Discussion: Management of Multiply Resistant Infections in Urology Today

1400–1410
MRSA
Daniel Shoskes, USA

1410–1420
ESBL and FQ Resistance
Kurt Naber, Germany

1420–1430
Discussion

1430–1445
Male Circumcision for the Prevention of HIV
Ira Sharlip, USA
1315–1445

ABSTRACT SESSIONS

PODIUM SESSION 1
▶ Bladder Cancer

Chair: Michael Stöckle, Germany

——— Room: Hall 9 ———

1315–1325
POD–01.01
Invasion of Urothelial Carcinoma Cells: Standardized Evaluation in a Novel Electrophysiological Assay
Christian Bolenz, Germany

1325–1335
POD–01.02
Transitional Cell Bladder Cancer Proteomic Mapping and Risk of Progression
Isabel Galante Romo, Spain

1335–1345
POD–01.03
Role of Estrogen, Progesterone and Androgen Receptors on Formation and Progression of Urothelial Carcinoma of the Bladder
Gholamreza Pourmand, Iran

1345–1355
POD–01.04
Does Neobladder Created from Short Ileal Segment Reduce Delayed Metabolic Complications After Cystectomy?
Vladimir Bancevic, Serbia

1355–1405
POD–01.05
Apoptosis of Urinary Bladder Cancer Cells Caused by Effect of Gemcitabine-Cisplatin
Oleksandr Iatsyna, Ukraine

1405–1415
POD–01.06
Our Experience in the Use of JJ-Stent after Resection of the Ureteric Orifice During TURB
Barbara Cristina Gentile, Italy

1415–1425
POD–01.07
Challenging Boundaries: An Enhanced Recovery Programme for Radical Cystectomy
Saheel Mukhtar, UK

1425–1435
POD–01.08
Upper Urinary Tract Tumour with or Without Previous Bladder Cancer: Does It Make a Difference?
Joan Palou, Spain

1435–1445
POD–01.09
Trans-Urethral Resection of Bladder Tumour (TUR-BT) in Patients Taking Platelet Antiaggregant Monotherapy
Stefano Picozzi, Italy
MODERATED POSTER SESSION 1

Stones

Chairs: Ben Chew, Canada
Robyn Webber, UK

Room: Salon 11/12

MP–01.01
Characterization of Morbidity of Double J Ureteral Stents
Khaled Mursi Hammoud, Egypt

MP–01.02
Nephrostomy Tubeless and JJ Stentless PCNL: Experience of 113 Cases
Mohammed Bhuiyan, Bangladesh

MP–01.03
Vitamin D Receptor Gene Polymorphisms in CaOx Kidney Stone Patients
Omer Onur Cakir, Turkey

MP–01.04
Non-Contact Infrared Temperature Measurement of Ultrasonic Lithotripters: A Comparison of Commonly Used Lithotripsy Devices
Christian Keil, Germany

MP–01.05
Vscan: A Pocket-Sized Ultrasound Device in Examination of the Genito-Urinary Tract
Joerg Neymeyer, Germany

MP–01.06
Medical Expulsive Therapy Reduces the Need for Surgery in the Management of Distal Ureteral Stones
Erkan Erkan, Turkey

MP–01.07
Management of Ureteral Calculi and Medical Expulsive Therapy in Emergency Departments
Stefano Picozzi, Italy

MP–01.08
Endothelin Plasma Concentrations as Parameter of Changes in Renal Perfusion After Extracorporeal Shockwave Lithotripsy
Hajrudin Spahovic, Bosnia and Herzegovina

MP–01.09
Ajay Bhandarkar, India

MP–01.10
In vitro Comparison of Two New Mechanical Impulse Lithotripsy Devices
Christian Keil, Germany

MP–01.11
Analysis of Clinical Factors Associated to Spontaneous Passage of Ureteral Calculi in Korean Patients: Long-Term, Single Institution Experience
Sang-Cheol Lee, South Korea
MP–01.12  
Retrograde Intrarenal Surgery for the Management of Renal Stones  
Marcos Cepeda Delgado, Spain

MP–01.13  
Is Percutaneous Nephrolithotomy Really a Minimally Invasive Procedure?  
Youssef Dakkak, Morocco

MP–01.15  
Computing Stone Burden for Selecting Cases for Reducing PCNL Tracts for Staghorn Calculus  
Ravindra Sabnis, India

MP–01.16  
Rate of Inaccessible Ureter and Effect of Passive Dilation by Pre-Stenting at Ureteroscopic Laser Lithotripsy  
Yuji Kato, Japan

MP–01.17  
The Capability of Antiretropulsion Devices to Redirect Fluid Irrigation During Ureteroscopy  
Dirk Lange, Canada

MP–01.18  
Bilateral Ureteroscopy: Evaluation After 100 Procedures  
Petrisor Aurelian Geavlete, Romania

MP–01.19  
Changes in Renal Pressure with Ureteral Catheters and Antiretropulsion Devices During Percutaneous Nephrolithotomy  
Dirk Lange, Canada

MP–01.20  
Complications After 6000 Ureteroscopies: The Experience of “Saint John” Emergency Clinical Hospital  
Petrisor Aurelian Geavlete, Romania

MP–01.21  
Spinal Anesthesia and Intercostal Access for Percutaneous Nephrolithotomy  
Seyed Habibollah Mousavi-Bahar, Iran

MP–01.22  
Postoperative Chest X-Ray After Supracostal Puncture: Mandatory After Every Case of Percutaneous Nephrolithotomy?  
Santosh Kumar Singh, India
MODERATED POSTER SESSION 2
Adrenal, Kidney, Ureter: Benign & Malignant Disease

Chairs: Dieter Jocham, Germany
Anil Kapoor, Canada

Room: Salon 13/14

MP–02.01
Is the Use of Metaiodobenzylguanidine Scintigraphy Necessary in the Diagnosis of Pheochromocytoma?
Jorge Hugo Almonacid Grunert, Spain

MP–02.02
Silodosin Reduces Pressure In Vivo of the Obstructed Rat Ureter and Inhibits Nerve-mediated Contractions of the Isolated Human Ureter
Luca Villa, Italy

MP–02.03
The Effects of Warm and Cold Ischemia on the Function of the Operated Kidney in Patients Undergoing Nephron-Sparing Surgery
Numan Baydilli, Turkey

MP–02.04
Use of Digestive Tract To Replace Ureter
Nabil Mhiri, Tunisia

MP–02.05
Laparoscopic Adrenalectomy for Adrenal Metastases: Points of Controversy
Masahiko Takemura, Japan

MP–02.06
Surgery of Renal Tumor with Intra-Atrial Tumor Thrombi Using Hypothermic Circulatory Arrest
Yutaka Takezawa, Japan

MP–02.07
Calcium-Dependent Bone Metastases in Renal Cell Carcinoma
Walburgis Brenner, Germany

MP–02.08
Identification of Cancer-Stem-Cell-Like Cells in a Papillary Renal Cell Carcinoma-Derived Cell Line
Rüdiger Sorg, Germany

MP–02.09
Long-Term Results of Percutaneous Radiofrequency Ablation (PRFA) of Small Renal Tumors in High-Risk Patients: A Single Institution Experience
Maurizio Brausi, Italy

MP–02.10
Difference Between Clinical and Pathologic Renal Tumour Size, Correlation with Survival and Implications for Patient Management
Sabine Brookman-May, Germany
**MP–02.11**
Collecting System Invasion and Fuhrman Grading but not Tumor Size Facilitate Prognostic Stratification of Patients with pT2 Renal Cell Carcinoma: Can the Current 7th Edition of TNM Classification Be Improved?
Sabine Brookman-May, Germany

**MP–02.12**
Active Surveillance of Small Renal Tumours: Clinical Outcomes
Muhammad Elmussareh, UK

**MP–02.13**
Oncological Long-Term Outcome of Patients Presenting with Chromophobe in Comparison to Non-Chromophobe Renal Cell Carcinoma
Sebastian Frees, Germany

**MP–02.14**
Outcomes of Surveillance Strategy and Surgical Management in Small Renal Masses: A Population-Based Study in Tayside, UK
Chi Kit Chuen, UK

**MP–02.15**
Outcomes and Tumour Growth Rate of Renal Masses Are Dependent on Size at Presentation in a Watchful Waiting Cohort
Naji Touma, Canada

---

**1315–1445**

**MODERATED POSTER SESSION 3**

**Prostate Cancer, Detection and Staging**

**Chairs:** Jan Fichtner, Germany  
Samir Taneja, USA

Room: Salon 15/16

**MP–03.01**
Functional Role of PGP 9.5 as Tumor Suppressor Is Inactivated by Promoter CpG Methylation in Human Prostate Cancer
Yozo Mitsui, Japan

**MP–03.02**
17–allylamino–17–demethoxygeldanamycin, a Heat Shock Protein 90 Inhibitor Suppresses Castration-Resistant Prostate Cancer Invasion, and Enhances DTX Antitumor Activity
Fuminori Sato, Japan

**MP–03.03**
HMGA2 Upregulation Is Related To Tumor Progression and let–7 Downregulation in High Risk Prostate Carcinoma
Martin Spahn, Germany

**MP–03.04**
The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-Resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug
Christian Thomas, Germany
**MP–03.05**
Can Prebiopsy MpmMRI Be Used To Preferentially Detect Significant Prostate Cancer?
Mohamed Abd Alazeez, UK

**MP–03.06**
Can Photodynamic Diagnosis Using 5–Aminolevulinic Acid (ALA) Predict Malignancy of Prostate Cancer Cells in the Urine, Obtained Following Prostate Massage?
Satoshi Anai, Japan

**MP–03.07**
Cost/Benefit of Incorporating Circulating Prostate Cell Detection in a Screening Programme for Prostate Cancer
Alexander Andrusco, Chile

**MP–03.08**
Incorporating Circulating Prostate Cell Detection in a Screening Programme for Prostate Cancer Does Not Detect Low Grade Small Volume Tumours
Alexander Andrusco, Chile

**MP–03.09**
Comparison Between PSA Kinetics and the Detection of Circulating Prostate Cells and Bone Marrow Micrometastasis To Determine Local or Systemic Biochemical Failure After Radical Prostatectomy: Clinical Implications
Alexander Andrusco, Chile

**MP–03.10**
Can Pre-Biopsy Multi-Parametric MRI Reduce the Number of TRUS Cores Required to Diagnose Prostate Cancer in an “At-Risk” Population of Men?
Louise Dickinson, UK

**MP–03.11**
Predictive Value of Number of Cores with High-Grade PIN and Atypical Acinar Proliferation in Prostate Biopsy for the Diagnosis of Prostate Cancer
Alberto Hernando Arteche, Spain

**MP–03.12**
The Value of Computer-Aided Ultrasonography in the Detection and Evaluation of Prostate Cancer
Apostolos P. Labanaris, Germany

**MP–03.13**
Every Three Years PSA Screening Is Sufficient to Detect Almost All Prostate Cancers While Still Curable in Men with Baseline PSA Less Than 2.1ng/mL: Findings of a Longitudinal Study in Natori, Japan
Sadafumi Kawamura, Japan

**MP–03.14**
The Influence of Positive Core Density on Predicting the Pretreatment Stage of Prostate Cancer
Jung Ki Jo, South Korea

**MP–03.15**
Pre-Operative Staging of Prostate Cancer with Histoscaning™ Facilitates Nerve-Sparing Prostatectomy and May Increase Complete Excision of Prostate Cancers
Lucy Simmons, UK
**MP–03.16**  
Blinded Comparison of Histoscan™ Volumetric Tumour Assessment with Whole Mount Step Sectioned Radical Prostatectomy Specimens  
Lucy Simmons, UK

**MP–03.17**  
Epidemiological Aspects, Anatomo-Clinic of Prostate Cancer in Cameroon  
Mekeme Mekeme Junior Barthelemy, Cameroon

**MP–03.18**  
Plasma Amino Acid Profile as a Novel Diagnostic Marker for Prostate Cancer: Multicentre Study  
Takeshi Miura, Japan

**MP–03.19**  
Efficacy of Transperineal Versus Transrectal 12-core Initial Prostate Biopsy with PSA Levels Between 4.0 and 20.0 ng/ml  
Shin Ohira, Japan

**MP–03.20**  
Prostate Cancer Angiogenesis: A Preliminary Experience with 64-Row Multidetector CT Perfusion. Do Quantitative Measurements Distinguish Tumor?  
Antonio Luigi Pastore, Italy

**MP–03.21**  
Prostate Cancer Detection Using Cadence Contrast Pulse Sequencing Technology for Targeted Biopsies  
George Daniel Radavoi, Romania

**MP–03.22**  
Cryoanalgesia for Prostate Biopsy  
Simon Robinson, UK

**MP–03.23**  
Prevalence and Classification of Prostatic Calcification and Correlation with Histology and Other Parameters  
Michal Smolski, UK

1315–1445

**VIDEO SESSION 1:**  
▶ Minimally Invasive Surgery I  
Room: Salon 17/18

1315–1325  
**VID–01.01**  
Laparoscopic Management of Symptomatic Paracalyceal Diverticulum  
Abbas Basiri, Iran

1325–1335  
**VID–01.02**  
Robotic Radical Prostatectomy: A Step-by-Step Approach  
Gianluca D’Elia, Italy

1335–1345  
**VID–01.03**  
Robotic Partial Nephrectomy: How to Reduce Ischemia Time  
Gianluca D’Elia, Italy
1345–1355
VID–01.04
Knotless Three-Layer Anastomosis During Radical Robotic Prostatectomy
Gianluca D’Elia, Italy

1355–1405
VID–01.05
A Technical Description of the Steps to Perform Robotic Radical Cystectomy
Gianluca D’Elia, Italy

1405–1415
VID–01.06
Laparoscopic Partial Cystectomy for Bladder Leiomyoma: Case Report
Marco Puglisi, Italy

1415–1425
VID–01.07
Expanding Indications of Transvesical LESS Surgery
René Sotelo, Venezuela

1315–1455

VIDEO SESSION 2:
▶ BPO/LUTS and Oncology

Chair: Jovan Hadzi-Djokic, Serbia
Ismail Khalaf, Egypt

Room: Hall 10

1315–1325
VID–02.01
Initial Experience of Prostate Resection with Bipolar Surgimaster Scalpel in a Centre with Over 2000 Bipolar TURP
Francesco Pisanti, Italy

1325–1335
VID–02.02
Initial Experience of Prostate Transurethral Vaporization with Botton TURIS in a Centre with Over 2000 Bipolar TURP
Francesco Pisanti, Italy

1335–1345
VID–02.03
Laparoscopic Extraperitoneal Adenomectomy: Comparative Study with Open Technique
Alejandro Garcia-Segui, Spain

1345–1355
VID–02.04
Cost-Effective Treatment of Stress Urinary Incontinence and Complete Reconstruction of Pelvic Floor with Non-Tailored Mesh
Ivan Ignjatovic, Serbia
1355–1405
**VID–02.05**
Adjustable Transobturator Sling (Argus T®) for the Treatment of Post Radical Prostatectomy Urinary Incontinence
Flavio Trigo Rocha, Argentina

1405–1415
**VID–02.06**
Complications in Minimally Invasive Radical Cystectomy
René Sotelo, Venezuela

1415–1425
**VID–02.07**
Total Penectomy and Inguinal Lymphadenectomy: Step by Step
Luis Brandao, Brazil

1425–1435
**VID–02.08**
Robotic Assisted Inguinal Lymph Node Dissection: Preliminary Report
PN Dogra, India

1435–1445
**VID–02.09**
Initial Experience with the Reusable X-Cone Single Port System for Laparoscopic Varicocelectomy, Pelvic Lymphadenectomy and Renal Cyst Marsupialization
Florian Fuller, Germany

1445–1515
**BREAK**

1515–1645
**SURGICAL TIPS 1–2**
► Surgical Tips 1: Male Incontinence Surgery
Chair: Christian Hampel, Germany
Room: Hall 6
Faculty: Dirk De Ridder, Belgium
Vincent Delmas, France
Wilhelm Hübner, Austria

► Surgical Tips 2: Robotic Surgery
Chair: TBC
Room: Hall 7
Faculty: Vito Pansadoro, Italy
Ashutosh Tewari, USA
Joachim W. Thüroff, Germany

1645–1715
**VID–02.10**
Inferior Vena Cava Resection and Reconstruction During PC-RPLND for NSGCT in a Patient with Horseshoe Kidney
Paolo De Stefanis, Italy
ABSTRACT SESSIONS

PODIUM SESSION 2:
Prostate Cancer, Detection and Screening

Chairs: Peter Carroll, USA
Peter Hammerer, Germany

Room: Hall 9

1515–1525
POD–02.01
Detection of Prostate Cancer by HistoScanning™
Robin Epplen, Germany

1525–1535
POD–02.02
A Novel Stereotactic Prostate Biopsy System
Integrating Preinterventional MRI with Live
US Fusion
Boris Hadaschik, Germany

1535–1545
POD–02.03
Operator-Dependent Correlation Between Biopsy and
Prostatectomy Gleason Score: Potential Impact on
Clinical Management
Badar Mian, USA

1545–1555
POD–02.04
Predictive Value of Prostatic Inflammation in
the Development of Prostate Cancer
Benoit Molimard, France

1555–1605
POD–02.05
Temporal Trends in Prostate Cancer:
A 50–Year Period Database Analysis
Ivo Lopes, Portugal

1605–1615
POD–02.06
A Novel Robotic Assisted Prostate Biopsy Device
Allows Better Detection and Characterisation of
Prostate Cancer in Patients with TRUS Biopsy-
Detected HGPIN
Allen Sim, Singapore

1615–1625
POD–02.07
Development of a Risk-Based Decision Model for
Prostate Cancer Gene 3 Usage
Mark Speakman, UK

1625–1635
POD–02.08
Indications for Transperineal Ultrasound-Guided
Prostate Biopsy: Analysis Comparing Transperineal
versus Transrectal 14–Core Biopsy
Hiromi Uno, Japan

1635–1645
POD–02.09
Living with Untreated Prostate Cancer:
The Impact of Active Surveillance on
Quality of Life
Lionne Venderbos, The Netherlands
1515–1645

MODERATED POSTER SESSION 4
Bladder Cancer
Chair: Ricardo Rendon, Canada
Room: Salon 11/12

MP–04.01
Maintenance Bacillus Calmette-Guérin Intravesical Instillation Therapy Is Effective for Prevention of Recurrence in Japanese Non-Muscle-Invasive Bladder Cancer Cases
Takehiko Okamura, Japan

MP–04.02
Integrated Genetic Analysis of Allelic Imbalance and FGFR3 Mutation by SNP-Based Pyrosequencing in Urothelial Cancer
Yoshitomo Chihara, Japan

MP–04.04
Haematuria One Stop Clinic: First Experience in Italy with 150 Cases
Giorgio Bozzini, Italy

MP–04.05
The Clinical Significance of Serum and Urinary HER-2/neu Protein in Bladder Cancer Patients
Taek Sang Kim, South Korea

MP–04.06
Value of a Combination Assay of Survivin, Calreticulin and Urokinase Type Plasminogen Activator as a Non-Invasive Diagnostic Tool in Non-Muscle Invasive Bladder Cancer
Wael Sameh, Egypt

MP–04.07
Clinical Usefulness of Multimodality Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: Comparison of Outcome with Radical Cystectomy
Yasuhiro Hirano, Japan

MP–04.08
Predictive Capacity of Four Comorbidity Indices Estimating Perioperative Mortality After Radical Cystectomy for Urothelial Carcinoma of the Bladder
Roman Mayr, Italy

MP–04.09
Robotic Radical Cystectomy in the Elderly: Acceptable Postoperative Outcome?
Stefan Siemer, Germany

MP–04.10
Prognostic Value of Smoking in Bladder Cancer Patients Who Received Radical Cystectomy
Ju Hyun Lim, South Korea

MP–04.11
Maike Eylert, UK

MP–04.12
Transforming the Invasive Bladder Pathway: Implementation of the Enhanced Recovery After Surgery with Lean Management Principles
Samuel Grimsley, UK
MP–04.13
Pharmacokinetics, Pharmacological Stability, Safety and Efficacy of MMC Administered with a New Hyperthermia Device
Paolo Gontero, Italy

MP–04.14
Endoscopic Resection of Bladder Cancer in Patients Receiving Double Platelet Antiaggregant Therapy
Stefano Picozzi, Italy

MP–04.16
Uptake of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles in Bladder Cancer Cells and in Human Ureter and Mouse Bladder
Robert Weiss, USA

MP–04.17
Simultaneous siRNA-Mediated Inhibition of Antiapoptotic BCL2, BCL2L1, Survivin and XIAP in Different Bladder Cancer Cell Lines
Manfred P. Wirth, Germany

MP–04.18
Radical Cystectomy in Patients > 75 Years with Significant Co-Morbidities
Manfred P. Wirth, Germany

MP–04.19
Inter-Observer Variation in the Pathological Diagnosis of Non-Muscle Invasive Bladder Cancer Between Tertiary Care Centres and Central Pathology Review
Kazunori Hattori, Japan

MP–04.20
The Role of Secondary TUR in High Risk, Non-Muscle-Invasive Bladder Tumors
Mircea Radu Botoca, Romania

MP–04.21
Neoadjuvant Chemohyperthermia for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer: A Phase I Study
Alejandro Souza Escandon, Spain
MP–05.01
Evaluating the Efficacy and Safety of Fixed-Dose Combinations of Tamsulosin OCAS™ and Solifenacin in Male LUTS with Storage and Voiding Symptoms: An Overview of the NEPTUNE Trial
Marcus Drake, UK

MP–05.02
Combination Therapy with Tamsulosin OCAS™ and Solifenacin Is More Effective than Solifenacin Monotherapy as a Treatment for Male LUTS Associated with BPH: Results from the SATURN Trial
Jean Jacques Wyndaele, Belgium

MP–05.03
The Effects of Tamsulosin OCAS™ Plus Solifenacin on Quality of Life (QoL) Parameters in Men with LUTS Associated with BPH Participating in the SATURN Trial
Philip Van Kerrebroeck, The Netherlands

MP–05.04
Multicentre Prospective Study of the Evolve™: Dual 150W Laser for Bladder Outflow Obstruction: Preliminary Results
Lina Maria Carmona, UK

MP–05.05
Serial Change of Sexual Function After Holmium Laser Enucleation of the Prostate: A Short-Term Follow-Up Study
Min Su Jeong, South Korea

MP–05.06
Transurethral Electrovaporization of the Prostate (TUVP) Using the Olympus Button Vaporization Electrode: A Comparative Study
Vikas Agarwal, India

MP–05.07
Injection of Onabotulinumtoxin A in Patients with Benign Prostatic Enlargement Refractory to Standard Medical Therapy: Evaluation of a Single Injection During 24 Months
Tiago Gorgal-Carvalho, Portugal

MP–05.08
Preservation of Ejaculation in Monopolar TUR and Laser Vaporesection of Prostate in the Treatment of Bladder Outlet Obstruction
Christoph Lang, Germany

MP–05.09
Experience of Thulium Laser Vaporesection of Prostate for the Treatment of Benign Prostatic Hyperplasia
Shing-Hwa Lu, Taiwan

MP–05.10
TURis Botton Prostate Resection: Our Preliminary Experience
Francesco Pisanti, Italy
MP–05.11
Francesco Pisanti, Italy

MP–05.12
Gyrus Bipolar TURP and Post-Operative Erectile Function
Francesco Pisanti, Italy

MP–05.13
GreenLight™ HPS Laser Prostatectomy for Chronic Retention of Urine: A Safe and Efficacious Option
Carlo Luigi Augusto Negro, UK

MP–05.14
GreenLight™ HPS Laser 120 W Versus Diode Laser 150W Vaporization of the Prostate: Results of a Prospective, Randomized Study
Gheorghe Nita, Romania

MP–05.15
Long-Term Experience and Risk Factors for Reintervention in Photoselective Vaporisation of the Prostate (GreenLight™)
Ionel Valentin Popeneciu, Germany

MP–05.16
Hybrid LESS Prostatectomy for BPH: A Combined Technique
Pradeep Rao, India

MP–05.17
The Prostatic Urethral Lift: A New, Minimally Invasive Therapy for BPH
Claus G. Roehrborn, USA

MP–05.18
A Prospective Multi-Center Study of the Efficacy and Safety of the AMS Green Light Laser HPS in Men with Male LUTS and Clinical BPH
Claus G. Roehrborn, USA

MP–05.19
Identification of Incontinence Risk Factors After Holmium Laser Enucleation of the Prostate (HoLEP)
Bernhard Schoensee, Germany

MP–05.20
The Influences of Intravesical Prostatic Prominence on Changes of Voiding and Storage Symptoms After Bipolar Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia
Hong Seok Shin, South Korea

MP–05.21
Patients with Prostate Cancer Have a Higher Incidence of Venous Thromboembolic Events Following TURP Than Patients with Clinical BPH
Helen Simpson, UK

MP–05.22
Holmium Laser Enucleation Prostate (HoLEP) Is Time-consuming – Myth or Reality?
Anil Kumar Varshney, India
MP–05.23
Does Defining the Limits of Dissection Proximal To External Sphincter Prior To Enucleation of Prostate with Holmium Laser Minimize Incidence of Stress Urinary Incontinence (SUI)?
Anil Kumar Varshney, India

MP–05.23
Does Defining the Limits of Dissection Proximal To External Sphincter Prior To Enucleation of Prostate with Holmium Laser Minimize Incidence of Stress Urinary Incontinence (SUI)?
Anil Kumar Varshney, India

1515–1645

MODERATED POSTER SESSION 6
Renal Transplantation

Chairs: Hassan Abol-Enein, Egypt
Nasser Simforoosh, Iran

Room: Salon 15/16

MP–06.01
Real-Time Vascular Imaging Technique Using Indocyanine Green in Kidney Transplantation
Naoko Arichi, Japan

MP–06.02
Standard vs Variant Vascular Procedures in Renal Transplantation
Dragoslav Basic, Serbia

MP–06.03
Urological Complications After Renal Transplantation
Mihai Christian Harza, Romania

MP–06.04
Management of Localized Prostate Cancer by Retropubic Radical Prostatectomy in Kidney Recipients
Julien Fumey, France

MP–06.05
Learning Curve in Laparoscopic Donor Nephrectomy: Outcomes of an Experienced vs. an Inexperienced Laparoscopic Surgeon
Frank Friedersdorff, Germany

MP–06.06
Management of Urolithiasis in Kidney Donors
Arvind Ganpule, India

MP–06.07
Utility of Multidetector Computerized Tomography (MDCT) Angiography for Preoperative Evaluation of Vascular Anatomy in Living Renal Donors
Arvind Ganpule, India

MP–06.08
Is Graft Outcome Affected by Donated Kidney Volume Following Live Donor Kidney Transplantation?
Ravindra Sabnis, India

MP–06.09
The Impact of Donor Factor on Graft Function in Kidney Transplantation from Diseased Donor After Cardiac Death
Takeshi Ishimura, Japan

MP–06.10
Contemporary Experience with Renal Autotransplantation
Venkatesh Krishnamurthi, USA
MP–06.11
Contemporary Vascular Bypass Approach for Treatment of Retroperitoneal Tumors with Inferior Vena Cava and Atrial Extension: A 20-Year Single Institution Experience
Venkatesh Krishnamurthi, USA

MP–06.13
A Comparison of the Outcomes of Renal Transplantation from Heart-Beating and Non-Heart-Beating Cadaveric Donors Who Present Irreversible Cardiac Arrest Occurring Outside the Hospital
Federico De La Rosa Kehrmann, Spain

MP–06.14
Non-Heart-Beating Donors (Type I and II Maastricht Category): Results of Our Program
Federico De La Rosa Kehrmann, Spain

MP–06.16
Preoperative eGFR May Be the Sole Predictive Factor for Stage 3 Chronic Kidney Disease After Nephrectomy in Japanese Patients
Kazuhiro Nagao, Japan

MP–06.17
Dynamic Renogram and Urological Complications in Kidney Transplant: Is There a Role? Results of a Preliminary Monocentric Retrospective Study
Carlo Luigi Augusto Negro, UK

MP–06.19
A New Protocol for Immunoabsorption for ABO-Incompatible Kidney Transplantation
Chris Protzel, Germany

MP–06.20
Influence of Advanced Donor Age on the Evolution of Renal Transplantation
Nabil Mhiri, Tunisia

MP–06.21
Does Kidney Transplantation with Multiple Arteries Affect Graft Survival?
Nabil Mhiri, Tunisia
MENSTRUAL POSTER SESSION 7
Infertility/Male Sexual Dysfunction
Chair: Vipan Bhatia, UAE
Room: Hall 8

MP–07.04
Pharmacological Treatment of Non-Obstructive Azoospermia Increases Rates of Sperm Availability for IVF/ICSI
Alayman Hussein, Egypt

MP–07.06
Effect of Vardenafil Treatment in the Plasma Proteome of Patients with Erectile Dysfunction and Diabetes Mellitus
Ricardo Brime Menéndez, Spain

MP–07.09
The Study of Cavernous Arteries in Virtual Cavernoscopy
Kazuyoshi Izumi, Japan

MP–07.10
3D Cavernosography and Virtual Cavernoscopy With Low Pressure Dynamic Infusion Cavernosometry and Cavernosography
Yasuo Kawanishi, Japan

MP–07.11
Efficacy and Safety of Combination Therapy with Mirodenafil and Alpha-Blocker for Benign Prostatic Hyperplasia Accompanied by Erectile Dysfunction: A Multicenter, Open-Label, Prospective Study
Jung Ki Jo, South Korea

MP–07.14
Erectile Dysfunction and Metabolic Syndrome: Two Entities Related to Each Other
Clara Lahoz García, Spain

MP–07.15
Evaluation of Effect of Photoselective Vaporization of Prostate on Sexual Function in a Prospective Study: A Single Centre Experience of 150 Patients
Nayan Mohanty, India

MP–07.16
Can Sexual Bother After Radical Prostatectomy Be Predicted Pre-Operatively?
E. Andreas Svaboe Steinsvik, Norway

MP–07.17
The Impact of Statins in Erectile Dysfunction
Luis Figueiredo, Portugal

MP–07.18
Original Technique for Penile Curvature without Circumcision: Ten Years’ Experience
Giovanni Alei, Italy
1515–1645
MODERATED POSTER SESSION 7
▶ Infertility/Male Sexual Dysfunction

**MP–07.19**
Our Experience with Penile Girth Augmentation Through Acellular Porcine Dermal Grafts: A 69–Patient Series
Giovanni Alei, Italy

**MP–07.20**
Reconstruction of Iatrogenic Trapped Penis by Genital Skin Flaps
Vladimir Kojovic, Serbia

**MP–07.21**
Prospective Long-Term Follow-Up of Patients with Chronic Orchialgia After Double-Blind, Placebo-Controlled Blockades of the Spermatic Cord Followed By Microsurgical Denervation
Robert Oomen, The Netherlands

1515–1630
VIDEO SESSION 3:
▶ Trauma & Reconstruction

Room: Hall 10

**VID–03.01**
Robotics Repair of Vesico-Vaginal Fistula Using a Pedicled Peritoneal Flap
Gianluca D’Elia, Italy

1515–1525

1525–1535

**VID–03.02**
Vesico-Vaginal Fistula Repair: Our Robotic Technique
René Sotelo, Venezuela

1535–1545

**VID–03.03**
Robotic Repair of Complex Vesico-vaginal Fistulae
René Sotelo, Venezuela

1545–1555

**VID–03.04**
Surgical Treatment of Iatrogenic Recto-Urinary Fistula: York-Mason Technique
Pedro Bargão, Portugal

1555–1605

**VID–03.05**
The Reconstruction of a Completely Destroyed Urethra from the Sphincter up to the Meatus by the Use of Buccal Mucosa Graft
Jörn Beier, Germany
1605–1615
VID–03.06
Treatment of Recto-Urethral Fistula After Radical Prostatectomy with Gracilis Muscle Flap
Jose María Caballero Gine, Spain

1615–1625
VID–03.07
Hybrid Minimally Invasive Oral Mucosal Graft Urethroplasty for Pan Anterior Urethral Strictures
Amlesh Seth, India

1645–1800
SPONSORED SYMPOSIA

1645-1730
Recordati

► LUTS/BPH: The Clinical Advantages of the Novel Alpha Blocker Silodosin

1645–1650
Introduction
Francesco Montorsi, Italy

1650–1705
Clinical Case 1
Francesco Montorsi

1705–1720
Clinical Case 2
Matthias Oelke, Germany

1720–1730
Discussion and Conclusions
Francesco Montorsi
Matthias Oelke

1645–1800
prIME Oncology

► Evaluating the Current Therapeutic Landscape for Advanced Prostate Cancer

A prIME Oncology Symposium supported by Dendreon Corporation

Chair: Cora Sternberg, Italy

1645–1650
Welcome and Introduction
Cora Sternberg

1650–1705
Examining the Issues and Unmet Needs in the Treatment of Advanced Prostate Cancer
Cora Sternberg

1705–1725
Integration of Newly Approved Therapies into the Continuum of Care for Advanced Prostate Cancer
Thomas Powles, UK

1725–1745
What Are the Promising Novel Strategies on the Horizon in Advanced Prostate Cancer?
Karim Fizazi, France

1745–1800
Importance of the Multidisciplinary Team in Prostate Cancer: The Urologist’s Perspective
Peter Mulders, The Netherlands

1800
Concluding Remarks and Adjourn
Cora Sternberg
1800–2000

**SIU WORLD FORUM FOR PATIENTS: BENIGN PROSTATIC HYPERPLASIA (BPH)**
Chair: Rainer Kuntz

Room: ICC Lounge

This session will be conducted in German.

1900–2300

**SIU OKTOBERFEST NIGHT**

Berlin Station
UNMODERATED POSTER SESSION 1

Room: Exhibit Hall

Adrenal, Kidney & Ureter; Assessment of LUT/LUTD
Incl. Urodynamics; Basic Science; Bladder Cancer;
Female Urology; History; Imaging/Radiology;
Infections & Inflammatory Diseases; Infertility;
Kidney & Ureteral Cancer

UP–01.001
Effect of Haemodyalisis on Serum Concentration of
Nitric Oxide in Patients with End-Stage Renal Disease
Hajrudin Spahovic, Bosnia and Herzegovina

UP–01.002
The Tip-of-12th Rib Flank Incision for Nephron-
Sparing Renal Tumor Resection
Matei Andreoiu, USA

UP–01.003
The Indication and Limit of Laparoscopic
Adrenalectomy for Pheochromocytoma
Hirofumi Izaki, Japan

UP–01.004
Utilization of Allium Ureteral Stent in the Endoscopic
Treatment of Ureteral Stenosis: Our Experience and
Preliminary Results
Mariarita Salvitti, Italy

UP–01.005
Endovascular Management of Hemorrhagic
Complications After Percutaneous Nephrolithotomy
George Daniel Radavoi, Romania

UP–01.006
Clinical and Pathological Analyses of Adrenal
Lipomatous Tumors: Experience with 51 Cases in
China
Fu-Kang Sun, China

UP–01.007
Is the Short-Term Outcome of Transurethral Resection
of the Prostate Affected by Preoperative Degree of
Bladder Outlet Obstruction by Urodynamic Study?
Jeong Man Cho, South Korea

UP–01.008
Application of the SHEFPAT Questionnaire to Assess
Patient Feedback in a One-Stop Haematuria Clinic
Edmund Chedgy, UK

UP–01.009
Analysis of the Pressure-Flow Study in Weak Detrusor
Patients with Benign Prostatic Hypertrophy: How Do
We Manage?
Osamu Ishizuka, Japan

UP–01.010
Chronic Urinary Retention in Men: Can We Define It?
Carlo Luigi Augusto Negro, UK

UP–01.011
The Value of MELD Score in Predicting the Outcome of
Patients with Liver Cirrhosis Undergoing a Urological
Procedure
Cristian Surcel, Romania

UP–01.012
Sonication of Suprapubic Catheters: Frequency and
Characteristics of Colonizing Bacterial Biofilms
Gernot Bonkat, Switzerland
**UP–01.013**
On Functional Vesical Disturbances After Toxicants
Ulrich Haerlin, Germany

**UP–01.014**
Effect of Testosterone Ablation on Cardiac Muscle Electrophysiology: A New Insight to Side Effects Caused by Castration
Haluk Kulaksizoglu, Turkey

**UP–01.015**
Smooth Muscle Differentiation of Purified Human Skeletal Muscle Derived Cells for Urological Regeneration
Shing-Hwa Lu, Taiwan

**UP–01.016**
Changes in Intracorporeal Temperature of Tissue Pad After Using Ultrasonically Activated Devices
Teruyuki Ogawa, Japan

**UP–01.017**
Damage to the Urinary Tract Induced by Oral Illegal Ketamine in a Rat Model
Azad Hassan Abdul Razack, Malaysia

**UP–01.018**
Linear Correlations in Chromosomal-Based Gene Expression in Urinary Bladder Cancer
Ioannis Boulalas, Greece

**UP–01.019**
Identification of Cisplatin Resistance-Associated Proteins in Bladder Cancer by Two-Dimensional Gel Electrophoresis and Mass Spectrometry
Tadahiko Kikugawa, Japan

**UP–01.020**
Superoxide Dependant Differential Regulation of ERK Signaling Controls the Metastatic Potential of Human Bladder Cancer Cells
Badar Mian, USA

**UP–01.021**
The Role of Actinin–4 in Bladder Cancer Metastasis
Hiroyoshi Nakatsuji, Japan

**UP–01.022**
Increased Expression of the Oncogenic KLF6–SV1 in Bladder Cancer
Nishihara Chikako, Japan

**UP–01.023**
Stabilization of Urothelial Primary Culture and Chemosensitivity Assay in Transitional Cell Carcinoma
Antonio Luigi Pastore, Italy

**UP–01.024**
The Histone Deacetylase Inhibitor Valproic Acid Delays Cell Cycle Progression of Human Bladder Cancer Cells in vitro
Stefan Vallo, Germany

**UP–01.025**
Expression and Function Role of DNA Methyltransferase 1 in Human Bladder Cancer
Chun-Te Wu, Taiwan

**UP–01.026**
Narrow Band Imaging (NBI) Assisted TURBt: Does It Improve Detection and Treatment Rates?
Paulo Azinhais, Portugal
UP–01.029
Can Transrectal Ultrasound Be as Useful in Bladder Cancer as in Prostate Cancer?
Erkan Erkan, Turkey

UP–01.030
A Prospective Multi-Center Study of a Novel Urinary Diagnostic Test for the Detection of Transitional Cell Carcinoma in Patients with Gross Hematuria
Peter Gilling, New Zealand

UP–01.031
Does Atypia in Urine Cytology Predict Malignancy?
Cheong Yu, China

UP–01.032
NMP22 Bladder Check Tests Urine Cytology for Detecting NMIBC
Mariarita Salvitti, Italy

UP–01.033
Diagnostic Value of a Urine Based Tumor Marker for Screening Lower Urinary Tract in Low-Risk Patients with Asymptomatic Microscopic Hematuria
Hakki Ugur Ozok, Turkey

UP–01.034
Expression of CD147 in Patients with Non-Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder: Utility as a Marker of Presence of Tumour
Amlesh Seth, India

UP–01.035
Virtual Cystoscopy (Pneumo-Cystoscopy): Its Utility in the Prospective Evaluation of Bladder Tumor
Iqbal Singh, India

UP–01.036
Urinary Protein Patterns Discriminate Bladder Cancer Patients from Healthy Subjects
Derya Tilki, Germany

UP–01.037
The Value of Asymptomatic Microscopic Hamaturia for Diagnosis of Urologic Malignancies
Byung Hoon Kim, South Korea

UP–01.038
Urothelial Tumoral Disease: “En Bloc” Nephroureterectomy, Cystoprostatectomy and Urethrectomy
Cristian Surcel, Romania

UP–01.039
Chemoradiotherapy as a Bladder Sparing Treatment in Muscle Invasive Bladder Cancer (MIBC), Long-Term 16 Years Follow-Up: Experience of a Single Institution
Giuseppe Morgia, Italy

UP–01.040
Quality of Life in Patients with Bladder Cancer After Radical Cystectomy: Are There Changes?
Cristian Vasile Casu, Spain

UP–01.041
Justification for Radical Cystectomy in Octogenarians
Hector Garde, Spain

UP–01.042
A Retrospective Evaluation of Radical Cystectomy Versus Bladder Preservation Therapy in Patients 80 Years Old and Older with Muscle-Invasive Bladder Cancer
Roman Mayr, Italy
UP–01.043
Postoperative Recovery of Bowel Function After Extraperitoneal Retrograde Total Cystectomy for Patients with Invasive Bladder Cancer
Takehiko Segawa, Japan

UP–01.044
Ileal Orthotopic Bladder Replacement Without Stenting of Ureterointestinal Anastomosis: 10 Years’ Observation
Pavo Wozniak, UK

UP–01.045
Experience of Gemcitabine and Nedaplatin for Unfit Patients with Advanced Urothelial Cancer
Kazuya Mikami, Japan

UP–01.046
Intravesical Bacillus Calmette-Guérin Immunotherapy: The Experience of the Centro Hospitalar De Coimbra Urology Department
Paulo Azinhais, Portugal

UP–01.047
Cathepsin B in the Diagnosis of Transitional Cell Carcinoma of the Bladder
Pavel Dusek, Czech Republic

UP–01.048
Fast Track in Urology: Cystectomy Results from a General Hospital Provider
Anne Kiel, Germany

UP–01.049
pT0 After Radical Cystectomy: A Sign of Improved Outcome?
Peter Kronenberg, Portugal

UP–01.050
Analysis of Perioperative and 5–Year Oncological Outcome of 200 Cases of Open Radical Cystectomy: A Single Centre Experience
Nayan Mohanty, India

UP–01.051
Symptom Analysis for Patients Undergoing Mitomycin Hyperthermia Treatment
Saheel Mukhtar, UK

UP–01.052
Outcome of Treatment of High-Risk Non Muscle-Invasive Bladder Cancer with Mitomycin Hyperthermia with a Minimum Follow-Up of Two Years
Saheel Mukhtar, UK

UP–01.053
Is the Presence or Absence of Tumour Necrosis a Significant Predictor of Survival in Bladder Cancer?
Tahir Qayyum, UK

UP–01.054
Implementation of a Standardized Uro-Oncology Perioperative Protocol
Alexander Rawlinson, UK

UP–01.055
The Effect of Laparoscopic Radical Cystectomy on Postoperative CRP Level: Comparison with Open Radical Cystectomy
Fuminori Sato, Japan

UP–01.056
Improving Recovery After Cystectomy: Can Length of Stay Be Shortened?
Karan Wadhwa, UK
UP–01.057
Sub Staging of T1 Bladder Cancer: Relationship of Progression and Recurrence to Depth of Invasion
Irfan Ahmed, Pakistan

UP–01.058
Risk Stratification in High Risk Superficial Bladder Cancer: Does Imaging Have a Role?
Muhammad Rafiq, UK

UP–01.059
Evaluation of the Need for Transurethral Biopsy at First Follow-Up After Intravesical BCG Therapy for Superficial Bladder Cancer
Khaled Mursi Hammoud, Egypt

UP–01.060
Clinical Significance of Immediate Urine Cytology After Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer
Sang Deuk Kim, South Korea

UP–01.061
Ablative Efficacy of Sequential Intravesical Chemotherapy Using Gemcitabine and Mitomycin C for Superficial Bladder Carcinoma
Santosh Kumar, India

UP–01.062
Validation of EAU Guideline Risk Classification for Japanese Non-Muscle Invasive Bladder Cancer
Hideyasu Matsuyama, Japan

UP–01.063
Outcome of Patients Affected by Papillary Urothelial Neoplasm of Low Malignant Potential: Single Centre Cohort
Francesco Pisanti, Italy

UP–01.064
GreenLight 30 W and Bladder Cancer: Is It a Good Option in Elderly High Risk Patients? Preliminary Results of a Monocentric Prospective Study
Carlo Luigi Augusto Negro, UK

UP–01.065
Randomized Biopsy in the Diagnosis and Treatment of Superficial Bladder Cancer
Kairat Nitkaliyev, Kazakhstan

UP–01.066
Prognostic Factors in a Prospective Series of Non-Muscle-Invasive Bladder Cancer Treated with BCG
Paolo Gontero, Italy

UP–01.067
How Do Tumour Characteristics Influence Outcome Regarding Different Conservative Treatment Options for Non-Muscle Invasive Bladder Cancer T1G3?
Joan Palou, Spain

UP–01.068
Intravesical Non-alkalinized Lidocaine Instillation for Interstitial Cystitis/Bladder Pain Syndrome Patients
Teiichiro Aoyagi, Japan

UP–01.069
Does Transobturator Tape Procedure Affect Walking? A Prospective Study with 3D Computerized Gait Analysis
Emin Aydur, Turkey

UP–01.070
Assessment of Structural Changes and Complications in Obturator Fossa Due to Outside-In Transobturator Tape Procedure Using MRI
Emin Aydur, Turkey
UP–01.071
Surgical Management of the Complications Associated with Transobturator Sling Procedures
Gheorghe Bumbu, Romania

UP–01.072
Clinical Impact of Body Mass Index on the Outcome of the SPARC-Sling System for the Treatment of Female Stress Urinary Incontinence
Katja Fischereder, Austria

UP–01.073
Bladder Endometriosis: Clinical, Diagnostic and Therapeutic Aspects
Dario Garcia-Rojo, Spain

UP–01.074
Recurrent Bacterial Cystitis, Bladder Instillation with a Combined Solution of Sodium Halurate and Chondroitin Sulfate (IALURIL): One Year of Follow-Up
Barbara Cristina Gentile, Italy

UP–01.075
Tension-Free Vaginal Tape Versus Transobturator Vaginal Tape in Management of Female Stress Urinary Incontinence Long-Term Follow-Up: Which to Choose?
Khaled Mursi Hammoud, Egypt

UP–01.076
Use of Vaginal Flap Neighbourhood for Improving Continence in Cervical Fistula, Cervico-Urethral and Urethral-Vaginal Obstetrical Origin
Mekeme Mekeme Junior Barthelemy, Cameroon

UP–01.077
Impact of Intravesical Hyaluronic Acid and Chondroitin Sulphate on Bladder Pain Syndrome/Interstitial Cystitis
Daniele Porru, Italy

UP–01.078
Randomized Trial Comparing a Conventional Mid-Urethral Sling and Two Single-Incision Slings: Mid-Term Evaluation
Alexandre Resende, Portugal

UP–01.080
Comparing Results of Two Types of Transobturator Tape (TOT), In-Out Technique, Used in Women with Stress Urinary Incontinence
Cristian Surcel, Romania

UP–01.081
Pelvic Organ Prolapse on the Internet: Similarities and Differences Between English-Speaking Countries and Japan
Takeya Kitta, Japan

UP–01.082
Single Incision Technique Using RSD-Ney for Insertion of Titanium Coated Extra-Light Mesh Yields More Favourable Clinical Outcomes in Patients Suffering from Vaginal Vault Prolapse Resulting from Previous Pelvic Tumor Surgery
Joerg Neymeyer, Germany

UP–01.083
Application of Small Intestinal Submucosa Graft in Repair of Complicated Vesico-vaginal Fistula: Pilot Study
Mohamed Rasheed Taha, Egypt
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>UP-01.085</td>
<td>Urethral Catheterization: An Ancient Art</td>
<td>Rajendar Marri, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.086</td>
<td>High-Intensity Focused Ultrasound in Urology: An Amazing Journey of 15 Years of Clinical Use</td>
<td>Hemant Nemade, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.087</td>
<td>From Bats and Ships to Prostate and Kidneys: A Brief History of Ultrasound in Urology</td>
<td>Hemant Nemade, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.088</td>
<td>History of Aphrodisiacs: From Venus to Viagra</td>
<td>Sanjay Rajpal, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.089</td>
<td>Mitomycin-C: Historical Aspects of the Discovery of Most Commonly Used Chemotherapy Agent in Urology</td>
<td>Hemant Nemade, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.090</td>
<td>A Historical Approach to the Causes of Cancer</td>
<td>Apostolos Rempelakos, Greece</td>
<td>Greece</td>
</tr>
<tr>
<td>UP-01.091</td>
<td>Byzantine Surgical Techniques for Penile Diseases: Descriptions of the Eminent Surgeon Oribasius (4th C. AD)</td>
<td>Apostolos Rempelakos, Greece</td>
<td>Greece</td>
</tr>
<tr>
<td>UP-01.092</td>
<td>Practice of Paedo-Urology in Byzantine Constantinople</td>
<td>Apostolos Rempelakos, Greece</td>
<td>Greece</td>
</tr>
<tr>
<td>UP-01.093</td>
<td>Satyriasis and Priapism in Hellenistic Medical Literature</td>
<td>Apostolos Rempelakos, Greece</td>
<td>Greece</td>
</tr>
<tr>
<td>UP-01.094</td>
<td>Ithyphallism in Ancient Greek Art</td>
<td>Apostolos Rempelakos, Greece</td>
<td>Greece</td>
</tr>
<tr>
<td>UP-01.095</td>
<td>The Second Oldest Urological Department in Europe Is Over 90 Years Old: An Historical Review</td>
<td>Imre Romics, Hungary</td>
<td>Hungary</td>
</tr>
<tr>
<td>UP-01.096</td>
<td>The Reformator Martin Luther’s Stone Disease During His Time at Wartburg Castle</td>
<td>H. Matthias Weber, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>UP-01.097</td>
<td>The Impact of the Degree of Spongiofibrosis on Surgical Decision Making in Male Short Anterior Urethral Stricture</td>
<td>Alaa Elrifai, Egypt</td>
<td>Egypt</td>
</tr>
<tr>
<td>UP-01.098</td>
<td>Is Routine Diuresis Renography Indicated After Pyeloplasty?</td>
<td>Rami Issa, UK</td>
<td>UK</td>
</tr>
<tr>
<td>UP-01.099</td>
<td>Contrast-Enhanced Ultrasound (CEUS) in Imaging of Renal Space Occupying Lesion: What Is its Role?</td>
<td>Vikas Agarwal, India</td>
<td>India</td>
</tr>
</tbody>
</table>
UP–01.100
Transrectal Doppler Ultrasound Imaging of Cowper’s Bulbourethral Glands: A Preliminary Report
Adam Golab, Poland

UP–01.101
Clinical Value of Diffusion-Weighted Magnetic Resonance Imaging for the Detection of Prostate Cancer
Yoshio Maki, Japan

UP–01.102
Improved Image Assessment for Intravenous Excretion Urography by Different Speed Injections of Contrast Medium
Nobuyuki Nakamura, Japan

UP–01.103
Urologists’ Best Friend, “Mobile Urological Bag” (MUB): A Lot of Technology in Little Space
Joerg Neymeyer, Germany

UP–01.104
Emergency Percutaneous Nephrostomy in Supine Position by Urologist Under Local Anesthesia
Ada Ng, China

UP–01.105
Imaging for Acute Loin Pain Suggestive of Renal Colic: Are We Detecting More Clinically Significant Extra-Renal Findings Since the Emergence of CT KUB?
Rebecca Nicholas, UK

UP–01.106
Clinical Value of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in Urologic Cancers
Toru Nishiyama, Japan

UP–01.107
Retroperitoneal Dedifferentiated Liposarcoma with Production of Granulocyte Colony-Stimulating Factor (G-CSF) Accompanied by Spontaneous Rupture: PET/CT Imaging of a G-CSF-Producing Tumor
Shin Ohira, Japan

UP–01.108
Transrectal Ultrasonography in Assessing Vesico-urethral Anastomosis After Radical Prostatectomy. Can Cystography Be Avoided?
Giacomo Perugia, Italy

UP–01.111
A Series of Colo-Vesical Fistula Presenting as Recurrent Urinary Tract Infection
Shivadeo Bapat, India

UP–01.112
Short-Term Success Rates of Ureteral De-obstruction in Patients with Primary Retroperitoneal Fibrosis Undergoing Medical or Surgical Treatment
Hannes Cash, Germany

UP–01.113
A Randomized Single-Blind Comparison of the Cost-Effectiveness of the High-Level Disinfectants Tristel Fuse (Chlorine Dioxide) and Cidex Opa (Ortho-Phthaldehyde) for Use with Flexible Cystoscopes
Peter Gilling, New Zealand

UP–01.114
Wunderlich Syndrome: A Rare Complication of Renal Angiomyolipoma
Jan Breza, Slovak Republic
UP–01.115  
Effect of Urethral Catheter in Infection Rates After Prostate Biopsy  
Gokhan Koc, Turkey  

UP–01.116  
Does Diabetes Mellitus Affect the Infection Rates after Prostate Biopsy?  
Gokhan Koc, Turkey  

UP–01.117  
Masks of Kidney Tuberculosis  
Ekaterina Kulchavenya, Russia  

UP–01.118  
Urogenital Tuberculosis in Siberia  
Ekaterina Kulchavenya, Russia  

UP–01.119  
Laser Surgery in Complex Therapy of Urogenital Tuberculosis  
Ekaterina Kulchavenya, Russia  

UP–01.120  
Chronological Age Is Not an Independent Predictor of Clinical Outcomes after Radical Nephroureterectomy  
Shahrokh F. Shariat, USA  

UP–01.121  
Unexpected Multidrug Resistance of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Urine Samples: A Single Center Study  
Martin Schmudermaier, Austria  

UP–01.122  
Trends of Increasing Resistance of E.Coli and Non Significant Changes in Extended Spectrum Beta-Lactamase (ESBL) E.Coli in Urinary Tract Infections  
Martin Schmudermaier, Austria  

UP–01.123  
Risk Factor for Severe Infection in Patients with Urosepsis  
Yuzo Nakano, Japan  

UP–01.124  
About Isolation Sites, and Antimicrobial Agents Susceptibility of Extended-Spectrum Beta Lactamase-Producing E. Coli in My Hospital  
Hitoshi Oh-Oka, Japan  

UP–01.125  
The Scroto-Perineal Necrotizing Fasciitis: 30 Cases, 10 Years’ Experience  
Giandomenico Passavanti, Italy  

UP–01.126  
Impact of Urinalysis Results on Flexible Cystoscopy Lists  
Niyukta Thakare, UK  

UP–01.127  
Management of Fournier’s Gangrene: A Case-Series of 20 Patients  
Mee-Na Nina Wischnack, Germany  

UP–01.128  
The Role of Nitric Oxide Synthase Expression in the Pathogenesis of Varicocele  
Erkan Erkan, Turkey
UP–01.129
Do Varicocele and Varicose Veins Have Any Relation? A Prospective Work-Up
Hasan Soydan, Turkey

UP–01.130
Risk Factors for Developing Pain in Normospermia Varicocele Patients
Shiou-Sheng Chen, Taiwan

UP–01.131
Testicular Azoospermia: FSH Impact Factors on Testicular Biopsy Score for MESA, TESE and ICSI
Shalva Chovelidze, Georgia

UP–01.132
Ligation of the Dilated External Spermatic Veins Improves the Outcome of Microscopic Subinguinal Varicocelectomy
Tarek Abdelbaky, Egypt

UP–01.133
Surgery or Embolization for Varicoceles in Subfertile Men?
Pedro Moreira, Portugal

UP–01.135
Treatment of Post-Varicocelectomy Persistent Oligozoospermia with Oral Tamoxifen Citrate: A Randomized, Placebo-Controlled Study
Mohamed Abdel Aziz, Saudi Arabia

UP–01.136
Which Men Have More Likelihood of Success with a Testicular Biopsy?
Luis Figueiredo, Portugal

UP–01.137
IVF Using Surgically Obtained Spermatozoa May Be Preferred as the Primary Treatment Modality in Cases of Obstructive Azoospermia
M.A. Fischer, Canada

UP–01.139
The Role of Surgical Ligation of the Left Internal Spermatic Vein for the Management of Infertile Men with Subclinical Left Varicocele
Alexandros Theodosiou, Greece

UP–01.140
The Prognostic Value of C-Reactive Protein in Regard to Cancer-Specific and Overall Survival in Clear Cell Renal Cell Cancer Patients May in Part Be Explained by Vascular Endothelial Growth Factor
Gigja Gudbrandsdottir, Norway

UP–01.141
Elevated Preoperative Serum Levels of MCP-1 (CCL2) is a Prognostic Marker for Cancer-Specific and Overall Survival in Renal Cell Cancer Patients
Gigja Gudbrandsdottir, Norway

UP–01.142
Impact of CD133 Expression in Renal Cell Carcinoma
Walter Da Costa, Brazil

UP–01.143
Loss of the Tight Junction Protein Claudin-7 Correlates with Carcinogenesis and Grading of the Clear Cell Renal Cell Carcinoma
Mohamed Gadelmoula, Saudi Arabia
UP–01.144
Prognostic Value of MAGE A9 in Renal Cell Carcinoma
Gencay Hatiboglu, Germany

UP–01.145
Coexpression of Neural Cell Adhesion Molecule and Fibroblast Growth Factor Receptor 1 in Renal Cell Carcinoma
Cane Tulic, Serbia

UP–01.146
Identification of Potential Prognostic Markers with Gene Expression Analysis in Clear Cell Renal Cell Carcinoma
Matthias Maruschke, Germany

UP–01.147
Accuracy of Conventional Pathologic Predictive Factors in Histological Subtype Chromophobe Renal Cell Carcinoma
Joan Palou, Spain

UP–01.148
E2EPF as an Ubiquitin Carrier Protein Plays a Role in the Cancer Genesis of Papillary Renal Cell Carcinoma
Frederik Roos, Germany

UP–01.149
Immunophenotype, Differentiation Capacity and Tumor Promoting Potential of Renal Cell Carcinoma-Derived Mesenchymal Stem Cell-Like Stromal Cells
Rüdiger Sorg, Germany

UP–01.150
Impact of Body Mass Index and Weight Loss on Cancer-Specific and Overall Survival in Patients with Surgically Resected Renal Cell Carcinoma
Sabine Brookman-May, Germany

UP–01.151
María Del Carmen Cano García, Spain

UP–01.152
Renorrhaphy in Partial Nephrectomy: What Should We Use?
Somita Sarkar, UK

UP–01.153
Accuracy of Multi-Detector Computed Tomography (MDCT) in Staging of Renal Cell Carcinoma (RCC): Analysis of Risk Factors for Mis-staging and its Impact on Surgical Intervention
Mohammed Hassan, Egypt

UP–01.154
Bosniak IIF and III Complex Renal Cysts: Radiological and Clinical Outcomes
Muhammad Elmussareh, UK

UP–01.155
Correlation Between B7-H1/H3 Expression, Survival and Pathologic Parameters in Renal Cell Carcinoma Patients
Thomas Gutschi, Austria

UP–01.156
Reassessing the 2009 AJCC TNM Staging System for Renal Cell Carcinoma with Regard to Lymph Node Metastasis
Jumpei Iizuka, Japan

UP–01.157
Metastatic Renal Cancer in the Targeted Therapy Era: The Sherbrooke Experience
Michel Carmel, Canada
UP–01.158
Metanephric Adenoma: Unusual Renal Neoplasm, 2
Case Reports
Paulo Azinhais, Portugal

UP–01.159
Prognostic Factors and Survival of Renal Cell
Carcinoma in Japanese Patients
Yoshiyuki Miyaji, Japan

UP–01.160
Long-Term Follow-Up Is Necessary for Patients
Presenting with pT1 and pT2 Renal Cell Carcinoma
Sebastian Nestler, Germany

UP–01.161
Laparo-Endoscopic Single-Site Partial Nephrectomy:
Report of Two Initial Cases
Hoang Nguyen Phuc Cam, Vietnam

UP–01.162
Recurrence Pattern in Patients with Locally Advanced
Renal Cell Carcinoma (LARCC): Implications of
Clinico-Pathologic Variables
Wael Sameh, Egypt

UP–01.163
T3 Renal Cell Carcinoma: Has the TNM Classification
(7th Version) Got It Right?
Somita Sarkar, UK

UP–01.164
Serum Cystatin C: A Marker of Early Kidney Function
Damage After Tumor Nephrectomy?
Marianne Schmid, Germany

UP–01.165
Examination for Hyperuricemia after Operations of
Renal Cancer and Renal Pelvic Cancer
Morito Sugimoto, Japan

UP–01.166
Risk Factor of Hyperuricemia After Nephrectomy
Morito Sugimoto, Japan

UP–01.167
Successful Improvement of Ambulatory Function
by Direct Decompressive Surgery in Non-Ambulant
Patients with Extradural Spinal Cord Compression
Due to Spinal Metastasis of Renal Cell Carcinoma
Toshio Takagi, Japan

UP–01.168
Incidence of Lymph Node Involvement According to
Pathological T Stage or Tumor Grade in the Urothelial
Carcinoma of the Upper Urinary Tract
Toshio Takagi, Japan

UP–01.169
Impact of the Tumor Enhancement Pattern in
Computed Tomography in Detecting Renal Cell
Carcinoma from Small Renal Masses: Who Really
Requires Biopsy?
Toshio Takagi, Japan

UP–01.171
Age and Gender, Independent Prognostic Factors of
Renal Cell Carcinomas: A Multicenter Study
In Rae Cho, Korea, South

UP–01.172
Metastasis in Renal Cell Carcinoma is Characterized
by a Specific miRNA Signature
Kerstin Junker, Germany
UP–01.173
Impact of Diabetes Mellitus on the Prognosis of Renal Cell Carcinoma
Sascha Pahernik, Germany

UP–01.174
Methylenetetrahydrofolate Reductase Genotype and Haplotype May Be Associated with the Aggressiveness and Prognosis of Clear Cell Renal Cell Carcinoma
Shigeru Sakano, Japan

UP–01.175
The Demography of Renal Cell Carcinoma in Bloemfontein, South Africa: Has it Changed Over the Past 15 Years?
Frederik Claassen, South Africa

UP–01.176
Accuracy of Biopsy in Tumors of Renal Parenchyma Smaller than 4 Centimeters
Dario Garcia-Rojo, Spain

UP–01.177
Renal Mass Qualitative Enhancement Using Cadence Contrast Pulse Sequencing Technology
George Daniel Radavoi, Romania

UP–01.178
Does Multidetector Row Computed Tomography Improve Accuracy in T Staging of Upper Urinary Tract Urothelial Carcinoma?
Toshiaki Tanaka, Japan

UP–01.179
Use of Quantitative Shotgun Proteomics to Identify Fibronectin 1 as a Novel Plasma Biomarker for Clear Cell Renal Cell Carcinoma
Akira Yokomizo, Japan

UP–01.180
Expression of Claudin-1 and 7 in Clear Cell Renal Cell Carcinoma and Its Clinical Significance
Byung Hoon Kim, South Korea

UP–01.181
Laparoscopic Partial Nephrectomy for ≥ cT1b Renal Masses: A New Surgical Paradigm
Ricardo Rendon, Canada

UP–01.182
Tuberous Sclerosis with Cutaneous Phenotype: Clinical Particularities
Cristian Surcel, Romania

UP–01.183
Box Counting Fractal Analysis in the Management of Small Renal Masses
Cristian Surcel, Romania

UP–01.184
Mathematical Models for Estimating the Severity of Postoperative Acute Kidney Injury After Radical Nephrectomy
Cristian Surcel, Romania

UP–01.185
Intermediate Term Follow-Up of a Cohort of 63 Old and Comorbid Patients with Renal Masses Primarily Treated with Observation
Christian Beisland, Norway

UP–01.187
Partial Nephrectomy for Kidney Cancer: Functional Results after First 43 Cases
Tommaso Brancato, Italy
UP–01.188
Laparoscopic Radical Nephrectomy: Initial Experience and Comparison with Experienced Surgeon Perioperative Outcomes
Fernando Cabrera Meiras, Spain

UP–01.189
Impact of Renal Vein Invasion and Fat Invasion in PT3a Renal Cell Carcinoma
Walter Da Costa, Brazil

UP–01.190
The Fuhrman Grading System and CD44: Revisited Themes
Walter Da Costa, Brazil

UP–01.191
Nephron-Sparing Surgery: Treatment of Choice for Localized Renal Cell Cancer?
Jasenko Djovic, Serbia

UP–01.192
Nephroureterectomy for Upper Tract TCC: Can We Predict Outcome?
Somita Sarkar, UK

UP–01.193
Oncological Outcomes of Partial Nephrectomy for Tumors Greater than 4 cm: A 10-Year Systematic Review
Ricardo Rendon, Canada

UP–01.194
Laproendoscopic Single Site (LESS) Radical Nephrectomy and Radical Nephroureterectomy
Arvind Ganpule, India

UP–01.195
Treatment of Metastatic Renal Cell Carcinoma with Sunitinib: 4-Year Experience in Our Department
Tiago Gorgal-Carvalho, Portugal

UP–01.196
Radiofrequency Ablation of Small Renal Cell Carcinoma: Embolization before RFA
Alexey Kalpinskiy, Russia

UP–01.197
Invasive Bladder Tumor Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Masashi Kato, Japan

UP–01.198
Partial Nephrectomy vs Laparoscopic Radical Nephrectomy Renal Function Outcomes
Paulo Azinhais, Portugal

UP–01.199
Nephron-Sparing Surgery in The Treatment of T1b RCC: Our Experience and Review of the Literature
Mariarita Salvitti, Italy

UP–01.200
Oncological Long-Term Results of Elective Nephron-Sparing Surgery versus Radical Nephrectomy for Renal Tumours Larger Than 4 cm
Sherif Mehrallivand, Germany

UP–01.201
Impact of the Primary Tumor in situ on the Response of Metastatic Lesions to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
Masahiro Nozawa, Japan
UP–01.202
Endoscopic Management of Upper Tract TCC: Long Term Follow-Up
Gheorghe Nita, Romania

UP–01.203
Experience in Cryoablation of Small Renal Masses from a Single UK Centre
Hemant Nemade, UK

UP–01.204
Surgery + Intraoperative Radiotherapy + Additive External Beam Radiation: A Promising Option for Treatment ofLocally Recurrent Renal Cell Carcinoma
Markus Riedl, Germany

UP–01.205
Is Obesity an Important Predictor of Outcome in Patients Undergoing Radical Nephrectomy with Concomitant IVC Thrombectomy for Renal Cell Carcinoma
Philippe E. Spiess, USA

UP–01.206
Prognosis and Characteristics of Renal Cell Carcinoma in Hemodyalisis Patients: Comparison Between Unilateral and Bilateral Occurrence
Toshio Takagi, Japan

UP–01.207
Thermal Damage of the Soft Coagulation in Pig’s Kidney
Ota Tomonori, Japan

UP–01.208
Survival Following Nephrectomy for Advanced Renal Cell Tumors with Renal Vein Involvement
Hemant Nemade, UK

UP–01.209
Integrating Robot-Assisted Laparoscopic Partial Nephrectomy to the Robotic Surgery Program: The City of Hope Experience
Bertram Yuh, USA

UP–01.210
Benefits of Embarking on a Robotic Nephroureterectomy Programme for Surgeon and Patient
Rhana Zakri, UK

UP–01.211
Comparison Between the Group Who Showed Pain Relief by Alpha Blocker Agent and the Group Who Did Not in Patients with CP/CPPS
Jung Ki Jo, South Korea
0630–0745

SPONSORED SYMPOSIUM
American Medical Systems

- Panel Discussion: Male Urinary Incontinence
  - Room: ICC Lounge

0630–0642
Introduction and Overview of Male Stress Urinary Incontinence
Kurt McCammon

0642–0655
Patient Selection for Anti-Incontinence Procedures
William Lynch, Australia

0655–0710
AdVance and AdVance XP
Ricarda Bauer, Germany

0710–0725
AUS Tips and Tricks
Michael Metro, USA

0725–0745
Patient Presentations and Question and Answer

0800–1600

LIVE SURGERY FROM CHARITÉ HOSPITAL, BERLIN

This presentation was supported by an unrestricted educational grant from the following: American Medical Systems, Inc., Karl Storz GmbH & Co. Kg.*.

Room: Hall 3

0815-0930
Urethral Reconstruction

0930-1000
Break

1000-1130
Urolithiasis

1130-1230
Break

1230-1400
Renal Surgery

1400-1415
Break

1415-1545
BPH Laser Therapy

*At press time.
0630–0800

INSTRUCTIONAL COURSES IC05–IC09

► IC05: Robotic Partial Nephrectomy
Chair: Craig Rogers, USA

Room: Salon 11/12

0630–0655
Robotic Partial Nephrectomy
Craig Rogers, USA

0655–0720
Robotic Nephroureterectomy and Upper Urinary Tract Reconstruction
Ashok K. Hemal, USA

0720–0740
Establishing a Multiservice Surgical Robotic Program: Essential Elements of Clinical Safety and Financial Success
Surena Matin, USA

0740–0800
Robotic Nephrectomy and Donor Nephrectomy
Jacques Hubert, France

► IC06: Urethral Strictures: Three Ways to Solve Every Stricture (Penile, Panurethral, Bulbar, Traumatic)
Chair: Miroslav Djordjevic, Serbia

Room: Hall 9

0630–0700
Graft Urethroplasty: Is It Always Possible?
Francisco Martins, Portugal

0700–0730
Flap Urethroplasty: Tricks and Traps
Miroslav Djordjevic

0730–0800
Anastomotic Urethroplasty: Challenges and Limits
Allen Morey, USA

► IC07: Laparoscopic Donor Nephrectomy
Chair: Alexander Bachmann, Switzerland

Room: Salon 15/16

0630–0645
LESS and Donor Nephrectomy: Is There Still a Market?
Andre Van der Merwe, South Africa

0645–0700
Laparoscopic Donor Nephrectomy: Better than Open?
Serdar Deger, Germany

0700–0715
Cosmetic Aspects of Live Kidney Donors: Are They Really Important?
Nicole Ebinger Mundorff, Germany

0715–0730
The Advantages of the Transperitoneal Route
Nasser Simforoosh, Iran
0730–0745
Retroperitoneoscopic Donor Nephrectomy: Our Technique and Results
Kazunari Tanabe, Japan

►IC08: Premature Ejaculation
Chair: Ira Sharlip, USA

Room: Salon 17/18

0630–0635
Introduction
Ira Sharlip

0635–0655
Epidemiology of Premature Ejaculation
Ira Sharlip

0655–0715
Genetics of Premature Ejaculation
Marcel Waldinger, The Netherlands

0715–0735
Oral Therapy for Premature Ejaculation
Craig Donatucci, USA

0735–0755
Non-Oral Therapy for Premature Ejaculation
Hossein Sadeghi, USA

0755–0800
Questions and Wrap-up
All

►IC09: Focal Ablative Prostate Therapy
Chair: John F. Ward, USA
Room: Hall 10

0630–0635
Introductory Remarks
John F. Ward

0635–0655
Prostate Biopsy for Patient Selection
John F. Ward

0655–0700
Q&A

0700–0720
Prostate Cancer Imaging (MRI and Histoscanning)
Mark Emberton, UK

0720–0725
Q&A

0725–0745
Targeted Prostate Cancer Ablation: Techniques and Outcomes
Thomas Polascik, USA

0745–0750
Q&A

0750–0800
Panel Discussion with Audience and Closing Remarks
0745–1000

PLENARY 2
Bladder Cancer

Chairs: Patrick Coloby, France  Joachim W. Thüroff, Germany

0745–0755
Clinical Pearls: The Past Year in Review: Oncology
Vijay Sangar, UK

0755–0810
The 2004 WHO Classification of Urothelial Neoplasms Revisited
Ruth Knüchel-Clarke, Germany

0810–0825
Re-TURB: Why, When and How?
Harry Herr, USA

0825–0840
BCG for CIS: What Is Proven After 30 Years?
Maurizio Brausi, Italy

0840–0925
High Grade pT1 BCA: How Early Cystectomy?
Moderator: Mark Soloway, USA
Panelists: Hassan Abol-Enein, Egypt  Richard Hautmann, Germany  Wiking Månsson, Sweden  Juan Palou, Spain  Vito Pansadoro, Italy

0925–0940
Neoadjuvant Chemotherapy
Cora Sternberg, Italy

0940–1000

Pro-Con Debate: Lymph Node Dissection Is Curative in Urological Cancers vs. Staging Only
Moderator: Arturo Mendoza Valdés, Mexico
Curative
Urs E. Studer, Switzerland
Staging Only
Joachim W. Thüroff, Germany

1000–1130

SIU CONGRESS 1914 IN BERLIN:
UROLOGY A CENTURY AGO

Chairs: Alain Jardin, France  Dirk Schultheiss, Germany

0925–1130
Cells, Microbes and Salvarsan in Berlin: A Medical Metropolis in the Long 19th Century
Thomas Schnalke, Germany
History of the Early Years of the SIU
Heinrich Moll, Germany
James Israel (1848–1926): Founding Member of the SIU and Leading Kidney Surgeon of His Time
Dirk Schultheiss, Germany
Urology in Germany Between 1933 and 1945
Heiner Fangerau, Germany
1000–1200

PARALLEL PLENARIES 6–8

PARALLEL PLENARY 6
▶ Urinary Diversion

Chairs: Hassan Abol-Enein, Egypt
Richard Hautmann, Germany

Room: Hall 6

1000–1020
CAU Lecture: Urinary Diversion: The Latin American Perspective
Antonio Carlos Pompeo, Brazil

1020–1100
Laparoscopic/Robotic vs. Open Urinary Diversion After Laparoscopic Cystectomy?
Moderator: Arnulf Stenzl, Germany
Panelists: Hassan Abol-Enein, Egypt
Octavio Castillo, Chile
Richard Gaston, France
Raj S. Pruthi, USA
Stefan Siemer, Germany
Peter Wiklund, Sweden

1100–1120
SIU-Albert Schweitzer Lecture
Ismail Khalaf, Egypt

PARALLEL PLENARY 7
▶ Trauma From MIS

Chairs: René Sotelo, Venezuela
Ingolf Tuerk, USA

Room: ICC Lounge

1000–1015
Bleeding and Extravasation in Percutaneous Nephrolithotripsy
Mahesh Desai, India

1015–1030
Ureteral Damage in Ureteroscopy
Christoph Klinger, Germany

1030–1045
Bleeding, Bowel Injury, Conversion in Laparoscopic/Robotic Surgery
Ingolf Tuerk, USA

1045–1055
Septic Complications
Pilar Laguna, The Netherlands

1055–1105
Urinary Extravasation
Jens Rassweiler, Germany

1105–1115
The Forgotten Stent
Gunter Janetschek, Austria

1115–1155
Round Table Discussion Based on Case Presentations: “Nihil Nocere”
Moderator: René Sotelo
Panelists: All

1120–1135
Is There Still a Role for Continent and Urinary Diversion?
Urs E. Studer, Switzerland

1135–1150
The Long-Term Metabolic and Neoplastic Consequences of Urinary Diversion
Randall Rowland, USA
PARALLEL PLENARY 8
► Prostate Cancer

Chairs: Christopher Cheng, Singapore
Arnould Villers, France

Room: Hall 7

1000–1015
Quality of Life and Satisfaction with Therapy Amongst PCA Survivors
Martin Sanda, USA

1015–1105
Panel Presentations and Discussion: Cost/Benefit Ratio of Chemoprevention
Chair: Peter Albertsen, USA

1015–1025
Dietary Measures
Hideyuki Akaza, Japan

1025–1035
Lifestyle Changes
Arturo Mendoza-Valdés, Mexico

1035–1045
Antioxidants/Anti-Inflammatory Agents
Ahmad Shabsigh, USA

1045–1055
5–α-Reductase Inhibitors
Gerald Andriole, USA

1105–1155
Panel Discussion Based on Case Presentations: Management of High-Risk Locally-Confined PCA
Moderator: Peter Scardino, USA
Panelists: Arturo Mendoza-Valdés, Mexico
Michael Stöckle, Germany
Hendrik van Poppel, Belgium
Thomas Wiegel, Germany

1200–1315
BREAK

SPONSORED SYMPOSIA
Astellas Pharma Inc.

► The Male LUTS Debate
Chair: Paul Abrams, UK

Room: Stockholm

1200–1205
Introduction and Audience Polling
Paul Abrams

1205–1310
The Motion: α1-Adrenoceptor Antagonist Monotherapy Is the Right First-Line Treatment for All Men with Bothersome LUTS
Presentations, Panel Debate, Audience Polling
For the Motion: François Desgrandchamps, France
Mark Speakman, UK
Against the Motion: Marcus Drake, UK
Matthias Oelke, Germany

1310–1315
Take-Home Messages
Paul Abrams
CME-certified Symposium – International State of the Science of Immunotherapy in Prostate Cancer

This activity is supported by an independent educational grant from Dendreon Corporation. Jointly sponsored by the Postgraduate Institute for Medicine and the Institute for Medical Education and Research, Inc.

Room: Oslo

Chairs: Charles G. Drake, USA
        Adam S. Kibel, USA

1200–1205
Activity Overview
Charles G. Drake

1205–1225
International Comparison of the Changing Landscape of Advanced Prostate Cancer Management
Kurt Miller, Germany

1225–1240
Optimal Incorporation of Immunotherapy in Early-Stage CRPC
Charles G. Drake

1240–1255
Practical Application Case Series
Adam S. Kibel

1255–1315
Panel Discussion and Q&A
Charles G. Drake
Adam S. Kibel
Noel W. Clarke, UK
Kurt Miller
Francesco Montorsi, Italy

NEW FINDINGS/RECOMMENDATIONS FROM THE 2011 INTERNATIONAL CONSULTATION ON UROLOGIC DISEASES (ICUD) ON PROSTATE CANCER, PART I

Chairs: Gerald Andriole, USA
        Manfred P. Wirth, Germany

Room: ICC Lounge

1315–1600

1315–1335
A Brief History of Prostatic Diseases
Peter Thompson, UK

1335–1355
Issues Related to Early Detection
Monique Roobol, The Netherlands

1355–1415
Advances in Biomarkers for Prostate Diseases
Samir Taneja, USA

1415–1435
New Developments in the Anatomical and Metabolic Imagery of the Prostate and Metastatic Sites
John Coleman, USA

1435–1455
Patients’ Perspectives on Prostate Diseases
Paul Lange, USA

1455–1515
Metastatic PCA and Systemic Therapies
Mario Eisenberger, USA

1515–1600
Questions/Answers/Case Discussions
TUESDAY
October 18

1315–1445

PARALLEL PLENARIES 9–10

PARALLEL PLENARY 9
Female Incontinence

Chair: E. Ann Gormley, USA
Ajay Singla, USA

Room: Hall 7

1315–1330
Urge or Stress: How Much Urodynamics Is Necessary?
Marcus Drake, UK

1330–1345
Severity of Incontinence Is Definition-Dependent:
Results of a Prospective Randomized Study (TVT vs. Burch)
Paul Hilton, UK

1345–1400
Pharmacotherapy of OAB
Karl-Erik Andersson, USA

1400–1430
Pro-Con Debate: Vaginal Sacrospinous Fixation vs. Abdominal Sacrocolpopexy
Moderator: Eckhard Petri, Germany
Vaginal Surgery: Heinz Kölbl, Germany
Abdominal Surgery: Christian Hampel, Germany

1430–1445
Complications of Alloplastic Slings/Meshes
Eckhard Petri, Germany

PARALLEL PLENARY 10
Urethral Reconstruction: Global Perspectives

Chair: Sanjay Kulkarni, India
Richard Santucci, USA

Room: Hall 6

1315–1325
Anastomotic Repair of Long Bulbar Stricture
Allen Morey, USA

1325–1335
Non-Transecting Anastomotic Bulbar Urethroplasty
Daniela Andrich, UK

1335–1345
Pan-Urethral Stricture Repair with Combined Penile and Scrotum Skin Flap
Qiang Fu, China

1345–1355
Pan-Urethral Stricture Repair with One Side Dissection: Dorsal Onlay BMG Urethroplasty
Sanjay Kulkarni, India

1355–1405
Reconstruction of a Posterior Stricture Associated with a Rectourethral Fistula after Prostate Cancer Brachytherapy Using Gracilis Flap Interposition
Reynaldo Gómez, Chile

1405–1415
Perineal Urethrostomy
Guido Barbagli, Italy

1415–1425
Female Urethral Reconstruction
Igor Vaz, Mozambique

1425–1445
Discussion
1315–1445

ABSTRACT SESSIONS

PODIUM SESSION 3
► Prostate Cancer, Advanced

Chairs: Christopher Cheng, Singapore
        Fred Saad, Canada

Room: Hall 8

1315–1325
POD–03.01
Risk Assessment for Prostate Cancer Metastases by Using the Capra Score: Results from 3239 European Patients
Lars Budäus, Germany

1325–1335
POD–03.02
Prognostic Factors for Locally Advanced Prostate Cancer: A Multi-Center Experience
Steven Joniau, Belgium

1335–1345
POD–03.03
Increased Cardiac Admission Rates in Prostate Cancer Patients Treated with Androgen Deprivation Therapy in England
Edward Jefferies, UK

1345–1355
POD–03.04
A Phase III Randomized Trial of Intermittent vs. Continuous Androgen Suppression for PSA Progression After Radical Therapy (NCIC CTG PR.7/SWOG JPR.7/
        CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013)
Laurence Klotz, Canada

1355–1405
POD–03.05
Significance of Cyr61 Overproduction Induced by N-Acetylcysteine in Human Prostate Cancer PC-3 Cells
Changho Lee, South Korea

1405–1415
POD–03.06
GTx-758, an Oral ERα Agonist Being Developed for ADT, Lowers Serum Testosterone
Ronald Morton, USA

1315–1445

MODERATED POSTER SESSION 8
► Infections

Chairs: Florian Wagenlehner, Germany
        Chris F. Heyns, South Africa

Room: Salon 13/14

MP–08.01
Does Intestinal Preparation Before Prostate Biopsy Guided by Transrectal Ultrasonography Affect Infection Rates?
Gokhan Koc, Turkey

MP–08.02
Xanthogranulomatous Pyelonephritis in Children
Nabil Mhiri, Tunisia

MP–08.03
Effects of DM on Treatment Prognosis in Acute Pyelonephritis
Kyung Seo Park, South Korea
MP–08.04
Effects of Thermotherapy and Medical Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study
Hong Sup Kim, South Korea

MP–08.05
Disintegrating Perineum Disease in Patients Who Present with Urethral Strictures: A Review of 21 Cases
Frederik Claassen, South Africa

MP–08.06
Ultrasound and Morphological Conformity with Chronic Prostatitis
Akhmed Pshikhachev, Russia

MP–08.07
Randomized Clinical Trials on Antibiotic Prophylaxis in Flexible Urethroscopy
Clara Lahoz Garcia, Spain

MP–08.08
New Mutation in parE. Contribution to Quinolone Resistance in Extended-Spectrum-Lactamase-Producing Escherichia coli Isolates
Clara Lahoz Garcia, Spain

MP–08.09
Minimally-Invasive Management of Prostatic Abscess: Transrectal Ultrasound Guided Aspiration of Prostatic Abscess Under Local Anesthesia: Ganga Ram Needle
Sudhir Khanna, India

MP–08.10
Role of DNA PCR in Early Diagnosis of Genitourinary Tuberculosis
Sudhir Khanna, India

MP–08.11
Clinical Features of Mumps Orchitis in Vaccinated Postpubertal Males: A Single-Center Series of 62 Patients
Jong Hyun Yoon, South Korea

MP–08.12
Bacterial Growth in the Rectum and Urine Before and After Trans-Rectal Ultrasound-Guided Prostate Biopsy
Peter Black, Canada

MP–08.13
Diagnosis and Treatment for Male Genital Tuberculosis
Ekaterina Kulchavenya, Russia

MP–08.14
Multiple Resistant Enterobacteriaceae Implied in Urinary Tract Infections in an Ambulatory Urological Ward
Martha Orsolya, Romania

MP–08.15
Significance of Pyospermia in Patients with Varicocele
Seung Ki Min, South Korea

MP–08.16
Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteraeae in the Urinary Tract: Emerging Epidemiological Situation in University Hospital Basel
Georg Müller, Switzerland
MP–08.17
Is the Adjuvant Amikacin Effective as Antibiotic Prophylaxis for Transrectal Prostate Biopsy in Patients with Fluoroquinolone-Resistance in the Rectal Flora?
Yoshitsugu Nasu, Japan

MP–08.18
Alpha-Blockers, Antibiotics and Anti-Inflammatories Have a Role in Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
J. Curtis Nickel, Canada

MP–08.19
Prevalence of Antimicrobial Resistance in Rectal Normal Flora of Patients Undergoing Transrectal Ultrasonography-guided Prostate Biopsy in Korea
Seung Chol Park, South Korea

MP–08.20
The “Ketamine Bladder”: An Emerging Public Health Problem?
Sanjay Rajpal, UK

MP–08.21
Correlation with Urinary Epithelium and Primary Symptoms in Interstitial Cystitis: Investigation of Scanning Electron Microscopy
Teruhiko Yokoyama, Japan

MP–08.22
Predictive Factors of Bacteriuria in Emergency Patients of Ureteral Calculi Without Fever
Choong-Hee Noh, South Korea

MODERATED POSTER SESSION 9
BPO/LUTS
Chairs: Karl-Erik Andersson, USA
Luc Valiquette, Canada
Room: Salon 15/16

MP–09.01
Hydrodynamic Aspects of Intravesical Protrusion of the Prostate in Patients with Voiding Dysfunction
Gaku Sakuyama, Japan

MP–09.02
Role of Resistive Index as Prognostic Indicator in Treatment of BPH
Harvinder Singh, India

MP–09.03
Operative Impacts on Lower Urinary Tract Symptoms of Patients with BPH and Prostatitis: Comparison of Post Transurethral Resection State
Choong-Hee Noh, South Korea

MP–09.04
The Long-Term Benefits of Combined Therapy of Chronic Non-Bacterial Prostatitis
Razvan Bardan, Romania

MP–09.05
Treatment with Once-Daily Tadalafil: Improvement in Symptoms of Benign Prostate Hyperplasia and Related Quality of Life for Men with or Without Erectile Dysfunction
Kim Drasa, Albania
MP–09.06
Role of Combined Use of Ketoconazole and Tamsulosin in the Management of Acute Urinary Retention Due to Benign Prostatic Obstruction
Mohamed Elbendary Elnady, Egypt

MP–09.07
New Direction in the Treatment of Benign Prostate Hyperplasia Using Adenoprosin: Biologically Active Entomological Medicine
Vitalii Ghicavii, Moldova

MP–09.08
Serum Prostate Specific Antigen Level Predicts the Effectiveness of Silodosin in Patients with Benign Prostate Hyperplasia
Fumio Nakajima, Japan

MP–09.09
Efficacy and Safety of Combination of Alfuzosin and Low Dose Udenafil Once Daily versus Monotherapy in Patients with Comorbid Lower Urinary Tract Symptoms and Erectile Dysfunction: Randomized Prospective Open-Label Study
Deok Hyun Cho, South Korea

MP–09.10
Rapid Increases in Healthcare Utilization and Cost Due to Benign Prostatic Hyperplasia in South Korean Males: Retrospective Population-Based Analysis
Woo Suk Choi, South Korea

MP–09.11
Prevalence of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in Ghanaians
Edward Donkor Yeboah, Ghana

MP–09.12
Prostatic Urethral Angulation Can Predict Urinary Flow Rate and Urinary Symptom Score in Men with Lower Urinary Tract Symptoms
Won Sik Ham, South Korea

MP–09.13
Contribution of Common Medications to Lower Urinary Tract Symptoms Among Community Dwelling Men
Melanie Wuerstle, USA

MP–09.14
Comparison Between 70w-12w-150w in the Vaporesection of BPH with Thulium Laser
Stefano Mattioli, Italy

MP–09.15
Photoselective Vaporization of Prostate vs TURP: A Prospective, Randomized Study with One-Year Follow-Up
Nayan Mohanty, India

MP–09.16
Does a Patient with Parkinson's Disease and Benign Prostatic Obstruction or Hypocontractility of the Detrusor Benefit from a Transurethral Resection of the Prostate?
Andreas Neisius, Germany

MP–09.17
Medication Adherence and Strategies for Improvement of Tamsulosin in Elderly Benign Prostatic Hyperplasia Patients
Hitoshi Oh-Oka, Japan
1315–1445

MODERATED POSTER SESSION 10

Stones

Chair: Shiv Bhanot, UK

Room: Salon 11/12

MP–10.02
Increased Risk of Diabetes on Patients with Urinary Calculi: A Population-Based Follow-Up Study
Wei-Che Wu, Taiwan

MP–10.03
Evaluation of Risk Factors for Prognosis of Temporary Renal Impairment After Secondary Extracorporeal Shock Wave Lithotripsy (ESWL) in Renal Stone Treatment
Manfred P. Wirth, Germany

MP–10.05
Complications of Semirigid Ureteroscopy: The Experience of a Single Academic Tertiary Center with More Than 2500 Cases
Mircea Radu Botoca, Romania

MP–10.06
Retrograde Intrarenal Surgery: Experience of 76 Cases with Recurrent Renal Calculi
Mohamed Gadelmoula, Saudi Arabia

MP–10.07
PCNL Monotherapy for Complex Renal Calculi
Rajesh Kukreja, India

MP–10.08
Chest Complications Following Supracostal PCNL May Be Delayed and Are More Common on the Right Side
Amlesh Seth, India

MP–10.09
Early Ureterolithotripsy for Obstructive Stones in Single Kidney Patients
Barbara Cristina Gentile, Italy

MP–10.10
Ureteroscopy Complications: Our Long-Term Experience
Barbara Cristina Gentile, Italy

MP–10.11
Ureteroscopy: Role of Post-Operative Renal Ultrasonography
Barbara Cristina Gentile, Italy

MP–10.13
Particularities of Retrograde Ureteroscopy for Impacted Proximal Ureteral Stones: Experience of 200 Cases
Razvan Multescu, Romania

MP–10.14
Simultaneous Antegrade and Retrograde Approach for Complex Upper Tract Stones in Modified Supine Valdivia Position: Early Experience
Ada Ng, China

MP–10.15
The Dilemma of Infected Hydronephrosis Treatment Due To Ureteric Calculi: To Stent or To Perc?
Michael Nomikos, Greece
1315–1445
MODERATED POSTER SESSION 10
Stones

MP–10.16
Cystatin-C, Interleukin-18 and N-GAL Levels as Biomarkers of Inflammatory Response After Extracorporeal Shock Wave Lithotripsy
Michael Nomikos, Greece

MP–10.18
One Shot Versus Amplatz Sequential Fascial Dilatation Technique for Tract Creation in PCNL
Sanjeev Tonshal, India

MP–10.19
Effect of Dilatation Type Used During Percutaneous Nephrolitotomy Operations on Operation and Fluoroscopy Times, Preoperative and Postoperative Hemocrit and Creatinine Levels
Gokhan Koc, Turkey

MP–10.20
The Effect of Body Mass Index on Operative and Fluoroscopy Time, Postoperative Hemocrit and Creatinin Values in Percutaneous Nephrolitotomy
Gokhan Koc, Turkey

1315–1445
MODERATED POSTER SESSION 11
Pediatric Urology

MP–11.01
Laparoendoscopic Single-Site Surgery (LESS) In Paediatric Patients Less Than 5 Years of Age
Arvind Ganpule, India

MP–11.02
The Role of Urodynamical Findings in the Management of Children’s Overactive Bladder
Martha Orsolya, Romania

MP–11.03
Screening for Mutations in Id2 Gene in Familial Hydronephrosis
Yoshitaka Aoki, Japan

MP–11.04
The Assessment of Electromyography Study Tracing in Children with Lower Urinary Tract Symptoms
Frederik Claassen, South Africa

MP–11.05
Epididymitis in Children: New Insights on an Old Problem
Catherine deVries, USA
MP–11.06
Ileal Neobladder in Pediatric Population: Objective Assessment of the Long-Term Sequelae
Ali Ahmed Abdelhalim, Egypt

MP–11.07
A Third of Patients With a Unilateral Palpable Undescended Testes Have a Contralateral Patent Processus
Barry A. Kogan, USA

MP–11.08
Hypospadias Management in High Familial Incidence Area of Jizan, Saudi Arabia: A Prospective Study
Akhileswar Jha, Saudi Arabia

MP–11.09
Tubularized Preputial Double Faced Flap Urethroplasty Is a Good Alternative Surgery in Management of Proximal Hypospadias with Chordee, or Unhealthy Urethral Plate Requires Orthoplasty
Tarek Abdelbaky, Egypt

MP–11.10
Free Tube Graft Urethroplasty for Repair of Hypospadias with Chordee
Kenji Obara, Japan

MP–11.11
Primary Vesico-ureteral Reflux: Comparison of Factors Between Infants and Children
Jae Shin Park, South Korea

MP–11.12
Role of Laparoscopy in Diagnosis and Management of Non-Palpable Undescended Testis
Khaled Mursi Hammoud, Egypt

MP–11.15
Application of Deflux® Gel Injection Into the Bladder Neck Area in Patients with Neuropathic Sphincter Failure
Lidia Skobejko-Wlodarska, Poland

MP–11.16
Uretero-Pelvic Junction Obstruction in Double Kidneys
Christopher Ziesel, Germany

1315–1445
 VIDEO SESSION 4
 ▶ Minimally Invasive Surgery II

Chairs: Petrisor Geavlete, Romania
Jens Rassweiler, Germany

Room: Hall 10

1315–1325
VID–04.01
Laparoendoscopic Single-Site Surgery Approach for Simultaneous Bilateral Nephrectomy
Amit Bhattu, India

1325–1335
VID–04.02
Bilateral Simultaneous Laproendoscopic Single Site Surgery (LESS) Pyeloplasty in a 4-Month-Old Child
Arvind Ganpule, India

1335–1345
VID–04.03
Percutaneous Nephrolithotomy (PCNL) in Patient with Severe Spinal Deformity
Ravindra Sabnis, India
### VIDEO SESSION 4: Minimally Invasive Surgery II

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1345–1355</td>
<td>VID–04.04 Hybrid Laparoendoscopic Single Site Radical Prostatectomy</td>
<td>Paul Rouse, UK</td>
<td></td>
</tr>
<tr>
<td>1355–1405</td>
<td>VID–04.05 A Novel Intracorporeal Knotting Technique for Laparoendoscopic Surgery</td>
<td>Paul Rouse, UK</td>
<td></td>
</tr>
<tr>
<td>1405–1415</td>
<td>VID–04.06 NOTES Hybrid Transvaginal Upper Pole Heminephrectomy</td>
<td>René Sotelo, Venezuela</td>
<td></td>
</tr>
<tr>
<td>1415–1425</td>
<td>VID–04.07 Laparoscopic Management of Incisional Hernias at the Site of Extraction after Robotic Prostatectomy</td>
<td>René Sotelo, Venezuela</td>
<td></td>
</tr>
<tr>
<td>1425–1435</td>
<td>VID–04.08 Laparoscopic Resection of a Large Functional Paraganglioma in the Organ of Zuckerkandl (PZ)</td>
<td>Domenico Veneziano, Italy</td>
<td></td>
</tr>
</tbody>
</table>

### VIDEO SESSION 5: Kidney & Ureteral Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1315–1325</td>
<td>VID–05.01 Laparoscopic Partial Nephrectomy: “Zero-Ischemia” Technique with Controlled Hypotension</td>
<td>René Sotelo, Venezuela</td>
<td>Room: Salon 17/18</td>
</tr>
<tr>
<td>1325–1335</td>
<td>VID–05.02 Laparoscopic Partial Nephrectomy in Polycystic Kidney</td>
<td>Juan Peña, Spain</td>
<td></td>
</tr>
<tr>
<td>1335–1345</td>
<td>VID–05.03 Partial Nephrectomy by Retroperitoneoscopy Without Hilar Clamping</td>
<td>Juan Peña, Spain</td>
<td></td>
</tr>
<tr>
<td>1345–1355</td>
<td>VID–05.04 Simultaneous Double Partial Nephrectomy for a Double Ipsilateral Tumor</td>
<td>Juan Peña, Spain</td>
<td></td>
</tr>
<tr>
<td>1355–1405</td>
<td>VID–05.05 Endoscopic Treatment of Multiple Ureteral Tumors in an Eighty-Year-Old Patient</td>
<td>Tomislav Pejcic, Serbia</td>
<td></td>
</tr>
</tbody>
</table>
1405–1415
VID–05.06
Laparo-Endoscopic Single Site Transvesical Bladder Cuff Excision
René Sotelo, Venezuela

1415–1425
VID–05.07
Pluck Detachment of the Intramural Ureter Using Bipolar Plasma Vaporization: An Innovative Endoscopic Method During Nephroureterectomy
Razvan Multescu, Romania

1425–1435
VID–05.08
Investigation of an Extended Set of Specialized Fiber Probes During the Application of Thermal Energy at Parenchymal Tissue
Joerg Neymeyer, Germany

1435–1445
VID–05.09
Improved Precision and Therapy Outcome During the Use of Laser Energy with a New Fiber Design and NBI (Narrow Band Imaging) Technology for the Treatment of Tumor Tissue at the Renal Pelvis
Joerg Neymeyer, Germany

1445–1515
BREAK

1515–1645
SURGICAL TIPS SESSIONS 3–4

SURGICAL TIPS 3
Female Incontinence Surgery
Chair: Marcus Drake, UK
Faculty: Heinz Kölbl, Germany
Eckhard Petri, Germany
Christian Hampel, Germany
Room: Hall 7

SURGICAL TIPS 4
Hypospadias Repair
Chair: Dragana Filipas, Germany
Faculty: Raimund Stein, Germany
Antoine E. Khoury, USA
Paolo Caione, Italy
Room: Hall 6

1515–1645
ABSTRACT SESSIONS

PODIUM SESSION 4
BPO/LUTS
Chair: Reynaldo Gómez, Chile
Rainer Kuntz, Germany
Room: Hall 8

1515–1525
POD–04.01
Comparing Holmium Laser Enucleation of Prostate (HoLEP) with Bipolar Transurethral Resection of Prostate: A Prospective Randomized Controlled Trial
Ajay Bhandarkar, India
TUESDAY
October 18

1515–1645
PODIUM SESSION 4
➤ BPO/LUTS

1525–1535
POD–04.02
A Prospective Randomized Study Between Transurethral Vaporisation Using Plasmakinetic Energy and Transurethral Resection of Prostate: 8 Years’ Follow-Up
Ponnambalam Chandrasekar, UK

1535–1545
POD–04.03
Holmium Laser Enucleation of the Prostate (HoLEP) and Incidental Prostate Cancer: Clinical Significance of Histology in Laser Prostatectomy in Men <70 Years
Luis Alex Kluth, Germany

1545–1555
POD–04.04
Bipolar Plasma Vaporization Versus Monopolar and Bipolar TURP: Results of a Prospective, Randomized, Long-Term Comparison
Bogdan Florin Geavlete, Romania

1555–1605
POD–04.05
Comparison Between Plasmakinetic Resection of Prostate and Monopolar TURP: A Prospective Randomized Trial with 5-Year Follow-up
Suresh Patankar, India

1605–1615
POD–04.06
The Effect of Increasing Doses of a Saw Palmetto Fruit Extract on Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Randomized Trial
Claus G. Roehrborn, USA

1615–1625
POD–04.07
Intravesical Prostatic Protrusion in Benign Prostatic Hyperplasia: Does It Make Any Difference in Results After Transurethral Resection of the Prostate?
Jae Shin Park, South Korea

1625–1635
POD–04.08
Management Algorithm for Bladder Outlet Obstruction in Women
Manu Gupta, India

1515–1645
PODIUM SESSION 5
➤ Bladder Cancer

1515–1525
POD–05.01
Narrow Band Imaging Cystoscopy Improves the Detection of Bladder Cancer
Rami Issa, UK

1525–1535
POD–05.02
5–Aminolevulinic Acid-Based Photodynamic Detection for Diagnosing Urothelial Cancer Cells in Urine Sediments
Kiyohide Fujimoto, Japan
1535–1545
POD–05.03
Treatment Changes and Long-Term Recurrence Rates After HAL Fluorescence Cystoscopy: Does Blue Light Really Make a Difference in the Long Run?
Bogdan Florin Geavlete, Romania

1545–1555
POD–05.04
Stage pT0 After Radical Cystectomy: Are All Patients Equal?
Shahrokh F. Shariat, USA

1555–1605
POD–05.05
Risk Stratification of Patients Who Are pT0N0 After Radical Cystectomy
Shahrokh F. Shariat, USA

1605–1615
POD–05.06
Optical Coherence Tomography (OCT) as an Adjunct to Conventional Cystoscopy and Pathology for Non-Invasive Endoscopic Staging of Bladder Tumors
Seth P. Lerner, USA

1615–1625
POD–05.07
Smoking Behaviour Is a Risk Factor for Recurrence After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Rianne Janna Marie Lammers, The Netherlands

1625–1635
POD–05.08
Bipolar Plasma Vaporization and NBI for Large Non-Muscle Invasive Bladder Tumors: Results of a Prospective, Randomized, Long-Term Comparison to the Standard Approach
Bogdan Florin Geavlete, Romania

1515–1645
POD–06.01
Minimally Invasive Open Tumor Enucleation vs. Percutaneous Radiofrequency Ablation vs. Active Surveillance of Small Renal Masses <3 cm in Old Patients: Long-Term Results of a Prospective Follow-Up Study
Maurizio Brausi, Italy

1525–1535
POD–06.02
Establishing a Viable Robotic Service: A Twelve-Month Experience of the Challenges
Rami Issa, UK

1535–1545
POD–06.03
Prostate Tumour Identification Using a Force-Sensitive Rolling Indentation Probe
Pardeep Kumar, UK

1545–1555
POD–06.04
Laparoscopic Versus Open Radical Cystectomy: Prospective Nonrandomized Comparison of Morbidity and Pathological Measures of Early Oncological Efficacy
Said Mohammed Moudouni, Morocco
1555–1605  
POD–06.05  
Unusual Complications of Laparoscopic Surgery and Lessons Learnt  
Suresh Patankar, India

1605–1615  
POD–06.06  
Multi-Institutional Analysis of Robotic Assisted Partial Nephrectomy for Clinical Stage T1b Renal Tumors: Perioperative Outcomes in 445 Patients  
Craig Rogers, USA

1615–1625  
POD–06.07  
Laparoscopic Transvesical Urological Procedure Is Safe and Feasible: Report of the First UK Experience  
Hemant Nemade, UK

1515–1645  
MODERATED POSTER SESSION 12  
▶ Trauma & Reconstruction  
Chairs: Guido Fechner, Germany  
Allen Morey, USA  
Room: Salon 11/12

MP–12.02  
The Electronic Modular Artificial Sphincter ARTUS: Results of the Cadaver Study  
Roland Dahlem, Germany

MP–12.03  
Management of Iatrogenic Rectourinary Fistulas: A Six-Year Experience  
Karen De Baets, Belgium

MP–12.04  
Tissue-Engineered Buccal Mucosa Urethroplasty: Outcome of Our First Patients  
Oliver Engel, Germany

MP–12.05  
Transvaginal Repair of Genital Prolapse with Prolift System: Morbidity and Anatomic Outcomes After 6 Years of Use: A Multicentric Study  
Sebastien Kozal, France

MP–12.06  
Reconstruction of Extended Urethral Strictures with a Buccal Mucosal Graft: Success Rates After 60 Months of Follow-up: Analysis of 184 Patients  
Abhishek Pandey, Germany
MP–12.07
Dynamic and Radiologic Evidence for Improved Function of Detubularized Isolated Ureterosigmoidostomy (Atta Pouch)
Wael Sameh, Egypt

MP–12.08
Management of Bladder Exstrophy Epispadias Complex in Patients Presenting in Adulthood
Amlesh Seth, India

MP–12.09
Late Oral Morbidity of Oral Mucosal Graft Harvest Site for Substitution Urethroplasty
Joachim Steffens, Germany

MP–12.10
Vascularization of Free Preputial Grafts: Does Dorsal vs Ventral Graft Placement Make a Difference? An Experimental Study
Anastasios Tahmatzopoulos, Greece

MP–12.11
The Buccal Mucosa “Snodgraft” Hypospadias Repair: Our Experience
Sorin Patrascoiu, Romania

MP–12.12
Practice Patterns of US Urologists Treating Urethral Stricture: A Quality of Care Issue
Frank Burks, USA

MP–12.13
Does Previous Endoscopic Urethrotomy Affect Results of Anastomotic Urethroplasty? Hong Kong Experience
Cheung Hing Cheng, China

MP–12.14
Treatment of Male Urethral Strictures: Repeated Dilation and Internal Urethrotomy Re-Evaluated
Jo Van der Merwe, South Africa

MP–12.15
Repeated Endoscopic Treatment of Bulbar Urethral Strictures Is Associated With Increased Stricture Complexity and Duration of Symptoms
Steven Hudak, USA

MP–12.16
Short-Term Outcome of Contemporary Urethroplasty at a Tertiary Care Center
Luis Alex Kluth, Germany

MP–12.17
Extended Long-Term Results of Surgery for Urethral Stricture
Luis Alex Kluth, Germany

MP–12.18
Transpubic Repair of Urethral Pathology in Women
Durwood Neal, USA

MP–12.19
The Mesh-Graft-Urethroplasty: Is There Still an Indication?
Philip Reiss, Germany
MODERATED POSTER SESSION 13
Prostate Cancer, Localized

Chairs: Paul Lange, USA
Kurt Miller, Germany

Room: Salon 13/14

MP–13.01
Radical Prostatectomy in Men with Continued Oral Aspirin Medication: Revisiting an Old Paradigm?
Lars Budäus, Germany

MP–13.02
First Experience Worldwide with a New Radioactive Fiducial Marker for External Beam Radiation Therapy for Localized Prostate Cancer: The Urological Aspects
Robert Davits, The Netherlands

MP–13.03
Does Repeat Focal Ablation Using High Intensity Focused Ultrasound (Sonablate 500) Compromise Morbidity or Genito-Urinary Functional Outcome in Men with Localized Prostate Cancer?
Louise Dickinson, UK

MP–13.04
Clinical Significance of Surgical Margins Status in Patients Subjected to Radical Prostatectomy
Jakub Dobruch, Poland

MP–13.05
Five Years’ Experience with High-Intensity Focused Ultrasonography for Prostate Cancer Treatment: A Mid-Term Follow Up
Elmar Heinrich, Germany

MP–13.06
Complications of Open Radical Prostatectomy: More Than 18 Years’ Experience at One Center
Mark S. Soloway, USA

MP–13.07
Surgical Margin Status Is Not Associated with Overall Survival After Radical Prostatectomy
Mark S. Soloway, USA

MP–13.08
The Hybrid Interactive Method in Permanent Prostate Brachytherapy Reduces Excess Seeds
Tsuyoshi Iwata, Japan

MP–13.09
Outcome Analysis of Positive Surgical Margins in Consecutive 428 Retropubic Radical Prostatectomies
Jagdeesh Kulkarni, India

MP–13.10
Prostate Cancer Focality and Selection of Patients for Focal Therapy
Barbara Cristina Gentile, Italy

MP–13.11
Prediction of Prostate Cancer Tumour Volume from Biopsy Cores: A Simple Guide by Gland Volume
Simon Robinson, UK
MP–13.12
Robotic Assisted Laparoscopic Prostatectomy: Perioperative Complications and Oncological Outcomes
Claus G. Roehrborn, USA

MP–13.13
Robotic Assisted Laparoscopic Prostatectomy: Functional Outcomes and Learning Curve
Claus G. Roehrborn, USA

MP–13.14
High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Ten-Year Follow-Up
Toyoaki Uchida, Japan

MP–13.15
Low Dose Rate Brachytherapy: Oncological Outcomes in Prostate Cancer Patients
Luis Busto Martin, Spain

MP–13.16
Multiple (12-Cores) Vesico-Urethral Anastomosis Biopsy After Radical Prostatectomy: Outcomes of 43 Patients with Biochemical Failure
Renat Guspanov, Russia

MP–13.17
Evaluation of Non-Invasive MRI Technique in the Diagnosis of Prostate Cancer
Ihab Hekal, Saudi Arabia

MP–13.18
Presence of Neutrophilic Infiltration in the Prostate and Its Relationship with Serum PSA Levels in Asymptomatic Patients
Omer Onur Cakir, Turkey

MP–13.19
Clinically Significant Prostate Cancer Is Present Anteriorly in Nearly Fifty Percent of Men Classified as Presumed Low-Risk on Diagnostic TRUS Biopsies
Paras Singh, UK

MP–13.20
Diminished Expression of Selected Micrornas Correlates with Upregulation of Prostate Cancer Associated Genes
Manfred P. Wirth, Germany

MP–13.21
Concomitant Incubation of Prostate Cancer Cells with the Platinum-Based Chemotherapeutic Carboplatin and Carbon Nanoparticles Enhances Cytotoxicity
Manfred P. Wirth, Germany
1515–1645

**VIDEO SESSION 6**

▶ Stones

Chairs: Tarik Esen, Turkey  
      Anup Patel, UK

Room: Salon 15/16

1515–1525  
**VID–06.01**  
Micro PCNL: The New Cutting Edge Technology in Renal Stone  
Vikas Agarwal, India

1525–1535  
**VID–06.02**  
AH-1 Stone Removal System to Treat Bladder Stones  
Aihua Li, China

1535–1545  
**VID–06.03**  
Nephroscopy with Carbon Dioxide in Combination with Laparoscopy in the Treatment of Urinary Stones  
Alejandro Garcia-Segui, Spain

1545–1555  
**VID–06.04**  
Tubeless PCNL with Patients in Supine Position Under Epidural Anesthesia  
Hosein Karami, Iran

1555–1605  
**VID–06.05**  
Is Ureteral Stenting Necessary During Laparoscopic Ureterolithotomy for Management of Large Ureteric Calculi?  
Hosein Karami, Iran

1605–1615  
**VID–06.06**  
Retrograde Ureteroscopy for Large Stones: Why Use a Small Caliber Ureteroscope When a Nephroscope Can Be Used?  
Mohammed Lezrek, Morocco

1615–1625  
**VID–06.07**  
Tricks of Percutaneous Surgery with the Split-Leg Modified Lateral Position  
Mohammed Lezrek, Morocco

1625–1635  
**VID–06.08**  
Techniques to Overcome Renal Mobility During Percutaneous Tract Creation  
Mohammed Lezrek, Morocco

1635–1645  
**VID–06.09**  
Laparoscopic Anatrophic Nephrolithotomy Technical Modifications with Reduced Ischemia Time  
René Sotelo, Venezuela
VIDEO SESSION 7
Prostate Cancer

Chairs: Martin Schostak, Germany
       John Ward, USA

Room: Salon 17/18

1515–1525
VID–07.01
The Intrafascial Nerve Sparing Radical Perineal Prostatectomy
Jörn Beier, Germany

1525–1535
VID–07.02
Advantages of Extraperitoneal Robotic Prostatectomy: Description of Technique and Comparison to Transperitoneal Approach
Rami Issa, UK

1535–1545
VID–07.03
Ureteral Stenting During Endoscopic Extraperitoneal Radical Prostatectomy (EERP): An Easy Solution for a Complex Problem
Juan Peña, Spain

1545–1555
VID–07.04
Steps and Challenges of Extraperitoneal Robotic Assisted Radical Prostatectomy
Juan Peña, Spain

1555–1605
VID–07.05
Endoscopic Approach as a First Step in Robotic Assisted Radical Prostatectomy After Prostate Surgery
Joan Palou, Spain

1605–1615
VID–07.06
Extraperitoneal Robot Assisted Radical Prostatectomy Revisited
PN Dogra, India

1615–1625
VID–07.07
Recognition and Management of Rectal Injury During Robotic Prostatectomy
René Sotelo, Venezuela

1625–1635
VID–07.08
Better Nerve Handling with Open Prostatectomy? Exploring Retrograde Robotic Radical Prostatectomy
René Sotelo, Venezuela

1635–1645
VID–07.09
Complications During Robotic Radical Prostatectomy
René Sotelo, Venezuela
SPONSORED SYMPOSIA
GlaxoSmithKline

Men with BPH in 2011: Evidence to Support First Treatment Decisions
Chair: Peter Hammerer, Germany

Welcome and Introduction
Peter Hammerer

BPH Patients and Current Practice: Is There an Unmet Clinical Need?
Interactive discussion moderated by Peter Hammerer

What is the Role of Combination Therapy in First Treatment Decisions for BPH?
Interactive discussion moderated by J. Curtis Nickel, Canada

How has BPH Treatment Changed with Recent Updates in Clinical Guidelines?
Interactive discussion moderated by Michael Marberger, Austria

Summary and Conclusions
Peter Hammerer

Sanofi Pasteur

Chair: Mark Soloway, USA

Welcome and Introduction
Mark Soloway

The Need for Bacillus Calmette-Guérin (BCG) for Optimizing Outcomes in NMIBC: Review of Current Literature
Andreas Böhle, Germany

The Optimal Management of NMIBC: Review of Current Guidelines
Joan Palou, Spain

Are We Practicing What We Preach? Overview and Key Findings from the International NMIBC Individual Patient Data Survey (IPDS)
Fred Witjes, The Netherlands

Panel Discussion
Assessing the Care Gap: Comparison of IPDS Results to Recommended Clinical Practice
1750–1800
Audience Discussion
Closing the Care Gap: How to Improve the Management of NMIBC
1800
Summary and Close
Mark Soloway

1800–2000

SIU WORLD FORUM FOR PATIENTS
Prostate Cancer
Chair: Kurt Miller, Germany

This session will be conducted in German

1830–2300

OPTIONAL ACTIVITIES

UNMODERATED POSTER SESSION 2
Room: Exhibit Hall

BPO/LUTS; Minimally Invasive Surgery; Prostate Cancer

UP–02.001
Distribution of Onabotulinumtoxin A in the Human Prostate After Transrectal Injection and Localization of the High-Affinity Receptors for the Toxin
Tiago Gorgal-Carvalho, Portugal

UP–02.002
Open Label, Randomized Clinical Trial To Evaluate the Safety and Efficacy of “Herbmed Plus” for Ureteral Stent Discomfort Against Tolterodine
Suresh Patankar, India

UP–02.003
The Evaluation of Lower Urinary Tract Symptoms in Nigeria: Practice and Limitations
Leslie Akporiaye, Nigeria

UP–02.004
Risk Factor Analysis of Patients’ Dissatisfaction After Holmium Laser Enucleation of the Prostate (HoLEP) for Benign Prostatic Hyperplasia
Kazuhiko Fukumoto, Japan

UP–02.005
Preferences with Regard to Position During Digital Rectal Examination and Perceptions of Pain During and After Digital Rectal Examination Among Men with Lower Urinary Tract Symptoms
Chris F. Heyns, South Africa
UP–02.006
Correlation of the Visual Prostate Symptom Score (VPSS) and International Prostate Symptom Score (IPSS) with Uroflow Parameters in Men Presenting with Lower Urinary Tract Symptoms
Chris F. Heyns, South Africa

UP–02.007
Urethral Vibration Under Irrigation: A Possible Parameter for Estimating Urethral Flexibility
Kohei Horiuchi, Japan

UP–02.008
Patients’ Characteristics and Urodynamic Parameters of Pressure-Flow Study Failure of Patients in Our Institution
Takeya Kitta, Japan

UP–02.009
Clinical Significance of Intravesical Prostatic Protrusion/Prostate Volume
Seung Ki Min, South Korea

UP–02.010
Urinary PSA: Marker of Benign Prostatic Hyperplasia?
Tomislav Pejcic, Serbia

UP–02.011
Biofeedback Treatment for Dysfunctional Voiding Diagnosed in Adulthood
Emin Aydur, Turkey

UP–02.012
The Advantages of Bipolar Vaporization in the Therapy of Benign Prostatic Hyperplasia
Viorel Bucuras, Romania

UP–02.013
Bipolar RF Thermotherapy for Chronic Prostatitis: Two Years’ Follow-Up
Christian Beck, Germany

UP–02.014
Safety of Tamsulosin OCAS™ Plus Solifenacin in Men with LUTS Associated with BPH in the SATURN Trial
Philip van Kerrebroeck, The Netherlands

UP–02.015
Outcome and Complications of 323 Cases with 120 W Greenlight™ High-Performance System for Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Hyperplasia in a Single Center
Woo Suk Choi, South Korea

UP–02.016
Five-Year Follow-Up of 80W Green Light Laser Photoselective Vaporisation of the Prostate: A Prospective Dual Centre Experience
Judith Dockray, UK

UP–02.017
Holmium Laser Enucleation of the Prostate for Prostates Larger Than 100ml
Takahiro Haraguchi, Japan

UP–02.018
Transurethral Enucleation with Bipolar for Prostatic Hyperplasia Beyond 100 cc
Kenji Kawamura, Japan

UP–02.019
Is TURis-P Really More Bio-Friendly Than Conventional TUR?
Shinsuke Hayami, Japan
UP–02.020
Safety and Efficacy of Holmium Laser Enucleation of the Prostate in Patients on Anticoagulant Therapy
Takaharu Ichikawa, Japan

UP–02.021
Influence of Preoperative Variables on the Outcome of Holmium Laser Enucleation of the Prostate
Tae Nam Kim, South Korea

UP–02.022
Is it Necessary to Perform Full-Blood-Counts and Serum Electrolytes on All Patients Post TURP?
Neil Maitra, UK

UP–02.023
Experience of Anteroposterior Dissection HoLEP: The First 65 Cases Performed in a Single Center
Shingo Minagawa, Japan

UP–02.024
Endoscopic up to 100 gr Prostate Resection Gyrus Versus OPSU: Long-Term Results
Barbara Cristina Gentile, Italy

UP–02.025
Comparative Efficacy of Endoscopic Bipolar vs Monopolar Prostate Resection: Single Centre Experience
Francesco Pisanti, Italy

UP–02.026
Memokath 045TW Stent in Intractable Bladder Neck Stricture: Preliminary Experience
Carlo Luigi Augusto Negro, UK

UP–02.027
Intermediate-Term Efficacy of Tm:YAG Laser Prostate Vaporesection for Bladder Outlet Obstruction: Initial Experience from a UK Teaching Hospital
Raj Pal, UK

UP–02.028
The Incidence of Erectile Dysfunction and Retrograde Ejaculation Following Thulium Laser Prostate Vaporesection for Benign Bladder Outflow Obstruction: A Retrospective Study
Raj Pal, UK

UP–02.029
Are There Any Predictive Risk Factors for Persistent Bladder Irritative Symptoms After Transurethral Resection of the Prostate?
Cristian Gutue, Romania

UP–02.030
Transurethral Resection in Saline and Plasma Vaporization of the Prostate: Clinical Evaluation of Safety and Short-Term Results
Vasile Dan Stanca, Romania

UP–02.031
Effects of Detrusor Underactivity on Outcome of Transurethral Resection of the Prostate in Patients with Prostate Hyperplasia
Choong-Hee Noh, South Korea

UP–02.032
Does Anticholinergic Treatment with Tolterodine Improve the Results in BPH Patients Treated with Tamsulosin?
Mircea Radu Botoca, Romania
UP–02.033
The Change of Quality of Life Due to Urinary Symptoms After Treatment of Lutenizing Hormone Releasing Hormone Agonist Leuprolide Acetate for Patients with Severe BPH
Jung Moon Heo, South Korea

UP–02.034
Multicentre Study on the Efficacy and Tolerability of Permixon® in Patients with Chronic Benign Prostate Conditions Associated with Inflammation
Barbara Cristina Gentile, Italy

UP–02.035
Stratified Analysis of Effect of Silodosin on Symptoms of Benign Prostatic Hyperplasia
Tetsuo Murai, Japan

UP–02.036
Risk Factors for LUTS/BPH Progression: A View from the Urologist’s Office
Predrag Nikic, Serbia

UP–02.037
The Association Between the Self-Perception Period of Lower Urinary Tract Symptoms and the International Prostate Symptom Score
Sung Ryul Shim, South Korea

UP–02.038
Ketamine Addiction: Need to Raise Awareness of Its Bladder Complications
Rozh Jalil, UK

UP–02.041
Initial Treatment of Incident Benign Prostatic Hyperplasia Cases in the United States, 2006
Alexander McBean, USA

UP–02.042
Therapeutic Efficacy of Bipolar Radio Frequency Thermal Treatment for Patients with Benign Prostate Hyperplasia
Joonhwa Noh, South Korea

UP–02.043
Pubic Symphysitis Following Transurethral Resection of the Prostate: A Rare Complication
Christopher Ziesel, Germany

UP–02.044
Laparoscopic Partial Nephrectomy Using Radiofrequency Ablation: Comparision of Original and Standard Techniques
Alexey Kalpinskiy, Russia

UP–02.046
Percutaneous Nephropexy with a Suture Passed Between the Lower and the Upper Pole of the Kidney
Mohammed Lezrek, Morocco

UP–02.047
Experience with Single One Centimeter Port Laparoscopic Radical Prostatectomy
Christian Bach, UK

UP–02.048
Laparoscopic Management of Pelviureteric Junction Obstruction
Mohammed Bhuiyan, Bangladesh
UP–02.049
LESS Transumbilical Adrenalectomy: Initial Experience and Comparison with Conventional Laparoscopy
David Castelo, Portugal

UP–02.050
Surgical Treatment of Renal Hydatid Cyst: Open Surgery or Laparoscopy?
Nabil Mhiri, Tunisia

UP–02.051
Single Port Laparoscopic Varicocelectomy: Initial Experience
Rhana Zakri, UK

UP–02.052
Video Documentation and Quality Assurance of Extraperitoneal Endoscopic Radical Prostatectomy
Bheena Karunyam, UK

UP–02.054
Effect of Patient-Centered Goal on Postoperative Satisfaction in Patients with HoLEP Surgery
Jong Kil Nam, South Korea

UP–02.055
No-Clamp, No-Stop Watch Pure Laparo-Endoscopic Single-Site Surgery Partial Nephrectomy
Hemant Nemade, UK

UP–02.056
Efficacy of Early Salvage Radiotherapy After Radical Prostatectomy in Patients with Rising PSA Levels Below the Conventional Threshold of 0.2ng/mL
Ladislav Jarolim, Czech Republic

UP–02.057
Single Port Transumbilical Laparoscopic Radical Nephrectomy and Bilateral Ovarian Cystectomy: First Clinical Case
Yeh Hong Tan, Singapore

UP–02.058
A New Approach of Renal Hilum Control in Retroperitoneoscopic Radical Nephrectomy
An Wei, China

UP–02.059
Laparoscopic Versus Open Partial Nephrectomy
An Wei, China

UP–02.060
Combined Robotic Lobectomy and Adrenalectomy for Lung Cancer and Solitary Adrenal Metastasis
Bertram Yuh, USA

UP–02.061
Incidence of Port Site Hernia After Laparoscopic Surgery
Miroslav Zalesky, Czech Republic

UP–02.062
Clinical, Biochemical and Radiologic Benefit of the Treatment with Sunitinib in Monotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer After Failure of Docetaxel
Cristian Vasile Casu, Spain

UP–02.063
Evaluation of the Early Impact of the LHRH Analogues Treatment in Prostate Cancer Under Psycho-Cognitive, Emotional and Quality of Life Parameters
Cristian Vasile Casu, Spain
UP–02.064  
Safety and Efficacy of Degarelix in the Treatment of Prostate Cancer in a Cohort from a German Office-Based Registry for Uro-Oncological Quality Assurance  
Götz Geiges, Germany

UP–02.065  
Clinical Versus Histological Diagnosis of Advanced Prostate Cancer: Comparative Evaluation of Treatment Outcome After Bilateral Orchidectomy  
Jacques Basson, South Africa

UP–02.066  
Is Radical Prostatectomy a Viable Treatment Option in Patients with Initial PSA > 20ng/ml?  
Alexander Hinev, Bulgaria

UP–02.067  
The Low Dose CDDP+UFT Therapy Brings a Decrease of PSA to the Docetaxel Resistance Prostate Cancer  
Fukuta Katsuhiro, Japan

UP–02.068  
Central Venous Catheter Utilization During the IMPACT (D9902B) Trial: A Review of Central Venous Catheter Incidence and Associated Adverse Events  
Neal Shore, USA

UP–02.069  
Safety of Leukapheresis in Advanced Prostate Cancer Patients Receiving Sipuleucel-T  
Thomas Price USA

UP–02.070  
Efficacy of Estramustine Phosphate According To Risk Classification of Castration-Resistant Prostate Cancer  
Akinori Minato, Japan

UP–02.071  
Bipolar Plasma Vaporization in Prostate Cancer Patients: A Palliative Application of a New Technique  
Bogdan Florin Geavlete, Romania

UP–02.072  
Impact of High-Intensity Focused Ultrasound on BALB/c Mice with RenCa Tumor  
Akira Ishikawa, Japan

UP–02.073  
Treatment Outcomes of Oral Ethinylestradiol for Castration-Resistant Prostate Cancer, and Docetaxel for Relapsed Prostate Cancer After Treatment with Ethinylestradiol  
Toru Onita, Japan

UP–02.074  
Premature Discontinuation of Docetaxel-Based Chemotherapy in Men with Castration-Resistant Prostate Cancer  
Seung Chol Park, South Korea

UP–02.075  
Ketoconazole Treatment in Castration-Resistant Prostate Cancer  
M. Andreas Roder, Denmark

UP–02.076  
GTx-758, an Oral ERα Agonist Being Developed for Advanced Prostate Cancer Avoids Many Estrogen Deficiency Side Effects Commonly Observed with ADT  
Ronald Morton, USA

UP–02.077  
Is Radical Cystectomy a Treatment Option for Very High-Risk T4-Prostate Cancer?  
Martin Spahn, Germany
UP–02.078
What Can We Tell Patients Newly Diagnosed with Gleason 8 or 9 Disease? A UK-Population Study
Hidekazu Yamamoto, UK

UP–02.079
Prognostic Significance of the Quantification of Circulating Tumor Cells in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Luis Guillermo Celada, Spain

UP–02.080
Prognostic Value of Chromogranin A in Prostate Biopsy at the Moment of Diagnosis of Patients with Hormone-Refractory Prostate Cancer
Javier Casado Varela, Spain

UP–02.081
The Association of Serenoa Repens-Selenium-Lycopene Is More Effective than Serenoa Repens Alone in Preventing Testosterone-Induced Prostatic Hyperplasia and PC3 Cell Growth via the Activation of the Apoptotic Machinery
Giuseppe Morgia, Italy

UP–02.082
Diagnostic Role of GSTP1 CpG Island Hypermethylation Detection in Prostate Cancer Patients
Radu Minciu, UK

UP–02.083
Prognostic Significance of Percent Tumor Involvement According to Disease Risk Group in Men Treated with Radical Prostatectomy
Sung Kyu Hong, South Korea

UP–02.084
Active Inflammatory State and Reactivity of Normal Prostate Epithelium and Aggressive Prostate Cancer
Vincent Fradet, Canada

UP–02.085
Antigen-Specific T-Cell Responses Against Tumor-Antigens Are Controlled by Regulatory T-Cells in Prostate Cancer Patients
Boris Hadaschik, Germany

UP–02.086
Comprehensive Analysis of Intratumoral Steroidogenesis in Castration-Resistant Prostate Cancer
Agus Rizal A.H. Hamid, The Netherlands

UP–02.087
Gastrin-Releasing Peptide: Novel Predictor of Castration-Resistant Prostate Cancer?
Elmar Heinrich, Germany

UP–02.088
Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Prostate Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes Against Prostate Cancer Cells
Taek Won Kang, South Korea

UP–02.089
Genetic Differentiation of Prostate Cancer Using CGH for Prognosis Evaluation
Eveline Hauschild, Germany
UP–02.090
Expression of CD147 Protein Is Not Useful as Pre-Surgical Diagnostic Factor in Human Prostate Cancer
Martin Schmudermaier, Austria

UP–02.091
A Proposed New Technique in Prostate Cancer Tissue Bio-Banking: Our Experience with a New Protocol
Stefano Picozzi, Italy

UP–02.097
Induction of Apoptosis and Enhancement of Chemosensitivity by Downregulating of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 in Castration-Resistant Prostate Cancer Cells
Chong Koo Sul, South Korea

UP–02.098
The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo
Christian Thomas, Germany

UP–02.099
Expression of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1) in Prostate Cancer
Kenji Yasuda, Japan

UP–02.100
Antitumor Effect of Sodium Meta-Arsenite on the Prostate Cancer Cell and Its Mechanism
Ju Hyun Lim, South Korea

UP–02.101
BK Polyomavirus Infection in Prostate Tissue Derived From Patients with Prostate Adenocarcinoma
Shan Zhong, China

UP–02.102
Lithuania Prostate Cancer Early Diagnosis Program 2006–2010: Trends in Services
Robertas Adomaitis, Lithuania

UP–02.103
The Role of 3T Dynamic-Magnetic Resonance Imaging (MRI) To Avoid Superfluous Prostate Biopsy
Hiroyuki Amano, Japan

UP–02.104
The Significance of Contiguous Tumour Positivity in Needle Biopsies of Prostate
Christian Bach, UK

UP–02.105
TRUS Prostatic Biopsy: Our Update Protocol for Performing and Processing Prostatic Needle Biopsies
José Cadilhe, Portugal

UP–02.106
Changes of Transrectal Ultrasonography in Prostatic Cancer Patients Under Hormonal Treatment and Radiotherapy
Shiou-Sheng Chen, Taiwan

UP–02.107
Infectious Complication After Transrectal Ultrasound-Guided Prostate Biopsies: A Review of 1525 Cases
Cheung Hing Cheng, China
UP–02.108
Results of a Questionnaire-Based Assessment of the Morbidity of a Modified Transperineal Template-Guided Saturation Prostate Biopsy in 110 Patients with Previous Negative TRUSB
Kingsley Ekwueme, UK

UP–02.109
Outcome of a Modified Transperineal Template-Guided Saturation Repeat Prostate Biopsy
Kingsley Ekwueme, UK

UP–02.110
The Impact of Antibiotic Treatment on the Way to Transrectal Ultrasound Guided Biopsy for Detection of Prostate Cancer
Erkan Erkan, Turkey

UP–02.111
Outcomes of Negative TRUS Guided Biopsies with Persistently Elevated PSA (>4 µg/mL) in Men Suspected of Prostate Cancer: Tayside Population-Based Study
Dinesh Ganeswaran, Malaysia

UP–02.112
Use of Diffusion-Weighted Magnetic Resonance Imaging To Direct Repeat Prostate Biopsy in Patients with Previous Negative Biopsies and Rising Prostate Specific Antigen
Samuel Grimsley, UK

UP–02.113
Epidemiological Trends in Prostate Cancer in the South of Tunisia Over the Last 24 Years
Nabil Mhiri, Tunisia

UP–02.114
Experience of Individual Screening of Prostate Cancer in Southern Tunisia
Nabil Mhiri, Tunisia

UP–02.115
Comparison of Histological Results Performed by Two Pathologists of Histoscanning-Guided Prostate-Biopsies
Claudius Hamann, Germany

UP–02.116
Histoscanning-Guided Prostate Biopsy in Comparison to a Systemic 14-Fold Transrectal Prostate Biopsy
Claudius Hamann, Germany

UP–02.117
Two Different Learning Models in Practicing Real-Time Elastography of the Prostate
Julia Heinzelbecker, Germany

UP–02.118
Patients Less Than 50 Years: A Time to Change PSA Cutoff Point for Prostate Cancer Screening
Ihab Hekal, Saudi Arabia

UP–02.119
Sonographic Changes of the Prostate: An Update
Ihab Hekal, Saudi Arabia
UP–02.120
Prognostic Significance of the Number of Biopsies in the Diagnosis of Prostate Cancer
Alberto Hernando Arteche, Spain

UP–02.121
Power Doppler Ultrasonography-Directed Prostate Biopsy in Men with Elevated Serum Prostate Specific Antigen Levels
Christopher Chee Kong Ho, Malaysia

UP–02.122
Predictive Impact of Free PSA/Total PSA (%fPSA) on the Development of Prostate Cancer in Men with Baseline PSA Lower Than 2.0ng/ml: Baseline PSA-Adjusted Case Control Study
Kazuto Ito, Japan

UP–02.123
Pre-Biopsy PSA Kinetics in Prostate Cancer Screening: Analysis of Toyota Motor Corporation Employees
Yasuaki Kubota, Japan

UP–02.124
A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-Core Biopsy Scheme
Tito Leitão, Portugal

UP–02.125
BMI and Bio-Impedance Factors Among Candidates to Prostate Cancer Screening: Implication of Obesity on Actual Cancer Diagnosis
Ivo Lopes, Portugal

UP–02.126
Negative Predictive Value of Prostate Histoscanning (Computer-Aided Tissue Characterization for Detection of Prostate Cancer): Preliminary Results
Oliver Markovsky, Germany

UP–02.127
Topical Diltiazem Before Transrectal Ultrasonography Guided Biopsy of the Prostate: A Randomized, Double Blind, Placebo Controlled Trial
Daniel Marshall, New Zealand

UP–02.128
Prostatic Dynamic Contrast Enhanced MR: Comparison Before and After HIFU Treatment for Prostate Cancer
Barbara Cristina Gentile, Italy

UP–02.129
5 Years Using 2007 Chun’s Nomogram in Diagnosis of Prostatic Cancer at Rebiopsy
Francesco Pisanti, Italy

UP–02.130
The Use of PSA-IgM in the Diagnosis of Prostate Cancer
Barbara Cristina Gentile, Italy

UP–02.131
Irreversible Electroporation, a Novel Technique for Focal Ablation of Prostate Cancer: Results of an Interim Pilot Safety Study in Low-Risk Patients with PCa
Maurizio Brausi, Italy
UP–02.132
Prostate Cancer Detection Rate: Correlation Between Prostate Volume and Number of Biopsy Positive Samples
Barbara Cristina Gentile, Italy

UP–02.133
Real-time Virtual Sonography for Prostate-Targeted Biopsy Based on MRI Data: Evaluation of Accuracy with Resected Specimens
Tomoaki Miyagawa, Japan

UP–02.134
Bacterial Sepsis Following Prostatic Biopsy
Stefano Picozzi, Italy

UP–02.135
Atypical Small Acinar Proliferation in Extended Transrectal Prostate Biopsy: Meaning and Clinical Implications
Bogdan Nicolae Pietricica, Spain

UP–02.136
Comparison of Various Risk Calculators for Prostate Cancer
Monique Roobol, The Netherlands

UP–02.137
A Randomized, Controlled Trial Comparing Lidocaine Periprostatic Nerve Block and Lidocaine Gel Intrarectally Associated with Tramadol Per Os for Transrectal Ultrasound Guided Biopsy of Prostate
Said Mohammed Moudouni, Morocco

UP–02.138
The Prostate Cancer Gene 3 (PCA3) Urine Test: Improving Prediction of Initial Biopsy and Management
Surayne Segaran, UK

UP–02.139
Transperineal Template Guided Saturation Biopsy Should Be Offered to All Men with Very Low Volume Cancer Diagnosed on Conventional TRUS Biopsy and Considering Active Surveillance
Helen Simpson, UK

UP–02.140
Comparison of Efficacy of Periprostatic Nerve Block Versus Combination of Periprostatic Nerve Block and Intraprostatic Anaesthesia During Transrectal Ultrasound Guided Prostate Biopsy
Santosh Kumar Singh, India

UP–02.141
TargetScan 3D Mapping Biopsies of the Prostate in Men with Prior Negative Biopsies
Sergiy Tadtayev, UK

UP–02.142
Prostate Cancer Primary Topographic Prevalence and Volumetry in 1,000 T1-2 Cases
Stefan Thüroff, Germany

UP–02.143
Major Complications and Associated Risk Factors of Transrectal Ultrasound Guided Prostate Needle Biopsy: A Retrospective Study of 611 Cases
Tatsuya Uesugi, Japan
UP–02.144
Apostolos P. Labanaris, Germany

UP–02.145
The Impact of Prostate Size on Surgical, Oncologic and Functional Outcomes of Patients Undergoing Robotic Prostatectomy
Apostolos P. Labanaris, Germany

UP–02.146
Meanings of the Polyunsaturated Fatty Acid in Patients with Prostate Cancer
Daisuke Yamada, Japan

UP–02.147
Cyclooxygenase-2 Overexpression in Chronic Inflammation Associated with Benign Prostate Hyperplasia: Is It Related to Apoptosis and Angiogenesis of Prostate Cancer?
Byung Hoon Kim, South Korea

UP–02.148
Probability and Prediction of Gleason Score Migration after Radical Prostatectomy
Kirill Nyushko, Russia

UP–02.149
Evaluation of the Learning Curve of Robotic Assisted Radical Prostatectomies with the Primary Focus on the Positive Surgical Margin Rate
Stefan Siemer, Germany

UP–02.150
Combined Oncological and Functional Outcomes 24 Months After Open Radical Prostatectomy: Results from a Contemporary Series of Patients
David Castelo, Portugal

UP–02.151
Confusion of the PSA Rebound Phenomenon After I-125 Prostate Brachytherapy: A Cohort Study of Minimum 3-Year Follow-Up
Cristian Vasile Casu, Spain

UP–02.152
PSA Bounce After Brachytherapy: Looking for Predicting Factors and Correlations
Catharina van Herpen, The Netherlands

UP–02.153
An International Multi-Centre Phase II Prospective Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer
Louise Dickinson, UK

UP–02.154
Duration of Androgen Deprivation Therapy with Maximum Androgen Blockade for Localized Prostate Cancer
Naohiro Fujimoto, Japan

UP–02.155
Correlation Between Urinary Continence and Potency Recovery in Patients After Open Radical Retropubic Nerve-Sparing Prostatectomy
Elena Golubtsova, Russia
UP–02.156
Improving the Preoperative Consultation Before Radical Prostatectomy Using Multimedia Support: A Randomized Controlled Trial
Sascha Pahernik, Germany

UP–02.157
The Impact of Intermittent Androgen Deprivation Therapy for Biochemical Failure After Radical Prostatectomy
Tsukasa Igawa, Japan

UP–02.158
Avoiding the Transperitoneal Detour: The Extraperitoneal Approach Proves Feasible in Robotic Prostatectomy
Rami Issa, UK

UP–02.159
Multivariate Analysis of Functional Outcomes After Robotic Prostatectomy: Size and Gleason Grade Counts
Rami Issa, UK

UP–02.160
Prognostic Value of Insulin-like Growth Factor II mRNA Binding Protein 3 in Prostate Cancer
Shahrokh F. Shariat, USA

UP–02.161
Low Dose Rate Prostate Brachytherapy: Review of Our Experience
Andrius Ivanauskas, Lithuania

UP–02.162
Fiducial Markers for Image Localization Guidance in Prostate Gland Radiotherapy
Amir Kaisary, UK

UP–02.163
Transurethral Resection of Middle Lobe in Occlusive Trilobal Prostate Gland Prior To Brachytherapy
Amir Kaisary, UK

UP–02.164
Impact of Increasing Active Surveillance on Pathological Outcome After Radical Prostatectomy
Markos Karavitakis, Greece

UP–02.165
Clinical Outcome: SV(+) Localized Advanced Prostate Cancer with PSA Over 50 Treated by HDR (High-Dose-Rate) Brachytherapy
Isao Kuroda, Japan

UP–02.166
Is There a Role for Routine Pelvic MRI in Intermediate Risk Prostate Cancer?
Raj Pal, UK

UP–02.167
Prostate Cancer Tumour Volumes and Lymph Node Metastasis: Do We Need MRI?
Simon Robinson, UK

UP–02.168
Serum Testosterone as a Predictor of Biochemical Failure after Radical Prostatectomy in Patients with Localized Prostate Cancer
M. Andreas Roder, Denmark

UP–02.169
Time Trends in Prostate Cancer Surgery: Data from an Internet-Based Multicenter Database
Martin Schostak, Germany
UP–02.170
Does Prostate Tumor Proximity to Surgical Margin in pT2 Disease Correlate with Biochemical Recurrence or All-Cause Mortality?
Isabell Sesterhenn, USA

UP–02.171
Incidence and Management of Vesicourethral Anastomotic Strictures After Radical Prostatectomy
Hajrudin Spahovic, Bosnia and Herzegovina

UP–02.172
The Appropriateness of Active Surveillance and the Impact of Prostate Cancer Gene 3 in Low Risk Prostate Cancer: An Analysis of Expert Opinion
Mark Speakman, UK

UP–02.173
Robotic Radical Prostatectomy: Evaluation of the Learning Curve
Miroslav Strbavy, Czech Republic

UP–02.174
The Effects of Neoadjuvant Hormonal Therapy on Vascular Endothelial Growth Factor and Microvessel Density in Prostate Cancer
Chong Koo Sul, South Korea

UP–02.175
Non-Invasive Therapy of Incidental Prostate Cancer by Robotic High Intensity Focused Ultrasound: 65 Patients Followed 9 Years
Stefan Thüroff, Germany

UP–02.176
PSA Nadir After TUR and Robotic High Intensity Focused Ultrasound in Localized Prostate Cancer: 677 Monocentric Cases Followed 15 Years
Stefan Thüroff, Germany

UP–02.177
Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Patients with a Pre-Operative Serum Prostate-Specific Antigen Level Higher Than 100 ng/mL
Shinji Urakami, Japan

UP–02.178
Radical Prostatectomy (RP) and Extensive Pelvic Lymphnode Dissection (EPLD) for Clinical T3 (CT3) Prostate Cancer (PCa): Single Center Long-Term Results
Maurizio Brausi, Italy

UP–02.179
Active Surveillance for Prostate Cancer
Jennifer Willder, UK

UP–02.180
Initial Experience of Iodine-125 (I-125) Permanent Seed-Implant Brachytherapy for Localized Prostate Cancer
Akihisa Yao, Japan

UP–02.182
Prognostic Value of the Determination of Plasmatic Chromogranin A in Patients with Localized and Metastatic Hormone-Sensitive Prostate Cancer
Javier Casado Varela, Spain
UP–02.183
Applicability of PCA3 Gene in the Molecular Detection of Prostate Cancer
Radu Minciu, UK

UP–02.184
Urinary PCA3 and Cancer Progression Under Active Surveillance of Prostate Cancer
Vincent Fradet, Canada

UP–02.185
Associations Among Anabolic Endocrine Axes in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
Noboru Hara, Japan

UP–02.186
Identification of MAPK10 as Novel Epigenetic Marker for Chromophobe Kidney Cancer
Hyung-Lae Lee, South Korea

UP–02.187
Clinical Analysis of Patients with Prostate Cancer Who Initially Demonstrated a Markedly Elevated Prostate Specific Antigen Level
Hiroya Mizusawa, Japan

UP–02.189
Robotic Prostatectomy: Evaluation of Surgical Margin Status in Patients with Pathological Proven Organ-Confined Disease as well as Extraprostatic Extension
Apostolos P. Labanaris, Germany

UP–02.190
Lectin-Based Glycoproteomic Profiling of Serum Samples from Patients with Prostate Cancer
Keng Lim Ng, Malaysia

UP–02.191
Acute Myocardial Infarction Without Cardiogenic Shock Does Not Affect Serum Prostate Specific Antigen Levels: A Case-Control Study
Çetin Volkan Öztekin, Turkey

UP–02.192
Radical Prostatectomy in Patients 70 Years or Older: An 18-Year Experience at a Single Private Practice Center
Godofredo Neyra Lee-Eng, Mexico

UP–02.193
Soluble Circulating Receptor Endoglin in Patients with Different Prostate Biopsy Diagnosis
Ivo Lopes, Portugal

UP–02.194
Improved Detection of Prostate Cancer by the Combined Application of ERG and AMACR Immunohistochemical Stainings in Prostate Biopsy Specimens
Isabell Sesterhenn, USA

UP–02.195
Clinicopathological Correlation of ERG Protein Expression in Single Focus Prostate Cancer
Isabell Sesterhenn, USA

UP–02.196
High-Grade Prostatic Intraepithelial Neoplasia: Incidence, Morphological and Immunohistochemical Features
Razvan Bardan, Romania
UP–02.197
Diagnosis Difficulties in Subtypes and Variants of Prostate Adenocarcinoma
Viorel Bucuras, Romania

UP–02.198
Trends in Risk Groups in a Series of 1210 Radical Prostatectomies
Luis Busto Martin, Spain

UP–02.199
Oncological Outcome of Radical Prostatectomy Patients with PSA 2.5 to 4 and 4–10
Luis Busto Martin, Spain

UP–02.200
Oncological Outcomes in Young Patients Treated with Low Dose Brachytherapy
Luis Busto Martin, Spain

UP–02.201
Oxidative Stress and the Study of the Protective Function of Organisms in Patients with Prostate Tumors
Teimuraz Chigogidze, Georgia

UP–02.202
Analysis of Prostatectomy Specimens from Patients Meeting the Criteria for Active Surveillance
Youssef Dakkak, Morocco

UP–02.203
Capturing Re-Admission and Complication Rates from TRUS Biopsy Procedure Using Healthcare Informatics Software Programmes
Dinesh Ganeswaran, Malaysia

UP–02.205
Hydro-Dissection Technique for Fast and Safe Transperineal Spacer Injection
Gencay Hatiboglu, Germany

UP–02.206
Obesity-PSA Relationship: A New Equation
Ihab Hekal, Saudi Arabia

UP–02.207
Prevalence of Histological Prostatitis in Men with Benign Prostatic Hyperplasia or Adenocarcinoma of the Prostate Presenting Without Urinary Retention
Amir Zarrabi, South Africa

UP–02.208
Insulin and Insulin Resistance Are Associated with the Advanced Pathological Stage of Prostate Cancer in the Korean Population
Won Tae Kim, South Korea

UP–02.209
Plasma D-dimer Levels in Prostate Cancer Patients Treated with Androgen-Suppression Therapy
Satoshi Kitahara, Japan

UP–02.210
The Effect of Recurrent Biopsies on Infection Rates, Hematuria, Rectal Hemorrhage and Hematospermia
Gokhan Koc, Turkey

UP–02.211
Effect of the Anesthesia Method Used During Prostate Biopsy on Re-Biopsy Decision
Gokhan Koc, Turkey
UP–02.212
Evaluation of Total Serum Testosterone in Patients with Clinically Localized Prostate Cancer
Christian Kratzik, Austria

UP–02.213
ABETRUS: Randomized Controlled Trial to Investigate the Use of Antibiotics Before Transrectal Ultrasound Guided Biopsy of the Prostate and Effects on PSA
Tricia Kuo, Singapore

UP–02.214
New MRI Pre-Planning for Prostate Brachytherapy
Katsuyuki Kuratsukuri, Japan

UP–02.215
Does Size Matter (in Robotic Prostatectomy)?
Saheel Mukhtar, UK

UP–02.216
How Intuitive Is Intuitive? An Analysis of Single Surgeon Operative Parameters in Robotic Prostatectomy
Saheel Mukhtar, UK

UP–02.217
The Combination of Real Time Elastography and PCA3 in Urine Detects 97% of Patients with Significant Prostate Cancer
Yngve Nygard, Norway

UP–02.218
Surgical and Functional Outcomes Using a Novel Device for Urethro-Vesical Anastomosis in Extraperitoneal Videolaparoscopic Prostatectomy
Antonio Luigi Pastore, Italy

UP–02.221
Polylestradiol Phosphate (Estradurin®) in Castration Resistant Prostate Cancer
M. Andreas Roder, Denmark

UP–02.222
Active Surveillance for Prostate Cancer: 8-Year Outcomes in a UK District General Hospital
Surayne Segaran, UK

UP–02.223
Effect of a Suspension Suture in Addition to a Total Anatomical Reconstruction in Robot-Assisted Laparoscopic Prostatectomy: Does It Help Early Continence?
Taimur Shah, UK

UP–02.224
Prostate Cancer Progression Under Long-Term ADT Treated by Robotic High Intensity Focused Ultrasound (rHIFU): Ten Years’ Efficacy and Side Effects
Stefan Thüroff, Germany

UP–02.225
Active Surveillance for Low-Risk Prostate Cancer: 3 Years’ Experience at a Teaching Hospital
Kevin Williams, UK

UP–02.226
Impacts of Pathological and Biochemical Outcome of Robotic-Assisted Radical Prostatectomy Versus Radical Retropubic Prostatectomy in High Risk Group of Localized Prostate Cancer
Wen-Chi Chen, Taiwan
UP–02.227
A Possibility of Prostate Cancer Chemoprevention by Diet
Hideyuki Akaza, Japan

UP–02.228
High Fat Intake Increases Prostatic Specific Antigen in Normal Japanese Population
Fumiyasu Endo, Japan

UP–02.229
Anti-Inflammatory Effects of Fish Oil (Omega-3 Fatty Acids) on Normal Human Prostate Epithelium
Vincent Fradet, Canada

UP–02.230
Local Staging of Prostate Cancer; Correlation Between Endorectal Magnetic Resonance Imaging and Pathological Findings After Radical Prostatectomy in Habitual Clinical Use
Francisco Jose Blasco Casares, Spain

UP–02.231
Does Prostate Biopsy Pose Problems in the Staging of Prostate Cancer by Magnetic Resonance Imaging Scan?
Ponnambalam Chandrasekar, UK

UP–02.232
Are All T3 Prostate Cancers Equal? A Scoring System for Prediction of Treatment Failure in T3a/B Prostate Cancer Following Radical Prostatectomy
Rami Issa, UK

UP–02.233
Prospective Evaluation of the Effectiveness of Low Dose Spinal Saddle Block Anesthesia for Pain Relief During Transrectal Digitally Guided Prostate Biopsy
Anselm Okwudili Obi, Nigeria

UP–02.234
Tertiary Pattern 5 Is an Indicator of Favorable Prognosis in Gleason 8 and 9 Disease
Hidekazu Yamamoto, UK

UP–02.235
Robotic Extended Pelvic Lymphadenectomy for Prostate Cancer
Bertram Yuh, USA

UP–02.236
Impact of a Systematic Educational Program To Shorten the Learning Curve for Holmium Laser Enucleation of the Prostate
Yoshiyuki Shiga, Japan
0630–0800

INSTRUCTIONAL COURSES IC10–IC14

►IC10: Tips and Tricks in Ileal Neobladder Construction with Nerve and Seminal Vesicle Sparing Cystectomy
Chair: Richard Hautmann, Germany

Room: Salon 11/12

0630–0650
Nerve-Sparing RCX
Urs E. Studer, Switzerland

0650–0700
Seminal Vesicle-Sparing RCX
Richard Hautmann

0700–0715
Orthoptic Reconstruction of Both Sexes: Tricks of the Trade
Urs E. Studer

0715–0730
Tips and Tricks
Richard Hautmann

0730–0750
Potential Complications
Björn G. Volkmer, Germany

0750–0800
Questions and Answers

►IC11: Management of Urothelial Carcinoma: Stage- and Site-Specific Discussions
Chair: Wassim Kassouf, Canada

Room: Salon 13/14

0630–0700
Practical Tips in the Management of Non-Muscle Invasive Bladder Cancer
Ashish Kamat, USA

0700–0730
Optimizing Quality of Care for Muscle-Invasive Bladder Cancer
Wassim Kassouf, Canada

0730–0800
Comprehensive Update on Upper Tract Urothelial Carcinoma
Shahrokh Shariat, USA

►IC12: Robot-Assisted Radical Cystectomy
Chair: Juan Palou, Spain

Room: Salon 15/16

0630–0650
RRC Surgical Technique in a Man with or without Nerve Sparing Technique, and the Relation with Functional Results
Juan Palou

0650–0710
RRC in Women with or without Vaginal Resection
Magnus Annerstedt, Sweden

0710–0730
Lymphadenectomy: Anatomical Landmarks and Basic Oncological Principles
Ashok K. Hemal, USA
**WEDNESDAY**
October 19

**0630–0800**

**INSTRUCTIONAL COURSES IC10–IC14**

▶ IC12: Robot-Assisted Radical Cystectomy

**0730–0750**

Urinary Diversion: Intra or Extracorporeal Diversion in RCC?
Peter Wiklund, Sweden

**0750–0800**

Results of Open Cystectomy vs RRC (Complications, Bleeding)
Juan Palou

▶ IC13: New Developments in Renal Stone Treatment Surgery

Chair: Jean de la Rosette, The Netherlands

**0630–0700**

Supine versus Prone PCNL
Jean de la Rosette

**0700–0730**

Combined PCNL and URS
Olivier Traxer, France

**0730–0800**

Drainage After PCNL: Percutaneous, Internal, None
Glenn Preminger, USA

▶ IC14: Prostatitis, Chronic Pelvic Pain Syndrome and Male Adnexitis

Chairs: J. Curtis Nickel, Canada
T. E. Bjerklund Johansen, Denmark

Room: Salon 17/18

**0630–0700**

Bacterial Prostatitis: Diagnosis and Therapy
Florian Wagenlehner, Germany

**0700–0730**

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Clinical Evidence Revisited Provides Rationale for Therapeutic Strategy
J. Curtis Nickel

**0730–0800**

Andrological Implications in Chronic Adnexitis
Wolfgang Weidner, Germany

**0800–1000**

PLENARY 3

▶ Benign Prostatic Hyperplasia

Chairs: Paul Abrams, UK
Mostafa Elhilali, Canada

Room: Hall 1

**0800–0810**

Clinical Pearls: The Past Year in Review: Lower Urinary Tract Dysfunction
Frank Lee, UK

**0810–0825**

LUTS Suggestive of BPO: Is a Pressure-Flow Study Always Needed?
Paul Abrams, UK
0825–0840
BPH and OAB
Luc Valiquette, Canada

0840–0900
AUA Lecture: Medical Therapy for Male LUTS and BPH: An Update in 2011
Claus Roehrborn, USA

0900–0915
Acute Urinary Retention (AUR) Secondary to BPO
John M. Fitzpatrick, Ireland

0915–0945
Pro-Con Debate: Is TURP Still the Gold Standard of Surgical Therapy?
Moderator: Mostafa Elhilali, Canada
Con: Oliver Reich, Germany
Pro: Michael Marberger, Austria

1000–1200
PARALLEL PLENARIES 11–13
PARALLEL PLENARY 11
► Stones
Chair: Petrisor Geavlete, Romania
Mahesh Desai, India

Room: Hall 7

1000–1030
Panel Discussion Based on Case Presentations: Management of Staghorn Stones Today
Chair: Mahesh Desai, India
Staghorn Calculus Large Volume/Bilateral Stones
Tarik Esen, Turkey
Staghorn Calculus with Bleeding Diathesis/Anticoagulant
Anup Patel, UK
Staghorn Calculus with Renal Failure
Petrisor Geavlete, Romania
Staghorn Calculus: The Planning of Surgery Lap Nephrolithotomy
Nasser Simforoosh, Iran

1030–1045
Retrograde Intrarenal Stone Surgery
Anup Patel, UK

1045–1100
Combined Percutaneous and Retrograde Ureteroscopic Approach
Roberto M. Scarpa, Italy

1100–1115
Laparoscopic Stone Removal
René Sotelo, Venezuela

1115–1145
Pro-Con Debate: ESWL vs. URS for Ureteral Stones
Moderator: TBC
ESWL: David Tolley, UK
URS: Andreas Gross, Germany

1145–1200
Where Is the Place for Medical Stone Therapy (Prevention, Chemolysis)?
Glenn Preminger, USA
PARALLEL PLENARY 12
Kidney Cancer
Chairs: Jan Breza, Slovakia
Simon Tanguay, Canada
Room: Hall 3

1000–1015
Active Surveillance: In Whom, Outcomes and Risks
Michael Jewett, Canada

1015–1030
Energy Ablative Therapy: In Whom, Which Access?
Michael Marberger, Austria

1030–1045
Robotic Tumor Resection: New Standard for Open Surgeons?
Joachim W. Thüroff, Germany

1045–1100
Management of RCC with IVC Thrombus
Markus Hohenfellner, Germany

1100–1115
Metastatic RCC: TKIs, mTOR 1/n Inhibitors or Antibodies?
Samir Taneja, USA

1115–1200
Panel Discussion Based on Case Presentations:
Which Treatment for Which Patient?
Moderator: Hein van Poppel, Belgium
Panelists: All

PARALLEL PLENARY 13
Diagnosis of Urothelial Tumors
Chairs: Imre Romics, Hungary
Fred Witjes, The Netherlands
Room: ICC Lounge

1000–1015
Urinary Markers
Yves Fradet, Canada

1015–1030
Fluorescence Cystoscopy
Marek Babjuk, Czech Republic

1030–1045
Optical Coherence Tomography
Seth Lerner, USA

1045–1100
Narrow Band Imaging
Jean de la Rosette, The Netherlands

1100–1115
Confocal Laser Endomicroscopy
Wolfgang Jäger, Germany

1115–1155
Panel Discussion: Clinical Potential and Cost/Benefit Analysis
Moderator: Fred Witjes
Panelists: All
1200–1315

BREAK

SPONSORED SYMPOSIUM
Bayer HealthCare

► CRPC: An Evolving Treatment Paradigm
Chair: Kurt Miller, Germany

Room: Stockholm

1200-1205
Introduction
Kurt Miller

1205-1225
Introduction to CRPC and Overview of New Treatment Options
Kurt Miller

1225-1245
Alpharadin (Radium-223) Preclinical and Early Clinical Trials
Sten Nilsson, Sweden

1245-1305
Presentation of the ALSYMPCA Data
Chris Parker, UK

1305-1315
Discussion

1315–1445

PARALLEL PLENARIES 14–16

PARALLEL PLENARY 14
► Neuro-Urology
Chair: Francisco Cruz, Portugal
Reynaldo Gómez, Chile

Room: Hall 7

1315–1335
Pro-Con Debate: How to Detect the “Aggressive Detrusor”

1315–1325
Leak Point Pressure
Sophie Fletcher, USA

1325-1335
Video Urodynamics
Juergen Pannek, Switzerland

1335-1350
Posterior Rhizotomy ± Electrical Stimulation
Helmut Madersbacher, Austria

1350-1405
Botox Detrusor Injections
Kurt McCammon, USA

1405-1420
Bladder Augmentation ± Sphincteric Augmentation
Anthony Mundy, UK

1420-1445
Case Presentations and Discussion
PARALLEL PLENARY 15
LESS Invasive Surgery
Chairs: Claude Abbou, France
Octavio Castillo, Chile
Room: ICC Lounge
1315–1330
LESS
Mihir Desai, USA
1330–1345
SMART
Jens Rassweiler, Germany
1345–1400
NOTES
René Sotelo, Venezuela
1400–1415
MIES
Pradeep Rao, India
1415–1445
Panel Discussion: Translating the Plethora of Acronyms into Clinical Reality
Moderator: Gunter Janetschek, Austria
Panelists: All

PARALLEL PLENARY 16
Urogenital Fistula
Chairs: Suzy Elneil, UK
Serigne Gueye, Senegal
Room: Hall 6
1315–1330
Evaluation and Classification of VVF
Oumarou Sanda Ganda, Niger
1330–1355
Surgical Principles and Early Management of VVF
Serigne Gueye
1355–1410
Iatrogenic Genitourinary Fistula: Clinical Features and Management
Dirk De Ridder, Belgium
1410–1425
Global Perspectives on Fistula Care and Training
Suzy Elneil
1425–1445
Discussion
ABSTRACT SESSIONS

PODIUM SESSION 7
Prostate Cancer, Localized

Chairs: Gerald Andriole, USA
Felix Chun, Germany

Room: Hall 8

1315–1325
POD–07.01
Dose Escalation with High-Dose 3D-Conformal Radiotherapy (HD-3D-CRT) or Low-Dose 3D-Conformal Radiotherapy Plus HDR Brachytherapy (LD-3D-CRT+HDR-B) for Intermediate-or High-Risk Prostate Cancer: Higher PSA Control with Lower Toxicity
Benjamin Guix, Spain

1325–1335
POD–07.02
Positive Surgical Margin at Bladder Neck Is an Independent Predictor of Local Failure and Prostate Cancer Mortality in pT3-Prostate Cancer. Results of a Prospective Single Institution Series
Martin Spahn, Germany

1335–1345
POD–07.03
Pathology Results of Radical Prostatectomy in Patients Initially Managed by Active Surveillance
Mark S. Soloway, USA

1345–1355
POD–07.04
Active Surveillance for Prostate Cancer: An Update on the Miami Experience
Mark S. Soloway, USA

1355–1405
POD–07.05
Radical Prostatectomy for High-Risk, Clinically Localized Adenocarcinoma of the Prostate
Paul Cozzi, Australia

1405–1415
POD–07.06
Inter-Observer Variability in the Interpretation of HistoScanning™ Characterisation of Prostate Cancer
Suzanne Van Den Heuvel, The Netherlands

1415–1425
POD–07.07
Long-Term Cancer Outcomes After Radical Prostatectomy and Selective Salvage Radiotherapy in 1670 Pt2-3N0M0 Patients by Margins Status: Quantification of Overtreatment with Adjuvant Radiotherapy for All Positive Margins
Vincent Fradet, Canada

1425–1435
POD–07.08
Morbidity of High Intensity Focused Ultrasound as a Primary Monotherapy for Low-Risk Localized Prostate Cancer: Outcomes from the ENLIGHT Trial
Cary Robertson, USA
1315–1445

MODERATED POSTER SESSION 14
Minimally Invasive Surgery

Chair: Joachim Thüroff, Germany

Room: Salon 11/12

MP–14.01
An Alternative Method for Veress Needle Access To Avoid Insertion Complications
Cetin Yesilli, Turkey

MP–14.02
Open vs Robot-Assisted Laparoscopic Nephron-Sparing Techniques: Are the Tumor-Free Margins Equivalent?
Matei Andreoiu, USA

MP–14.03
During the Learning Curve, Does the Robot-Assisted Partial Nephrectomy Have Equal Outcomes to the Open Partial Nephrectomy?
Thomas Jankowski, Germany

MP–14.04
Accuracy of Predictive Scoring Systems in Laparoscopic Nephrectomy
Omar Jundi, UK

MP–14.05
Prospective Comparison of En Bloc Hilar Ligation to Conventional Ligation During Laparoscopic Radical Nephrectomy for Early Renal Cell Carcinoma
Tae Hyo Kim, South Korea

MP–14.06
Techniques for Early Recovery of Continence in Patients with Robotic-Assisted Radical Prostatectomy
Tae Hyo Kim, South Korea

MP–14.07
Robotic Versus Conventional Laparoscopic Pyeloplasty: A Single Surgeon Concurrent Cohort Review
Amlesh Seth, India

MP–14.08
Laparo-Endoscopic Single Site Surgery: The University of South Florida Initial Experience
Alejandro Rodriguez, USA

MP–14.09
Open Conversion Cases During Laparoscopic Surgery: The Sapporo City General Hospital Experience
Toshimori Seki, Japan

MP–14.10
Robotic Partial Nephrectomy Using Robotic Bulldog Clamps: Initial Series
Craig Rogers, USA

MP–14.11
Robotic Partial Nephrectomy in Patients with Baseline Renal Insufficiency
Craig Rogers, USA

MP–14.12
Intraoperative Finding of Gross Lymph Node Metastasis During Robotic Radical Prostatectomy
Craig Rogers, USA
**MP–14.13**
Robotic Partial Nephrectomy Using a Robotic Ultrasound Probe for Tumor Identification: Initial Series and Outcomes
Craig Rogers, USA

**MP–14.14**
Single Port Retroperitoneal Laparoscopic Adrenalectomy for Large Adrenal Mass
Yeh Hong Tan, Singapore

**MP–14.15**
Single Port/LESS Nephrectomy and Nephroureterectomy: Initial Experience in Singapore
Yeh Hong Tan, Singapore

**MP–14.16**
Laparoscopic Versus Open Ureteroplasty and Ureterocystanastomosis: Choices for the Treatment of Congenital Megaureter
An Wei, China

---

**1315–1445**

**MODERATED POSTER SESSION 15**

**Penile/Testis: Benign & Malignant Disease**

**MP–15.01**
Prognostic Significance of Extracapsular Spread in Inguinal Nodes in Penile Cancer
Hussain Alnajjar, UK

**MP–15.02**
Long-Term Survival Outcomes of Primary Penile Cancer in a Supra-Regional Centre
Hussain Alnajjar, UK

**MP–15.03**
Long-Term Follow-Up After Neodymium-YAG Laser Therapy for Penile Squamous Cell Carcinoma
Rosa Djajadiningrat, The Netherlands

**MP–15.04**
Penile Intraepithelial Neoplasia: Incidence in The Netherlands
Evelien Trip, The Netherlands

**MP–15.05**
Allelic Losses in Apoptosis Regulators Are Frequently Found in Penile Cancer
Chris Protzel, Germany
MP–15.06
Lymphadenectomy in Penile Carcinomas: Guideline Recommendations Versus Clinical Practice
Chris Protzel, Germany

MP–15.07
Penis Carcinoma: Retrospective Study of the Last 15 Years in a Central Hospital of Northern Portugal
Frederico Teves, Portugal

MP–15.08
Repeat Inguinal Lymph Node Dissection for Locally Recurrent Penile Cancer: A Potentially Curative Procedure
Philippe E. Spiess, USA

MP–15.09
Outcome of Using Two-Stage Buccal Mucosal Graft for Replacement of Long Segment of Penile Urethral Stricture
Tarek Abdelbaky, Egypt

MP–15.12
Penile Frenuloplasty: A Safe and Acceptable Alternative to Circumcision for Frenular Pain or Scarring
Judith Dockray, UK

MP–15.13
Management of Cryptorchidism in Adolescent and Adult Males
Chris F. Heyns, South Africa

MP–15.14
Epidemiology of Urethral Strictures: Temporal Changes in Etiology and Socio-Demographic Determinants
Jo Van der Merwe, South Africa

MP–15.15
Initial Results of Male Circumcision with the Shang Ring™ Device
Alexander Hinev, Bulgaria

MP–15.16
Recurrence Rate for Internal Urethrotomy in Group of Patients with Moderate Urethral Stenosis
Dimitrije Jeremic, Serbia

MP–15.17
Testicular Torsion with Necrotic Outcome: Dilemmas of Surgical Timing
Chukwudi Okorie, Kenya

MP–15.18
Long-Standing Hydrocele in Adult Black Africans: Is Automatic Ordering of Pre-Operative Scrotal Ultrasound Justified?
Chukwudi Okorie, Kenya

MP–15.19
Management of Testicular Ischaemia Following an Inguinal Hernia Repair
Taimur Shah, UK
MP–15.20
Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients with Disseminated Nonseminomatous Testicular Tumors: Is a Post-Chemotherapy Retroperitoneal Lymphadenectomy Needed After Complete Remission?
Djordje Argirovic, Serbia

MP–15.21
Two Decades Experience with Single Cycle Adjuvant Chemotherapy in Stage I Non-Seminomatous Testis Cancer
Luis Ebel, Chile

MP–15.20
Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients with Disseminated Nonseminomatous Testicular Tumors: Is a Post-Chemotherapy Retroperitoneal Lymphadenectomy Needed After Complete Remission?
Djordje Argirovic, Serbia

MP–15.21
Two Decades Experience with Single Cycle Adjuvant Chemotherapy in Stage I Non-Seminomatous Testis Cancer
Luis Ebel, Chile

1315–1445
MODERATED POSTER SESSION 16
Prostate Cancer: Staging, Advanced & Markers

MP–16.01
Cellular and Humoral Immune System Activation by Sipuleucel-T: Preliminary Data from the OpenACT Phase 2 Trial
Daniel Petrylak, USA

MP–16.02
Locally Advanced PCa T3-4 Treated by Robotic High Intensity Focused Ultrasound: 150 Patients Followed 9 Years
Stefan Thüroff, Germany

MP–16.03
Nadir Prostate Specific Antigen (PSA) Level and Time to PSA Nadir Following Primary Androgen Deprivation Therapy Are the Early Survival Predictors for Prostate Cancer Patients with Bone Metastasis
Takeshi Sasaki, Japan

MP–16.04
Intermittent Low Dosage Stilboestrol for Invasive Cancer of the Prostate
Deen Sharma, Guyana

MP–16.05
Cause of Death in Elderly Patients with High-Risk PCa, Treated by Androgen Deprivation Therapy Alone
Helen Simpson, UK
MP–16.06
Changes in Body Composition, Development of Metabolic Syndrome (X) and Pathological Fractures in Men on Long-Term Androgen Deprivation Therapy
Stanislav Ziaran, Germany

MP–16.07
Prognostic Values of AMACR, PSMA, PSCA, EGFR, and Bcl-2 in Patients Undergoing Radical Prostatectomy: A Study with Objective Staining Score of Tissue Microarray
In-Chang Cho, South Korea

MP–16.08
Is Pro PSA a More Cancer-Specific Form of Prostate Specific Antigen for the Early Detection of Prostate Cancer?
Jiri Klecka, Czech Republic

MP–16.09
Correlation of PCA3 and MRI with Biopsy Outcome
Gisele Leyten, The Netherlands

MP–16.10
Expression Profiling of Laser Micro Dissected Prostate Cancer Cells Delineates Genes Associated with Biochemical Recurrence After Radical Prostatectomy
Martin Mørck Mortensen, Denmark

MP–16.11
Pathologic Outcomes of Patients Who Are Potential Candidates for Active Surveillance or Focal Therapy
Kirill Nyushko, Russia

MP–16.12
Pre-Operative Urinary Prostate Cancer Gene 3 in the Prediction of Small Tumor Volume, Insignificant, Locally Advanced and Aggressive Prostate Cancer
Felix Chun, Germany

MP–16.13
Bone Scan Should No Longer Be the First Staging Test in Prostate Cancer
Lina Maria Carmona, UK

MP–16.14
Improved Grouping System Combining Gleason Score for Group IV of TNM Prognostic Grouping for Prostate Cancer: Results from J-CAP Database
Shiro Hinotsu, Japan

MP–16.15
A Critical Analysis of the Performance of MRI and Partin’s Nomogram in Prostate Cancer Patients Undergoing Radical Treatment
Vivekanandan Kumar, UK

MP–16.16
Younger Patients Have Worse Biochemical Outcome After Radical Prostatectomy in High Risk Prostate Cancer
Sung Kyu Hong, South Korea

MP–16.17
Detection of Bone Metastases from Prostate Cancer: A Prospective Study of 99mTc-MDP Whole-Body Bone Scintigraphy, 18F-Fluorocholine PET/CT, 18F-Fluoride PET/CT Compared with MRI
Mads Hvid Poulsen, Denmark
MP–16.18
Predicting Low-Volume and Insignificant Prostate Cancer in Core-Needle Biopsies: Is It Possible?
M. Andreas Roder, Denmark

MP–16.19
Can Pre-Biopsy MRI Accurately Identify Prostate Cancer Location? Imaging in a 140 Patient Cohort when Compared to Subsequent Transperineal Template Guided Saturation Biopsy
Helen Simpson, UK

MP–16.20
Trends of the Clinical Characteristics and Primary Therapy in Patients with Prostate Cancer in Nara Uro-Oncological Research Group (NUORG)
Nobumichi Tanaka, Japan

MP–16.21
Achieving the “Bifecta” Using Salvage Cryotherapy for Locally Recurrent Prostate Cancer: Analysis of the COLD Registry Data
Philippe E. Spiess, USA

1315–1445
VIDEO SESSION 8:
▶ Miscellaneous Topics
Chairs: William J. Lynch, Australia
Steffen Weikert, Germany

Room: Salon 17/18

1315–1325
VID–08.01
Retroperitoneal Laparoscopic Living Donor Nephrectomy: A Simple Technique in Cho Ray Hospital
Tran Sinh, Vietnam

1325–1335
VID–08.02
Correction of Epispadias in Adult After Failed Repair in Childhood
Miroslav Djordjevic, Serbia

1335–1345
VID–08.03
Novel Management of Complicated Cases of Induratio Penis Plastica Using Buccal Mucosa and Geometrical Plaque Incision
Aref Elseweifi, Germany

1345–1355
VID–08.04
Partial Penile Neurectomy for Management of Premature Ejaculation
Aref Elseweifi, Germany
### VIDEO SESSION 9

**Adrenal, Kidney & Miscellaneous**

Chair: Michael Marberger, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Video</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1315–1325</td>
<td>VID–09.01</td>
<td>Advantages of Single Optical Port in Laparoscopic Bilateral Adrenalectomy</td>
<td>Marcos Cepeda Delgado, Spain</td>
</tr>
<tr>
<td>1325–1335</td>
<td>VID–09.02</td>
<td>Robotic Pyelolithotomy and Pyeloplasty in Horseshoe Kidneys</td>
<td>Gianluca D’Elia, Italy</td>
</tr>
<tr>
<td>1335–1345</td>
<td>VID–09.03</td>
<td>Laparoscopic Exeresis of Large Ureterocele, Megaureter and Hydronephrotic Kidney</td>
<td>Nerea Felip Santamaría, Spain</td>
</tr>
<tr>
<td>1345–1355</td>
<td>VID–09.04</td>
<td>Endoscopic Treatment of Fibroepithelial Polyp of the Ureter</td>
<td>Dario Garcia-Rojo, Spain</td>
</tr>
<tr>
<td>1355–1405</td>
<td>VID–09.05</td>
<td>Minilaparoscopy for the Treatment of Pyeloureteral Junction Stenosis</td>
<td>Marco Puglisi, Italy</td>
</tr>
</tbody>
</table>

**VIDEO SESSION 8**

**Miscellaneous Topics**

<table>
<thead>
<tr>
<th>Time</th>
<th>Video</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1315–1325</td>
<td>VID–08.05</td>
<td>Gloves Model for Laparoscopic Pyeloplasty Training</td>
<td>Amit Bhattu, India</td>
</tr>
<tr>
<td>1405–1415</td>
<td>VID–08.06</td>
<td>Y Neobladder: An Easy, Fast and Reliable Technique</td>
<td>Paolo De Stefanis, Italy</td>
</tr>
<tr>
<td>1415–1425</td>
<td>VID–08.07</td>
<td>The Split-Nipple Technique for Ureteral Reimplantation: Endoscopic Aspect and Applications</td>
<td>Mohammed Lezrek, Morocco</td>
</tr>
<tr>
<td>1425–1435</td>
<td>VID–08.08</td>
<td>Simplified Technique for Parastomal Hernia Repair</td>
<td>Joan Palou, Spain</td>
</tr>
<tr>
<td>1435–1445</td>
<td>VID–08.09</td>
<td>Laparoscopic Ileal Conduit: An Intracorporeal Uretero-ileal Anastomotic Technique</td>
<td>Paul Rouse, UK</td>
</tr>
</tbody>
</table>
1405–1415
VID–09.06
Laparoscopic Varicocelectomy Using Bipolar Cautery Versus Open Inguinal Technique: A Randomized Clinical Trial
Hosein Karami, Iran

1415–1425
VID–09.07
Bipolar Plasma Vaporization of Secondary Bladder Neck Sclerosis
Bogdan Florin Geavlete, Romania

1445–1500
BREAK

1500–1630
GENERAL ASSEMBLY
Room: Hall 3

1800–2000
SIU WORLD FORUM FOR PATIENTS
Room: ICC Lounge
This session will be conducted in German

1900–2300
SIU GALA BANQUET
The Schlüterhof German Historic Museum

UNMODERATED POSTER SESSION 3
Room: Exhibit Hall

UP–03.001
Adult Urological Sarcomas: 20-Year Experience
Manfred P. Wirth, Germany

UP–03.002
Application of Method of Continent Urinary Stoma Construction Using Diagonal Tubularization of Ileum Segment
Lidia Skobejko-Wlodarska, Poland

UP–03.003
Setting-Up of a Pediatric Urological Division in an Adult Urological Department
Vasile Dan Stanca, Romania

UP–03.004
The Use of Kampo Formula (Bupleurum Root Drug Group) in Mentally Retarded Patients with Enuresis
Kuri Suzuki, Japan

UP–03.005
Ingenuity To Treat Pediatric Urological Tumors More Safely and More Effectively
Atsuko Watanabe, Japan
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UP–03.006</td>
<td>Immunoexpression and Prognostic Value of CD9 in Epidermoid Carcinoma of the Penis</td>
<td>Luiz Renato Montez Guidoni, Brazil</td>
</tr>
<tr>
<td>UP–03.007</td>
<td>Treatment of Carcinoma In-Situ (CIS) of the Penis with Topical Chemotherapy Agents</td>
<td>Hussain Alnajjar, UK</td>
</tr>
<tr>
<td>UP–03.009</td>
<td>Penile Fracture: Why Should It not Be Operated Late?</td>
<td>Braiek Salem, Tunisia</td>
</tr>
<tr>
<td>UP–03.010</td>
<td>Scrotal Surgery After Inguinal Hernia Repair with Mesh</td>
<td>Aleksandar Ilievski, Macedonia</td>
</tr>
<tr>
<td>UP–03.011</td>
<td>Handling and Outcomes of Male Urinary Incontinence by Suburethral Sling After Radical Prostatectomy</td>
<td>Emilio Izquierdo Morejón, Spain</td>
</tr>
<tr>
<td>UP–03.012</td>
<td>Optical Internal Urethrotomy Revisited: The Modified Way We Do It</td>
<td>Sudhir Khanna, India</td>
</tr>
<tr>
<td>UP–03.013</td>
<td>Efficacy of Holmium Laser Urethrotomy in Combination with Intravesical Triamcinolone in the Treatment of Urethral Stricture</td>
<td>Santosh Kumar, India</td>
</tr>
<tr>
<td>UP–03.015</td>
<td>Is Trans-Obturator Tape (TOT) a Safe and Long-Term Effective Procedure?</td>
<td>Shivadeo Bapat, India</td>
</tr>
<tr>
<td>UP–03.016</td>
<td>Transvaginal Urethral Diverticulectomy Using Small Intestinal Submucosa Interposition Graft</td>
<td>Karen De Baets, Belgium</td>
</tr>
<tr>
<td>UP–03.017</td>
<td>Management of Iatrogenic Ureteral Defects Due to Oncogynecological Surgery and/or Pelvic Irradiation</td>
<td>Alexander Hinev, Bulgaria</td>
</tr>
<tr>
<td>UP–03.018</td>
<td>Management of Difficult Urethrovaginal Fistula Using Peritoneal Flap: Single Centre Experience</td>
<td>Suresh Patankar, India</td>
</tr>
<tr>
<td>UP–03.019</td>
<td>Combined Buccal Mucosa Graft Urethroplasty for Refractory Glanular Stricture: Intermediate-Term Results</td>
<td>Apul Goel, India</td>
</tr>
<tr>
<td>UP–03.020</td>
<td>Post-Circumcision Urethro-Cutaneous Fistula: Attention to Detail Enhances Reconstruction Success</td>
<td>Charles Mkony, Tanzania</td>
</tr>
<tr>
<td>UP–03.021</td>
<td>Malignancies in Augmentation Ileocystoplasties: A Review</td>
<td>Christian Nayar, UK</td>
</tr>
</tbody>
</table>
UP–03.022
Buccal Mucosal Graft in Reconstructive Urology: Uses Beyond Urethral Stricture
Abhishek Pandey, Germany

UP–03.023
Vessel-Sparing Urethroplasty
Suresh Patankar, India

UP–03.024
Laparoscopic Reconstruction of the Ureter for Recurrent Strictures: An Experimental Study
Mahmoud Shalaby, Egypt

UP–03.025
Feasibility of Hand-Assisted Laparoscopic Bilateral Native Nephrectomy in Patients with Advanced Kidney Disease
Ravi Barod, UK

UP–03.026
Impact of Surgeon Experience on Complication Rates and Functional Outcomes of 484 Deceased Donor Renal Transplants: A Single Center Retrospective Study
Hannes Cash, Germany

UP–03.027
Renal Transplantation in Patients with Neurogenic Bladder Following Mitrofanoff Continent Urinary Diversion
Nabil Mhiri, Tunisia

UP–03.028
A Procedure To Transplant a Kidney with Short Vein Removing by Laparoscopy
Tran Sinh, Vietnam

UP–03.029
Results of Renal Transplantation in Children with Posterior Urethral Valves: A Single Center Comparative Study
Mohamed Kamal Gheith, Germany

UP–03.035
Modified Lich-Grégoir Technique in Renal Transplantation by Assisted Peroperative Transvesical Cystoscopy
Tran Sinh, Vietnam

UP–03.037
Erectile Dysfunction and Important Clinical Connections
Jan Breza, Slovak Republic

UP–03.038
Intralbugineous N-butyl-2-cyanoacrylate (Histoacryl) Injection After Subcapsular Orchiectomy To Preserve Testicular Configuration: Experimental Study
Fathy Moussa, Egypt

UP–03.039
Does Daily Intake of Sildenafil Preserve the Histological Integrity of Corpus Cavernosum After Androgen Deprivation? Experimental Study
Fathy Moussa, Egypt

UP–03.040
Severe and Long-Standing “Penile Angina” Are Additively Associated with Poor Exercise Performance in Erectile Dysfunction Patients with Hypertension
Apostolos Rempelakos, Greece
UP–03.042  
Female Genital Sensation: Our Experience with the Genital Sensory Analayzer  
Giovanni Alei, Italy

UP–03.043  
3D-CT Cavernosography in Deep Dorsal Vein  
Yoshito Kusuhara, Japan

UP–03.044  
Difference of Erectile Function Using IIEF 5 and Erection Hardness Score Before and After TURP in BPH Patients  
Doddy Musbadianto Soebadi, Indonesia

UP–03.045  
Electromyographic Profiles of Corpus Cavernosum (CC-EMG) Before and After Radical Prostatectomy with or without Neurovascular Bundle Sparing  
Sasa Vojinov, Serbia

UP–03.047  
Comparing the Length of Penile Mucosa in Men with and without Premature Ejaculation  
Mehdi Faraji Shovey, Iran

UP–03.048  
Comorbidity Profiles Among Patients with Erectile Dysfunction: A Nationwide Population-Based Study  
Shun-Fa Hung, Taiwan

UP–03.049  
Ejaculatory Disorders: Comparison Between South and North  
Ekaterina Kulchavenya, Russia

UP–03.050  
Overactive Bladder as a Reason for Sexual Dysfunction in Women  
Ekaterina Kulchavenya, Russia

UP–03.051  
How Does the Addition of Trospium Chloride to the Alpha Blocker Treatment Affect the Sexual Life of Patients with Lower Urinary Tract Symptoms and Overactive Bladder?  
Hasan Soydan, Turkey

UP–03.052  
Combination of Andropenis® Penile Extender and Oral Therapy (Peironimev®) Versus Intralesional Verpamil for Penile Curvature Due to Peyronie’s Disease: Preliminary Results of a Randomized Phase II Trial  
Paolo Gontero, Italy

UP–03.053  
Hypogonadism in Patients with Obesity  
Catalin Pricop, Romania

UP–03.055  
Original Technique for Penile Lengthening: Ten Years’ Experience  
Giovanni Alei, Italy

UP–03.056  
Peyronie’s Disease Treatment by Penile Prosthesis Implantation and Tunica Albuginea Incisions without Grafting  
Vladimir Kojovic, Serbia

UP–03.057  
Early Insertion of Inflatable Penile Prosthesis for Intractable Ischemic Priapism  
Carlo Luigi Augusto Negro, UK
UP–03.058
A Pilot Study of the Changes in Intrarenal Pressure During the Accordion™ Stop-Gap Device Deployment During Percutaneous Nephrolithotomy
Joon Jae Park, Singapore

UP–03.059
Female Sexual Function After Vaginal Surgery Using Transobturator Mesh for Cystocele and Stress Urinary Incontinence
Cristian Gutue, Romania

UP–03.061
Melamine-Induced Urolithiasis in a Drosophila Model
Wen-Chi Chen, Taiwan

UP–03.062
Identification of Conditioning Film Components on Indwelling Ureteral Stents and Their Role in Bacterial Adhesion
Dirk Lange, Canada

UP–03.064
Stone Clearance in Lower Pole Nephrolithiasis after Extra Corporeal Shock Wave Lithotripsy in Elderly Patients
Mohamed Abdel Aziz, Saudi Arabia

UP–03.065
Outcome of One Stage Ureteroscopy for Bilateral Ureteric Stones
Ehab Galal, Egypt

UP–03.066
Is Routine Post-Operative Renal Tract Stone Culture Necessary?
Darrell Allen, UK

UP–03.068
Clinical and Radiological Parameters Predicting Spontaneous Passage During Expectant Management for Ureteral Stone
Kwang Soo Lee, South Korea

UP–03.069
Urological Management of Cystine Nephrolithiasis; 20 Years of Experience in Four Different Centres
Ruud C. Wortel, The Netherlands

UP–03.070
Lemon Juice or Potassium Citrate for Recurrent Stone Former: A Prospective, Randomized, Crossover Study
Vikas Agarwal, India

UP–03.071
A Prospective Randomized Clinical Trial To Compare the Clinical Efficacy and Tolerability of Potassium Citrate Versus Phytotherapy in Medical Management of Minimal Burden (Less Than 8mm) Nephrolithiasis
Iqbal Singh, India

UP–03.072
New Management of Upper Urinary Tract Obstruction by Using Allium® Stents
Joachim Alefelder, Germany

UP–03.073
Perurethral Multimodal Management of Multiple Renal Calculi
Shivadeo Bapat, India

UP–03.074
Stone and Patient Related Factors in Connection with Short-Term Complications Following E.S.W.L. Stone Management
Ionut Dumitru Chira, Romania
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>UP–03.075</td>
<td>Extracorporeal Shock Wave Lithotripsy with Siemens Modularis Lithostar Vario: Initial Experience</td>
<td>Erkan Erkan, Turkey</td>
</tr>
<tr>
<td>UP–03.076</td>
<td>Safer and More Efficient Shock Wave Lithotripsy Using Dornier Lithotripter S II</td>
<td>Kazunori Haga, Japan</td>
</tr>
<tr>
<td>UP–03.077</td>
<td>The Combination of Automatic Vibrator, Diuresis and Inversion for Adjuvant Treatment of Lower Calyceal Stone After Shock Wave Lithotripsy</td>
<td>Lukman Hakim, Indonesia</td>
</tr>
<tr>
<td>UP–03.078</td>
<td>An Alternative Method in Ureteroscopic Extraction of Ureteral Stones</td>
<td>Kikyung Kim, South Korea</td>
</tr>
<tr>
<td>UP–03.079</td>
<td>Safety and Efficiency of a Novel Endoscope for Bladder Stone</td>
<td>Aihua Li, China</td>
</tr>
<tr>
<td>UP–03.080</td>
<td>Digital Semirigid Ureteroscopy: A Single Center Experience of 100 Cases</td>
<td>Petrisor Aurelian Geavlete, Romania</td>
</tr>
<tr>
<td>UP–03.082</td>
<td>Percutaneous Nephrolithotomy Under General Versus Spinal-Epidural Anesthesia</td>
<td>Cetin Yesilli, Turkey</td>
</tr>
<tr>
<td>UP–03.083</td>
<td>Study of Phosphocalcium Metabolism and Markers of Bone Modelling in Patients with Calcium Lithiasis</td>
<td>Clara Lahoz Garcia, Spain</td>
</tr>
<tr>
<td>UP–03.084</td>
<td>Effect of Alendronate Sodium and 2-Year Follow-Up of Patients with Recurrent Calcium Nephrolithiasis</td>
<td>Clara Lahoz Garcia, Spain</td>
</tr>
<tr>
<td>UP–03.085</td>
<td>One-Day Ureteral Catheter Placement After Ureteroscopic Lithotripsy: A Prospective Study</td>
<td>Jeong Man Cho, South Korea</td>
</tr>
<tr>
<td>UP–03.086</td>
<td>Small Bowel Injury After Extracorporeal Shock Wave Lithotripsy: A Case Report</td>
<td>Chien-Ming Huang, Taiwan</td>
</tr>
<tr>
<td>UP–03.088</td>
<td>Villa Tiberia Experience in the Treatment of Renal Stones with Retrograde Intrarenal Surgery</td>
<td>Barbara Cristina Gentile, Italy</td>
</tr>
<tr>
<td>UP–03.089</td>
<td>Removing Locking Nephrostomy Tubes-Beware the Retained Thread</td>
<td>Somita Sarkar, UK</td>
</tr>
<tr>
<td>UP–03.090</td>
<td>Endoscopic Extraction of Bladder Lithiasis Through a Mitrofanoff Continent Diversion: A New Surgical Procedure</td>
<td>Nabil Mhiri, Tunisia</td>
</tr>
</tbody>
</table>
UP–03.091
Can a Radiologic Finding Predict the Outcome of Extracorporeal Shockwave Lithotripsy for Ureteral Stone?
Kwang Soo Lee, South Korea

UP–03.093
Retrograde-Anterograde Combined Catheterization in Ureteral Injuries
Omar Bilal Halawa Gonzalez, Spain

UP–03.094
Laser Holmium Retrograde Lithotripsy: A Single-Center Experience
Paulo Azinhais, Portugal

UP–03.096
Minimally Invasive Endourologic Management of Calculi in Continent Urinary Reservoirs: Experiences Using the Swiss Lithoclast® Master
Pernille Skjold Kingo, Denmark

UP–03.097
Endoscopic Realignment for Obliterative Stenosis of the Posterior Urethra Following Surgery for Benign Enlargement of the Prostate
Sanjay Kulkarni, India

UP–03.098
Transpubic Double Anastomotic Urethroplasty for Exclusion of the Prostatic Urethra Due to Trauma
Sanjay Kulkarni, India

UP–03.099
PCNL: Expanding Scope with the Nephroscope: A Single Centre Experience of 1200 Cases
Rajesh Kukreja, India

UP–03.100
Anti-Retropulsion Devices Increase Stone Fragmentation Efficiency with Holmium:YAG Laser Lithotripsy
Dirk Lange, Canada

UP–03.101
Outcome of Percutaneous Management of 118 Kidney Calculi: Staghorn Calculi Still a Challenge
Ivo Lopes, Portugal

UP–03.104
Percutaneous Nephrolithotomy: Lessons Learned After 3000 Procedures
Razvan Multescu, Romania

UP–03.105
Pyelocaliceal Diverticulum: Retrograde Endoscopic Approach of a Rare Pathology
Razvan Multescu, Romania

UP–03.106
Percutaneous Nephrolithotomy for Staghorn Calculi
Hoang Nguyen Phuc Cam, Vietnam

UP–03.108
The Prevalence of Malignancy in Non-Palpable Testicular Lesions 10mm or Less in Size
Ranjan Arianayagam, Australia

UP–03.110
Does Cisplatin Based Chemotherapy Effect on Blood Lipid Levels of Patients with Germ Cell Testicular Tumor in Long-Term Follow-Up?
Gokhan Koc, Turkey
**UP–03.111**  
TIN Therapy as Salvage Chemotherapy for Cisplatin Refractory Germ Cell Tumors  
Terukazu Nakamura, Japan

**UP–03.112**  
Redo-Retroperitoneal Lymphadenectomy for Nonseminomatous Germ Cell Testicular Tumors: Clinical Presentation, Patterns of Recurrence and Outcome  
Djordje Argirovic, Serbia

**UP–03.113**  
Long-Term Follow-Up Using Testicular Sparing Surgery for Malignant and Benign Diseases  
Giorgio Bozzini, Italy

**UP–03.114**  
Testis-Preserving Surgery in the Management of Leydig Cell Tumours: The Importance of Pre- and Intra-Operative Ultrasound  
Judith Dockray, UK

**UP–03.115**  
Update on Phase 1/2 Evaluation of Chemotherapy Plus Residual Tumour Excision for Testis Conservation  
Tim Oliver, UK

**UP–03.116**  
Creation of a Genitourinary Cancer Survivorship Clinic at a Comprehensive Cancer Center: Start-Up Design and Assessment of Met and Unmet Needs of the Target Population  
John Davis, USA

**UP–03.117**  
Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: Assessment of Adequate Renal Function and Impact on Outcome  
Wassim Kassouf, Canada

**UP–03.118**  
The UroTutor Project: Production of Low-Cost, High-Definition Instructional Videos for Teaching Urology to Medical Students  
Chris F. Heyns, South Africa

**UP–03.119**  
Complexities of the Learning Curve in Robotic Prostatectomy: How Intuitive Is Intuitive?  
Rami Issa, UK

**UP–03.120**  
Regional Medical Collaboration Guidelines for Lower Urinary Tract Symptoms (LUTS)  
Fukuji Kondo, Japan

**UP–03.121**  
Complications of Continent Catheterizable Channels: A 25-Year Experience  
Reynaldo Gómez, Chile

**UP–03.122**  
Prostate Myths: What Is the Prostate Awareness in the General Male Population in Turkey?  
Haluk Kulaksizoglu, Turkey

**UP–03.123**  
What is the Best Technique for Primary Closure of the Bladder Neck in Continent Ileovesicostomy?  
Reynaldo Gómez, Chile
UP–03.124
Bladder Neck Closure for Continent Ileovesicostomy by Transurethral Resection of the Membranous Urethra
Reynaldo Gómez, Chile

UP–03.125
Is YouTube the Future of Patient Information? An Analysis of a Common Urological Surgical Procedure Posted on a Global Video Sharing Website
Jonathan Kehinde Makanjuola, UK

UP–03.126
Google as Open Source Patient Information on Bladder Cancer: Is There Reliable and Safe Information for a Patient with a New Bladder Cancer Diagnosis?
Manar Malki, UK

UP–03.127
On Global Approaches to Genito-Urology in Context of Health Policy
Michael Ch. Michailov, Germany

UP–03.128
Low-Cost Laparoscopic Training for Urological Residents: Time Necessary To Compare to an Expert
Raul Montoya-Chinchilla, Spain

UP–03.129
Urogenital Injuries Associated with Diastasis of Pubic Symphysis Caused by Land Mine Blast
Emin Aydur, Turkey

UP–03.130
To Evaluate Accuracy of Pre-Operative Sonourethrogram and Retrograde Urethrogram in Spongiofibrosis of Urethral Stricture Disease
Shivadeo Bapat, India

UP–03.131
Urethral “Sphincter” Strictures Post TURP: “Barbagli” Dorsal Buccal Mucosa Onlay Graft Repair
Cristian Surcel, Romania

UP–03.132
Long-Term Evolution of Missed Genitourinary Trauma Injuries in Serious Polytraumatized Patients: Importance of Tertiary Trauma Survey
Dario Garcia-Rojo, Spain

UP–03.133
Management of Kidney Trauma in Moroccan Military Active Population
Abdelaziz Hamdoune, Morocco

UP–03.134
Short-Term Outcome, Morbidity and Quality of Life of Artificial Urinary Sphincter: A Retrospective Study
Luis Alex Kluth, Germany

UP–03.135
Urology Trauma: Urban Battlefield: Our Experience of Establishing a Urology Trauma Service at a London Major Trauma Centre
Jonathan Kehinde Makanjuola, UK

UP–03.136
The Barbagli Technique: 3-Year Experience with a Modified Approach
Daniel Pfalzgraf, Germany

UP–03.137
Urethroplasty with Lingual Mucosa Free Graft-Long Term Results and Operative Techniques Used
Elenko Popov, Bulgaria
UP–03.138
Outcome of Dual Flange Metallic Sphincteric Urethral Stents in the Treatment of Neuropathic Bladder Dysfunction After Spinal Cord Injury
Andre Van Der Merwe, South Africa

UP–03.139
Endoscopic Laser Therapy as First-Line Treatment for Upper Urinary Tract Transitional Cell Carcinoma Smaller Than Two Centimeters
Elodie Beels, Belgium

UP–03.140
Endoscopic Laser Therapy as Alternative for Nephroureterectomy in Patients with Upper Urinary Tract Transitional Cell Carcinoma
Elodie Beels, Belgium

UP–03.141
Concomitant Transitional Cell Carcinoma of the Bladder in Patients with Urinary Tract Transitional Cell Carcinoma
Elodie Beels, Belgium

UP–03.142
Upper Urinary Tract TCC Recurrence Rate Following Radical Cystectomy for Bladder Cancer: A Meta-Analysis of 13,185 Patients
Giorgio Bozzini, Italy

UP–03.143
Analysis of Lymphadenectomy During Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
Hiroshi Furuse, Japan

UP–03.144
Surgical Options in Urothelial Tumors of the Upper Urinary Tract
Alexander Hinev, Bulgaria

UP–03.145
T2 Ureteral Tumor and Severe Hydronephrosis: Poor Prognostic Factors in Upper Urinary Tract Transitional Cell Carcinoma
Seung Il Jung, South Korea

UP–03.146
The Impact of Intravesical Recurrence on Prognosis After Nephroureterectomy for Upper Urinary Tract Urothelial Cancer
Junichi Inokuchi, Japan

UP–03.147
Predictive Factors for Bladder Recurrence after Radical Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma
Se Joong Kim, South Korea

UP–03.148
Large Pelvic Masses of Obscure Origin: Urologist’s Perspective
Santosh Kumar, India

UP–03.149
Endoscopic Circumferential Mobilization of Distal Ureter in Laparoscopic Nephro-Ureterectomy: A Safe Option for Suspected Cancer
Rhana Zakri, UK
UP–03.150
The Role of Lymph Node Dissection During Nephroureterectomy in the Management of Upper Urinary Tract Urothelial Carcinoma: The Canadian Experience
Ricardo Rendon, Canada

UP–03.151
Significance of Hemoglobin Value Before Gemcitabine/ Cisplatin or Carboplatin Treatment as an Independent Prognostic Biomarker in Advanced Urothelial Cancer
Shuichi Morizane, Japan

UP–03.152
Prognosis and Prognostic Factors in Renal Pelvis and Ureter Tumors
Jong Kil Nam, South Korea

UP–03.153
Modified Supine Position Hand-Assisted Transperitoneoscopic Nephroureterectomy
Sung Hyun Paick, South Korea

UP–03.154
Tumor Location, as a Predictor of Recurrence and Cancer-Specific Mortality, in Endourological Treatment of Upper Urinary Tract Urothelial Tumors
Joan Palou, Spain

UP–03.155
Results of BCG and MMC in Transitional Cell Carcinoma of Upper Urinary Tract: Spanish Cooperative Group Register of Upper Urinary Tract Tumors
Joan Palou, Spain

UP–03.156
Mitrofanoff’s Continent Urinary Diversion in Patients with Spinal Cord Injury: Indication and Results
Nabil Mhiri, Tunisia

UP–03.157
Intradetrusor Injection of Botulinum Neurotoxin Type A in Patients with Idiopathic Detrusor Overactivity Undergoing Radical Retropubic Prostatectomy
Apostolos P. Labanaris, Germany

UP–03.159
Early Experience Robot-Assisted Laparoscopic Radical Cystectomy and Neobladder without Redocking
Yong Seong Lee, South Korea

UP–03.160
Continent Cutaneous Diversion A.M. Lundiana in 200 Patients: Complications from Reservoir and Outlet
Wiking Månsson, Sweden

UP–03.161
The Diagnostic Role of Transabdominal Ultrasonographic Bladder Wall Thickness in Female Urinary Incontinence
Emin Aydur, Turkey

UP–03.162
Assessment of Effects of Pelvic Floor Muscle Exercises Performed with Music
Satoshi Honda, Japan

UP–03.163
Intravesical Intramuscular Botulinumtoxin-A-Injection (IIB-A-I) in Patients with Idiopathic and Neurogenic Detrusor Overactivity: 7 Years of Application
Christoph Lang, Germany
UP–03.164
Long-Term Urodynamic Evaluation in Patients Treated with Transobturator Vaginal Tape (TVT-O) for Urinary Incontinence
Mariarita Salvitti, Italy

UP–03.165
Urinary Incontinence and Erectile Dysfunction Post-Prostatectomy: Simultaneous or Delayed Surgical Correction?
Carlo Luigi Augusto Negro, UK

UP–03.166
A Classical Bulking Agent: GAX Collagen: A 10-Year Single Centre Experience
Cristian Persu, Romania

UP–03.167
Effectiveness of Biofeedback Training with EXTT-101™ in Female Stress Urinary Incontinence
Chong Koo Sul, South Korea

UP–03.168
Long-Term Follow-Up of Argus T® (Adjustable Transobturator Sling) for the Treatment of Post-Radical Prostatectomy Urinary Incontinence
Flavio Trigo Rocha, Argentina

UP–03.169
Preserved Micturition in Parkinson Patients Treated with Botulinum Toxin for Neurogenic Bladder Dysfunction
Stephanie Knüpfer, Germany

UP–03.170
The Effects of Pelvic Floor Muscle Targeted Pilates Versus Regular Aerobic Exercise on Urinary Incontinence
Haluk Kulaksizoglu, Turkey

UP–03.171
Efficacy and Safety of Onabotulinumtoxin A in Patients with Neurogenic Detrusor Overactivity: Pooled Analysis from Two Phase 3 Trials
Karl-Dietrich Sievert, Germany

UP–03.172
Pharmacotherapy with Donepezil for Voiding Dysfunction in Down Syndrome Patients
Mitsuru Noguchi, Japan

UP–03.173
Correlation Between the Overactive Bladder Questionnaire (OAB-Q) and Urodynamic Data of Parkinson’s Disease Patients Affected By Neurogenic Detrusor Overactivity During Antimuscarinic Treatment
Antonio Luigi Pastore, Italy

UP–03.174
Sacral Neuromodulation for Urinary and Bowel Control: Indications and First Results
Silvia Salm, Germany

UP–03.175
Granulocyte Macrophage Colony-Stimulating Factor Promotes Early Functional Changes of the Neurogenic Bladder after Compression-Induced Spinal Cord Injury in Awake Sprague-Dawley Rats
Sang Min Yoon, South Korea
UP–03.176
Suburethral Bone-Screwed Sling in Male Incontinence: Technique and Experience
Alexander Andrusco, Chile

UP–03.177
Minimally Invasive Surgical Treatment of Complex Genital Prolapse in Elderly Women: Impact on Quality of Life
Cristian Surcel, Romania

UP–03.178
Prognostic Factors for a Successful Therapy of Male Stress Incontinence with the ProACT System
Christoph Briel, Germany

UP–03.179
Effects of Solifenacin on Detrusor Function in Chinese Patients with Symptomatic Overactive Bladder
Yan Chen, China

UP–03.180
The Self Anchoring Adjustable Transobturator Male System (ATOMS®) in the Treatment of Stress Urinary Incontinence in Men: A Retrospective Multicenter Study of 99 Patients
Katja Fischereder, Austria

UP–03.181
Discrepancy Between Subjective and Objective Outcome of Surgery for Postprostatectomy Incontinence: Do We Need Multiple Outcome Assessments?
Henriette Veiby Holm, Norway

UP–03.183
The Association Between Urinary Incontinence, Low Back Pain, and Radiculopathy
Hulagu Kaptan, Turkey

UP–03.184
The Prevalence of Incontinence and Overactive Bladder Symptoms Among Randomly Sampled Non-Elderly Female Population and the General Knowledge About Female Urinary Dysfunction in the Female Community
Haluk Kulaksizoglu, Turkey

UP–03.185
Laparoscopic Artificial Urinary Sphincter for Female Stress Urinary Incontinence: Single Center Experience with 39 Cases
Tito Leitão, Portugal

UP–03.186
A Tertiary Experience of Male Bulbar Urethral Closure in Neuropathic and Non-Neuropathic Patients
Aidan Noon, UK

UP–03.187
Effect of Complete Bladder Neck Preservation on Oncological Outcome, Continence and QOL: A Randomised Controlled Trial
Joanne Nyarangi-Dix, Germany

UP–03.188
Timing of Repeat Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Patients’ Perspectives
Niyukta Thakare, UK
UP–03.189
Do Patients Prefer Being Taught Intermittent Self-Catheterisation Pre-Operatively Before Intravesical Botulinum Toxin A Injections?
Niyukta Thakare, UK

UP–03.190
Adverse Effects of Tolterodine Tartrate and Solifenacin Succinate on the Central Nervous System in Children
Masayuki Tsugaya, Japan

UP–03.191
Clinical Experience of Interstitial Cystitis Treated with Hydrodistension
Yasuyo Yamamoto, Japan

UP–03.192
Tibial Nerve Stimulation in Women with Non-Neurogenic Lower Urinary Tract Dysfunction
Emin Aydur, Turkey

UP–03.193
Surgical Treatment of Stress Urinary Incontinence with the ATOMS® System: One-Year Single Centre Experience
Christian Martenstein, Germany

UP–03.194
Correlation of Urinary Nerve Growth Factor Level with the Response of Antimuscarinic Therapy in Patients with Overactive Bladder
Teruhiko Yokoyama, Japan

UP–03.196
Drug-Taking History in Patients with Refractory Storage Symptoms
Emin Aydur, Turkey

UP–03.197
Early Clinical Outcome of Fesoterodine 4 Mg Treatment on 304 Patients with Overactive Bladder
Woo Suk Choi, South Korea

UP–03.198
The GnRH-Receptor Antagonist Degarelix Reduces Urodynamic Signs of Detrusor Overactivity in Awake Female Rats
Giorgio Gandaglia, Italy

UP–03.199
Long-Term Results of Anticholinergic Agents for the Treatment of OAB by Real-Life Clinical Practice
Naoki Itoh, Japan

UP–03.200
Brain-Derived Neurotrophic Factor: A New Potential Biomarker of Overactive Bladder Syndrome
Tiago Lopes, Portugal

UP–03.201
Role of the Addition of Trospium Chloride to the Treatment of Patients with Both Low Urinary Tract Symptoms and Overactive Bladder
Hasan Soydan, Turkey

UP–03.202
The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Responded Poorly to Previous Anticholinergic Agents
Masumori Naoya, Japan
UP–03.203
Role of Myosin Light Chain Kinase and Rho Kinase in Carbachol-Induced Contractions of Human Detrusor Smooth Muscle
Chris Protzel, Germany

UP–03.204
A Flexible Dose Transdermal Oxybutynin Gel for the Treatment of Overactive Bladder: Phase III Results
David Staskin, USA

UP–03.205
Nursing Approach to Potential Overactive Bladder Patients: A Prospective Study
Katsuki Tsuchiyama, Japan

UP–03.206
Comparison of Two Different Antimuscarinics, Imidafenacin and Solifenacin for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study
Aya Ohbatake, Japan

UP–03.207
Compensation Mechanisms of the Bladder in Bladder Outlet Obstruction by Concentric and Dilatative Vesicomyopathies
Saladin Alloussi, Germany

UP–03.208
Non-Invasive Urodynamics: Our Experience
Barbara Cristina Gentile, Italy

UP–03.212
Sacral Deafferentation in Neurogenic Detrusor Overactivity in Spinal Cord Injury and Implant Driven Micturition
Johannes Kutzenberger, Germany

UP–03.213
Better Modalities of Catheter Preservation Method Regarding Urinary Tract Infection of the Elderly Person from Clean Intermittent Catheterization
Hitoshi Oh-Oka, Japan

UP–03.214
The Place of the Ice Water Test During the Urodynamic Evaluation
Cristian Persu, Romania

UP–03.215
Pressure Transmission Through Ureteric Stents: A Novel In-Vivo Human Study
Wael Sameh, Egypt

UP–03.216
Should Urinalysis Be Routinely Performed Prior To Urodynamic Studies?
Niyukta Thakare, UK

UP–03.203
Role of Myosin Light Chain Kinase and Rho Kinase in Carbachol-Induced Contractions of Human Detrusor Smooth Muscle
Chris Protzel, Germany

UP–03.204
A Flexible Dose Transdermal Oxybutynin Gel for the Treatment of Overactive Bladder: Phase III Results
David Staskin, USA

UP–03.205
Nursing Approach to Potential Overactive Bladder Patients: A Prospective Study
Katsuki Tsuchiyama, Japan

UP–03.206
Comparison of Two Different Antimuscarinics, Imidafenacin and Solifenacin for Treatment of Overactive Bladder: A Prospective Randomized Controlled Study
Aya Ohbatake, Japan

UP–03.207
Compensation Mechanisms of the Bladder in Bladder Outlet Obstruction by Concentric and Dilatative Vesicomyopathies
Saladin Alloussi, Germany

UP–03.208
Non-Invasive Urodynamics: Our Experience
Barbara Cristina Gentile, Italy

UP–03.212
Sacral Deafferentation in Neurogenic Detrusor Overactivity in Spinal Cord Injury and Implant Driven Micturition
Johannes Kutzenberger, Germany

UP–03.213
Better Modalities of Catheter Preservation Method Regarding Urinary Tract Infection of the Elderly Person from Clean Intermittent Catheterization
Hitoshi Oh-Oka, Japan

UP–03.214
The Place of the Ice Water Test During the Urodynamic Evaluation
Cristian Persu, Romania

UP–03.215
Pressure Transmission Through Ureteric Stents: A Novel In-Vivo Human Study
Wael Sameh, Egypt

UP–03.216
Should Urinalysis Be Routinely Performed Prior To Urodynamic Studies?
Niyukta Thakare, UK
0800–1200

PLENARY 4

Chairs: Mahesh Desai, India
Luc Valiquette, Canada

0800–0810
Clinical Pearls: The Past Year in Review:
Stones/Endourology
Matthew Bultitude, UK

0810–0830
PAUSA Lecture: Bladder Carcinoma in Africa:
Epidemiology and Treatment
Ismail Khalaf, Egypt

0830–0850
Evidence-Based Medicine and Its Use in Everyday
Practice
John M. Fitzpatrick, Ireland

0850–0905
Meeting the Challenges of Evidence-Based Prostate
Cancer: Early Detection and Treatment
Peter Carroll, USA

0905–0920
Prevention
Timothy Wilt, USA

0920–0940
Epidemiology and Natural History of Prostate Cancer
Seth Strope, USA

0940–0955
Biomarker Identification of Active Surveillance
Candidates
Jack Schalken, The Netherlands

0955–1010
Low-Risk Localized PCA
Peter Carroll, USA

1010–1025
High-Risk Localized PCA
William Aronson, USA

1025–1110
Questions and Discussion

1050–1110
Special Lecture: The Cost of Prostate Cancer
Healthcare
Stephen Riggs, USA

1110–1130
UAA Lecture: Holmium Laser Enucleation of the
Prostate (HoLEP): Evolution of a Surgical Technique
Peter Gilling, New Zealand

1130–1135
Farewell
Joachim W. Thüroff, Germany

1135–1145
Invitation to SIU 2012 in Fukuoka
Mahesh Desai, India
Seiji Naito, Japan
READ-BY-TITLE ABSTRACTS

Given space and time constraints, these abstracts could not be scheduled for presentation. Abstracts are listed in order of corresponding author’s last name.

Sexual Dysfunction
Yasser Abbass, Qatar

The Value of Color Doppler Ultrasound (Twinkle Sign) in the Diagnosis of Urinary Stones
Mohamed Abdallah, Egypt

PSA and Prostate Cancer
Abdalla Abdel Rahman, Sudan

Laparoscopic Pyeloplasty Initial Experience
Elemam Abdelbaset, Egypt

Trends of Genito-Urinary Cancer Among Saudis
Mohammed Abomelha, Saudi Arabia

A Randomized Clinical Trial of Rectal Antisepsis Prior to Transrectal Ultrasound-Guided Prostate Biopsy
Zeid AbuGhosh, Jordan

A Very Rare Congenital Anomaly: An Interesting Case of Bladder and Urethral Agenesis with Solitary Kidney and Ectopic Ureter
Neeraj Agarwal, India

Relationship of Seminal Plasma, Spermatic Vein and Peripheral Blood Levels of IL–6 and TNF-alpha with Semen Parameters in Patients with Varicocele
Yadollah Ahmadi AsrBadr, Iran

The Effect of Botulinum Toxin A in Treatment of Painful Bladder Syndrome
Hassan Ahmadnia, Iran

Damaged Extracellular Matrix Alters Localization of DNA Methyltransferase Activity in Bladder Smooth Muscle Cells
Karen Aitken, Canada

Sexual Problems of Women with Spinal Cord Injury
R. Yavuz Akman, Turkey

Sexual Activity and Sexual Dysfunction in Men with Spinal Cord Injuries
R. Yavuz Akman, Turkey

Serum Zinc Level in Benign Prostatic Hyperplasia in Relation with the Clinical Manifestation Index
Hayder Ismael Al Amery, Iraq

Surgical Treatment of Phimosis of the Clitoris in Woman Presenting Sexual Dysfunction: A Case Report
Giovanni Alei, Italy

Initial Experience of Photodynamic Therapy in Prostate Cancer Patients
Boris Alekseev, Russia

Long-Term Outcome of Randomized Trial Between Cryoablation and External Beam Therapy for Locally Advanced Prostate Cancer (T2c–T3b)
Ali Al-Zahrani, Canada

Partial Nephrectomy for Tumors Over 4 cms: Clinical Outcomes and Assessment of Complication Using a Graded Score
Ali Al-Zahrani, Canada
### READ-BY-TITLE ABSTRACTS

<table>
<thead>
<tr>
<th>Abstract</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical Nephrectomy in Patients with Inferior Vena Cava and Renal Vein Involvement: Clinical Outcomes and Assessment of Complications Using a Graded Score</td>
<td>Ali Al-Zahrani</td>
<td>Canada</td>
</tr>
<tr>
<td>Role of Serum and Urinary Carbohydrate Antigen 19–9 in Diagnosis and Follow-Up of Patients with Ureteral Stone</td>
<td>Erfan Amini</td>
<td>Iran</td>
</tr>
<tr>
<td>Percutaneous Removal of Kidney Sludge Mimicking Complete Bilateral Renal Staghorn Stone</td>
<td>Mohsen Amjadi</td>
<td>Iran</td>
</tr>
<tr>
<td>The Influence of Incidentally Found Prostate Cancer on Overall Survival After Cystoprostatectomy at the Institute of Oncology of Vilnius University</td>
<td>Marius Anglickis</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Multidisciplinary Approach in Urinary Bladder Salvage Management</td>
<td>Tariq Ansari</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Long-Time Follow-Up of Hypospadias Treatment in Semnan Educational Hospital</td>
<td>Davood Arab</td>
<td>Iran</td>
</tr>
<tr>
<td>Retrocaval Ureter: Experience with 3 Patients</td>
<td>Ersan Arda</td>
<td>Turkey</td>
</tr>
<tr>
<td>Do Ureteral Catheterization Procedures Affect Sexual Functions in Patients? A Controlled Prospective Study</td>
<td>Ersan Arda</td>
<td>Turkey</td>
</tr>
<tr>
<td>Quality of Life Outcomes Following Treatment for Localized and Metastatic Prostate Cancer Patients and Optimal Time for the Questionnaire</td>
<td>Ersan Arda</td>
<td>Turkey</td>
</tr>
<tr>
<td>How to Improve the Efficacy of Extracorporeal Shock Waves: Application of Focal Energy Coefficient</td>
<td>Miguel Angel Arrabal-Polo</td>
<td>Spain</td>
</tr>
<tr>
<td>The Role of Intraprostatic Inflammation in the Acute Urinary Retention</td>
<td>Seyed Alaeddin Asgari</td>
<td>Iran</td>
</tr>
<tr>
<td>Severe Complications of Circumcision: An Analysis of 704 Cases</td>
<td>Seyed Alaeddin Asgari</td>
<td>Iran</td>
</tr>
<tr>
<td>The Less Invasive Open Pyeloplasty</td>
<td>Seyed Alaeddin Asgari</td>
<td>Iran</td>
</tr>
<tr>
<td>Treatment of Renal Colic with Papaverine Hydrochloride: A Prospective Double Blind Randomized Study</td>
<td>Seyed Alaeddin Asgari</td>
<td>Iran</td>
</tr>
<tr>
<td>Sutureless Circumcision</td>
<td>Seyed Alaeddin Asgari</td>
<td>Iran</td>
</tr>
<tr>
<td>Detrusor Myomectomy: Long-Term Functional Results</td>
<td>M Z Aslam</td>
<td>UK</td>
</tr>
<tr>
<td>Combining Endoscopy with Laparoscopic Pyeloplasty: Limitations and Challenges of the Procedure</td>
<td>Akram Assem</td>
<td>Egypt</td>
</tr>
<tr>
<td>The Role of Urinalysis in Women with Habit of Micturition Postponement and Non-Neurogenic LUTS</td>
<td>Emin Aydur</td>
<td>Turkey</td>
</tr>
<tr>
<td>Effect of Long-Acting Testosterone Injections for Treatment of Hypogonadism After Brachytherapy for Prostate Cancer</td>
<td>Felipe Balbontin</td>
<td>Chile</td>
</tr>
<tr>
<td>Cystitis Cystica Masquerading as a Bladder Tumor</td>
<td>Shivadeo Bapat</td>
<td>India</td>
</tr>
<tr>
<td>A Case of Ureteric Fibroepithelial Polyp with Impacted Calculus</td>
<td>Shivadeo Bapat</td>
<td>India</td>
</tr>
</tbody>
</table>
A Case of Migrated Intra Uterine Contraceptive Device into the Urinary Bladder
Shivadeo Bapat, India

A Study of Two Cases of Vesical Pheochromocytoma
Shivadeo Bapat, India

The Most Important Metabolic Risk Factors in Recurrent Urinary Stone Formers in Iran
Abbas Basiri, Iran

Brain Metastasis After Radical Cystectomy for Invasive Bladder Tumor
Catalin Baston, Romania

Prostate Cancer with Neuroendocrine Differentiation: Case Presentation
Catalin Baston, Romania

Primary Scrotal Melanoma
Catalin Baston, Romania

A Rare Case of Transitional Cell Carcinoma of the Bladder Presenting as Inguinal Lymph Node Metastasis Only
Vikram Batra, India

Extended Core TRUS Biopsy: Impact on Preoperative Grading of Adenocarcinoma Prostate
Amit Bhattu, India

The Role of Fascin in the Migration and Invasiveness of Prostate Carcinoma
Jian-Bin Bi, China

The pT1 High Grade Bladder Tumor: Early Versus Deferred Cystectomy
Julien Branchereau, France

Right Living Donor Nephrectomy: Is Laparoscopy Possible?
Julien Branchereau, France

Incidence of Delirium in Elderly Patients Undergoing Urologic Surgery: The Role of Comprehensive Geriatric Assessment (CGA) to Define a High-Risk Population for Delirium
Maurizio Brausi, Italy

Arterio-Venous Fistula with Pseudoaneurysm of Renal Artery: A Rare Complication of Invasive Interventions on the Kidney
Jan Breza, Slovak Republic

The First Experiences of Our Centre of Robotic Surgery in Usti Nad Labem, Czech Republic with Robotic Partial Nephrectomy
Marek Broul, Czech Republic

Three Years’ Experience with HoLEP (Holmium Laser Enucleation of Prostate) with AURIGA XL in BOO: A Well-Established Procedure Especially for a Small Urologic Department
Juergen R. Bubeck, Germany

Tachypnea as Useful Indicator to Mutiple Organ Dysfunction Syndrome Prevention in Urologic Patients
Sorin Bulgariu, Romania

Characterization of Single Nucleotide Polymorphisms Within the MMP–1 Promoter Region in Women with and without Pelvic Organ Prolapse
Lysanne Campeau, USA

Zinner’s Syndrome: Seminal Vesicle Cyst Associated with Renal Agenesis
Juan Pablo Caprini, Argentina

Salvage Robot Assisted Radical Prostatectomy after Radiation Failure and Focal Cryotherapy
Sanket Chauhan, USA

Early Retrograde Nerve Preservation During Robot-Assisted Radical Prostatectomy Improves Potency Outcomes
Sanket Chauhan, USA
READ-BY-TITLE ABSTRACTS

Robotic-Assisted Laparoscopic Dismembered Pyeloplasty (RALDP) for Primary and Secondary Ureteropelvic Junction Obstruction: A Multi-Institutional Experience
Sanket Chauhan, USA

Incremental Nerve Preservation During Robot Assisted Radical Prostatectomy
Sanket Chauhan, USA

Robot Assisted Bladder Diverticulectomy
Sanket Chauhan, USA

Robot Assisted Simple Prostatectomy: Technique of Vesico-Urethral Anastomosis
Sanket Chauhan, USA

Salvage Robot Assisted Radical Prostatectomy: Multi-institutional Outcomes
Sanket Chauhan, USA

Salvage Robot Assisted Radical Prostatectomy: Single Surgeon Experience
Sanket Chauhan, USA

Syndrome of Endogenous Intoxication in Men with Prostate Tumours
Teimuraz Chigogidze, Georgia

Neoadjuvant Chemotherapy for Locally Advanced and/or Regionally Metastatic Bladder Cancer in Chinese Chak Lam Cho, Hong Kong
LAN in Staghorn Calculi
Dae Yeon Cho, South Korea

The Influences of Urinary Stone Components on Outcomes of Electrohydraulic Lithotripsy
Sung Tae Cho, South Korea

The After Effect of Penile Vaselinoma in Case with a Penile Fracture
Sung Tae Cho, South Korea

Comparison of Clinical Results Between TURP and Holmium Laser Enucleation of the Prostate (HoLEP) Based on the Initial Experience on Patients with Obstructive BPH
Seong Choi, South Korea

Serum Testosterone Levels Significantly Correlate with Nocturia in Men Aged 40–79 Years
Liao ChunHou, Taiwan

The “Paradoxal” Backwards Movement of Lumbar Ureteral Stones or Fragments after Extracorporeal Shockwave Lithotripsy
Catalin Ciuta, Romania

The Treatment of Hypospadias at the Department of Urology, University of the Free State, South Africa: A Review of 88 Cases
Frederik Claassen, South Africa

Holmium Laser Enucleation of the Prostate for BPH: Our Initial Experience
Dorin Claici, Romania

Radical Perineal Prostatectomy: An Outdated Procedure?
Evi Comploj, Italy

Effectiveness and Cost Analysis of Different Methods of Anti-Refluxive Operations in VUR Grade 3 in a Single Institution
Evi Comploj, Italy

Can DNA Repair and Apoptosis Predict the Hormone Sensitivity/Insensitivity of Prostate Cancer?
Alin Adrian Cumpanas, Romania

Pseudotumor of the Urinary Bladder: Not to Be Confused with Cancer
Youssef Dakkak, Morocco
READ-BY-TITLE ABSTRACTS

Treatment of Proximal Ureteral Stones by Ureteroscopy: Is this a Good Solution?
Youssef Dakkak, Morocco

Results of Percutaneous Nephrolithotripsy (PCNL) of Upper Calices Stone with Subcostal Access
Mohammad Reza Darabi Mahboub, Iran

PCNL in Single-Kidney Patients: Ten Years’ Experience
Mohammad Reza Darabi Mahboub, Iran

Salvage Residual Tumour Resection for NSGCT: Presentation of an Extreme Indication
Paolo De Stefanis, Italy

Bone Resorption and Prostate Cancer Metastatic Disease
Yuri Demidko, Russia

Artificial Urinary Sphincter AMS 800 After Failed First Anti-Incontinence Procedures for Post-Prostatectomy Stress Urinary Incontinence
Andrea Di Stasio, Italy

Monitored Anesthesia Care or Subarachnoid Anesthesia in Trans-Obturator Midurethral Sling Procedures? A Randomized Controlled Trial
Andrea Di Stasio, Italy

Holmium Enucleation of the Prostate in Treating Patients with BPH
Alim Dymov, Russia

Likelihood of Pathologic Stage T0 Urothelial Carcinoma at the Time of Radical Cystectomy
John Eifler, USA

Does Capsular Perforation During Transurethral Resection of the Prostate Cause Erectile Dysfunction?
Ahmed El-Feel, Egypt

A Mouse Model of Type II Diabetes Induces Erectile Dysfunction
Riyad Ellati, USA

Tension-Free Vaginal Tape Versus Rectus Fascial Sling for the Management of Female Genuine Stress Urinary Incontinence: A Comparative Study with 2 Years’ Follow-Up
Tarek El-Leithy, Egypt

Effectiveness of a Single Immediate Mitomycin-C Instillation in Patients with Low-Risk Superficial Bladder Cancer: Short- and Long-Term Follow-Up
Tarek El-Leithy, Egypt

Long Fibroepithelial Polyp as a Cause of Ureteral Obstruction
Alireza Farshi Haghro, Iran

Outcome of Prostate Biopsy in Men Younger than 50 Years
Luis Figueiredo, Portugal

Collision Kidney Tumor: Synchronous Ipsilateral Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma with Liver Metastasis
Zoran Filipovic, Serbia

Failure to Perform a Testicular Biopsy Prior to Surgical Correction in Obstructive Azoospermia Results in Unnecessary Operative Interventions
M.A. Fischer, Canada

Partial Nephrectomy Thorough a Small Incision with Renal Parenchymal Clamping
Akitoshi Fukatsu, Japan

Solo Ultrasonography-Guided Percutaneous Nephrolithotomy for Single Stone Pelvis
Wael Gamal, Egypt
READ-BY-TITLE ABSTRACTS

Stentless Pediatric Ureteroscopic Holmium: YAG Laser Stone Disintegration: Is Gravels Retrieval an Issue?
Wael Gamal, Egypt

Modified N-Shaped Ileal Neobladder After Radical Cystectomy
Wael Gamal, Egypt

Penile Fracture: Long-Term Results of Surgical and Conservative Management
Wael Gamal, Egypt

Tubularized Incised-Plate (TIP) Repair Augmented by Spongioplasty for Distal and Midpenile Hypospadias
Wael Gamal, Egypt

Ureteroscopy with Two Guide Wires: A New Technique
Wael Gamal, Egypt

Development of Magnetic Hyperthermia Using Titanium Capsules for Brachytherapy to Treat Prostate Cancer
Tatsuo Gondo, Japan

Rare Cause of Hematuria: Oopharovesical Fistula
Hari Govind, India

Distal Ureteral Diverticulum Presenting as a Large Pelvic Cyst
Arvind Goyal, India

Feasibility of Laparoendoscopic Single-Site Radical Nephrectomy for Renal Cell Cancer in Patients with Increased Comorbidities and Previous Abdominal Surgery: Evaluation of Perioperative Results and Short-Term Outcomes
Francesco Greco, Germany

Characterization of Attenuating Effects of Intravesical Trospium Chloride on the Cholinergic Stimulation of Isolated Whole Pig Bladders: A Pharmacodynamic Model to Design a Intravesical Drug Delivery Device?
Joachim Grosse, Germany

Autotransplantation After Severe Avulsion Injury of the Ureter Following Ureteroscopy
Anil Gulia, India

Management of Chylous Ascites After Nephrectomy
Anil Gulia, India

Management of Failed Urethroplasty
Anil Gulia, India

Analysis of 1200 Cases of Laparoscopic Donor Nephrectomy from a Developing Country
Anil Gulia, India

RIRS Before Donor Nephrectomy
Anil Gulia, India

Gelatin Matrix Thrombin Sealant (Floseal) Injection to Salvage Refractory Post Renal Biopsy Bleed
Anil Gulia, India

Management of Iatrogenic Ureteric Injuries
Bakhman Guliev, Russia

Rupture of Continent Urinary Reservoirs
Bakhman Guliev, Russia

Percutaneous Nephroureterolithotomy for Large Proximal Ureteral Stones
Bakhman Guliev, Russia

Urodynamic Studies of Orthotopic Neobladder: Updated Experience in Different Groups
Bakhman Guliev, Russia

Bilateral Simultaneous Percutaneous Nephrolithotomy
Bakhman Guliev, Russia

Interest of the Treatment of Varicocele in Infertile and Azoospermic Men
Mourad Hadj Slimen, Tunisia

Peculiarities of the Association Between Bladder Cancers and Upper Urinary Tract Cancer
Mourad Hadj Slimen, Tunisia
Paratesticular Tumors: Report of 12 Cases
Abdelaziz Hamdoune, Morocco

Tumors of the Urinary Tract: Report of 8 Cases
Abdelaziz Hamdoune, Morocco

Combination Chemotherapy with Paclitaxel Plus Gemcitabine in Patients with Metastatic Bladder Cancer, Ureteral and Renal Pelvic Cancer as Second-Line Treatment
Kouji Harimoto, Japan

Angiotensin-Converting-Enzyme Gene Polymorphism and the Risk of Prostate Cancer in Iranian Patients
Mandana Hasanzad, Iran

Evaluation of a New Technique for Cutaneous Continent Urinary Diversion: The Embedded Nipple Technique
Mohamed Mohie Eldin Hashad, Egypt

Ileal Cystoplasty According to Us
Isa Haxhiu, Kosovo

DWI- MRI: Single Non-Invasive MRI Technique for Prostate Cancer Diagnosis
Ihab Hekal, Saudi Arabia

Surgical Management of Undescended Testes in Adults
Chris F. Heyns, South Africa

Laparoscopic Partial Nephrectomy: Experience in 118 Cases
Fumiya Hongo, Japan

Non-Disease-Related Prognostic Factors in Locally Advanced Prostate Cancer: A Multi-Center Experience
Chao-Yu Hsu, Belgium

Neoadjuvant Hormonal Treatment Did Not Improve the Outcome in Locally Advanced Prostate Cancer After Radical Prostatectomy: A Multi-Center Experience
Chao-Yu Hsu, Belgium

Huge Vesicle Stones Induced by a Straw: A Case Report
Chien-Ming Huang, Taiwan

Penis Augmentation by Oil Injection Inducing Foreign Body Granuloma and Dyspareunia: A Case Report
Chien-Ming Huang, Taiwan

Eosinophilic Cystitis Simulating Invasive Bladder Cancer
Chien-Ming Huang, Taiwan

A Novel Renal Stones Phantom for Extracorporeal Shock Wave Lithotripsy and Ultrasound Study
Chien-Ming Huang, Taiwan

Autonomic Dysreflexia during Urodynamic Examinations in Patients with Supra-sacral Spinal Cord Injury
Yu-Hui Huang, Taiwan

Failed Zuidex Injection for Female Stress Incontinence: What Next?
Sarah Huf, United Kingdom

Serum C-Reactive Protein Is Associated with Storage But Not with Empty Symptoms in Men with Lower Urinary Tract Symptoms
Shun-Fa Hung, Taiwan

Evaluation of the Role of Second TUR for Transurethral Resection of Bladder Tumor in One Piece (TURBO)
Hiroshi Ikeda, Japan

TUL for Right Upper Ureteral Stone in a Retrocaval Ureter without Surgical Correction
Yoshiyuki Ishiura, Japan

Outcomes of Laparoscopic Implementation Program with Successive Addition of Surgeons in a Secondary Hospital: After the First 160 Cases of Laparoscopic Radical Prostatectomy
Emílio Izquierdo Morejón, Spain
READ-BY-TITLE ABSTRACTS

Active Surveillance in a Community Practice from 2007 to 2011
Miles Jackson, Canada

The Effect of Korean Red Ginseng Extract on Relaxation Response on the Animal Bladder and Prostatic Urethra: In Vitro and In Vivo Study
Hoon Ah Jang, Korea

Prognostic Factors for Persistent Storage Symptoms Following Surgical Treatment in Patients with Benign Prostatic Obstruction
Hoon Ah Jang, Korea

Bladder Cancer and Human Papillomavirus Infection: A Meta-Analysis of the Relationship Between Them
Antonio Jimenez-Pacheco, Spain

Rare Case of Hematuria in a Female Patient
Ashish Jindal, India

Oncological Outcomes After Radical Prostatectomy in Locally Advanced Prostate Cancer: A Multi-Center Experience
Steven Joniau, Belgium

Comparative Analysis of Robotic-Assisted Laparoscopic Radical Cystectomy (RARC) and Hand-Assisted Laparoscopic Radical Cystectomy (HALRC) With Extracorporeal Urinary Diversion
Seil Jung, South Korea

Carcinoma Virilisation of the Suprarenal Gland
Mekeme Mekeme Junior Barthelemy, Cameroon

Etiologies and Management of Hydronephrosis of a Child: Experiment of the General Hospital of Yaounde
Mekeme Mekeme Junior Barthelemy Cameroon

Calcium Sensitization by Protein Kinase C Pathway in Contraction of Human and Guinea-Pig Detrusor Smooth Muscle Following Partial Bladder Outlet Obstruction
Shunichi Kajioka, Japan

The Role of Gap Junction Inhibitor and Tyrosine Kinase Inhibitor in Carbachol Induced Oscillatory and Tonic Contraction in Isolated Pig Detrusor Smooth Muscle
Shunichi Kajioka, Japan

Surgical Treatment for Synchronous Renal Cell Carcinoma
Boris Kajmakovic, Serbia

Impact of LUTS/BPH Treatment by Tamsulosin and Solifenacin Combination Therapy on Erectile Function
Sungchul Kam, South Korea

Effect of Tribulus Terrestris Extract in the Corporal Smooth Muscle of the Rabbit
Sungchul Kam, South Korea

Testicular Catch Up Following Adolescent Varicocele Repair
Mohammed Kamal, Egypt

Diagnostic Value of Helical CT on Stone Composition
Osman Karabacak, Turkey

Urodynamic Findings in Young Men with Chronic Lower Urinary Tract Symptoms
Hosein Karami, Iran

Urodynamic Findings in Children with High Grade Vesicoureteral Reflux
Hosein Karami, Iran

Ureterorenoscopy Made Easy with Perioperative Hyocine Butylbromide
Anurag Khaitan, India

Rare Bladder Tumors: Diagnostic Dilemma
Sudhir Khanna, India

Renal Carbuncle with Renal Vein and Inferior Vena Cava Thrombosis: Managed Conservatively by Novel Technique
Sudhir Khanna, India
<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complications of Open Living Donor Nephrectomy: A Review of 10-Years' Experience</td>
<td>Dinyar Khazaeli</td>
<td>Iran</td>
</tr>
<tr>
<td>Prevalence and Management of Complications of Ureteroscopy: A 7-Year Experience with Introduction of a New Maneuver for Prevention of Ureteral Avulsion</td>
<td>Dinyar Khazaeli</td>
<td>Iran</td>
</tr>
<tr>
<td>Orthotopic Continent Diversion With Only One Urethral Catheter No Routine Pouch Irrigation With Long-Acting Sandostatin</td>
<td>Mohannad Hatef Khorrami</td>
<td>Iran</td>
</tr>
<tr>
<td>How Can We Safely Use Ultrasonic Laparoscopic Coagulating Shears?</td>
<td>Jae-Sik Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>A Case of Bilateral Ureteral Endometriosis</td>
<td>Ju Sung Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>The Importance of Cancer Volume and Percentage of Cancerous Cells as Predictors of BCR of Pathological T2, T3 PC</td>
<td>Sea Young Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>The Effects of TOT for Patients of Neuropathic Bladder Including Stress Incontinence: The Results of 5-Year Follow-Up</td>
<td>Sea Young Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>Prostate Cancer Location Concordance Analysis Between Prostate Biopsies and Radical Prostatectomy Specimens</td>
<td>Sea Young Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>Clinical Efficacy of Tape Cutting as a Treatment for Complication in TOT</td>
<td>Sea Young Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>Initial Reports for Repair of Bladder Injury Using Laparoendoscopic Single Site Surgery in Comparison to Conventional Laparoscopic Repair</td>
<td>Tae Hyo Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>The Effects of Various Stressful Conditions on Erection and Manifestation of Oxytocin Positive Neuron of Apomorphine in Mice</td>
<td>Young-Joo Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>A New Method of Ureterolysis with Seprafilm Wrap for Retroperitoneal Fibrosis: A Report of Two Cases</td>
<td>Kyosuke Kimura</td>
<td>Japan</td>
</tr>
<tr>
<td>Nerve Sparing Procedure Improves Early Return of Continence After Robotic-Assisted Radical Prostatectomy</td>
<td>Young Hwii Ko</td>
<td>South Korea</td>
</tr>
<tr>
<td>Neoadjuvant Gemcitabine Plus Cisplatin Followed by Radical Cystectomy for cT3 Bladder Cancer</td>
<td>Kiichiro Kodaira</td>
<td>Japan</td>
</tr>
<tr>
<td>Causative Role of Sexually Transmitted Infections (STI) in Development of Chronic Cystitis</td>
<td>Yulia Kondratyeva</td>
<td>Russia</td>
</tr>
<tr>
<td>Endoscopic Management with Holmium Laser of Sub Urethral Tape after Bladder Neck Erosion</td>
<td>Charalampos Konstantinidis</td>
<td>Greece</td>
</tr>
<tr>
<td>Endoscopic Intradetrusoreal Botulinum Toxin Type A Injection for the Management of Neurogenic Detrusor Overactivity: Technique Demonstration</td>
<td>Charalampos Konstantinidis</td>
<td>Greece</td>
</tr>
<tr>
<td>Local Relapse in Ileum-Neobladder: 2 Cases and a Literature Survey</td>
<td>Xaver Krah</td>
<td>Germany</td>
</tr>
<tr>
<td>Prolonged Postoperative Ileus: Rare, But Do Not Underestimate Complication after Radical Prostatectomy</td>
<td>Xaver Krah</td>
<td>Germany</td>
</tr>
<tr>
<td>Malignant Testicular Sex Cord Stromal Tumor</td>
<td>Xaver Krah</td>
<td>Germany</td>
</tr>
</tbody>
</table>
READ-BY-TITLE ABSTRACTS

What’s After Gemcitabin and Platin for Metastatic Transitional Cell Cancer
Xaver Krah, Germany

pT0 at Radical Cystectomy: A Review of 14 Studies Encompassing 9623 Patients
Peter Kronenberg, Portugal

Gigantic Nephro-Thoracic Abscess: A Urologic Challenge
Peter Kronenberg, Portugal

Three-Dimensional 14-Core Extended Prostate Biopsy Under Local Anesthesia
Yuichi Kubo, Japan

Sexual Health in Siberians
Ekaterina Kulchavenya, Russia

Urethral Steinstrasse with Fistula and Stricture
Santosh Kumar, India

Laparoscopic Resection of Bilateral Large Adrenal Ganglioneuroma
Santosh Kumar, India

Emphysematous Pyelonephritis Following Embolisation of Renal Angiomyolipoma in a Patient Presenting with Massive Hematuria
Santosh Kumar, India

The Efficacy of Oral Bisphosphonates for Osteoporosis Induced by Androgen Deprivation Therapy for Localized Prostate Cancer
Isao Kuroda, Japan

Causes of Obstructive Azoospermia and Outcome of Microsurgical Reconstruction
Joong Shik Lee, South Korea

The Inverse Technique Can Improve the Safety and Efficacy of the Morcellation in HoLEP for BPH
Su Hyung Lee, South Korea

Temsirolimus Treatment in Advanced Renal Cell Carcinoma
Ivan Levakov, Serbia

Transurethral Intravesical Mesh Removal: Like a Natural Orifice Laparoscopic Single-Site Procedure
Mohammed Lezrek, Morocco

Increased Penile Expression of Transforming Growth Factor and Elevated Systemic Oxidative Stress in Rabbits with Chronic Partial Bladder Outlet Obstruction
Wei Yu Lin, Taiwan

Evaluation of Second-Look Transurethral Resection in Restaging of Patients with Non-Muscle-Invasive-Invasive Bladder Cancer
Michele Lodde, Italy

Prevalence of Metabolic Syndrome and Prostate Cancer
Daniel López-Laur, Argentina

Laparoscopic Nephrectomy: Our Cases and Evaluation of the Learning Curve
Giuseppe Lotrecchiano, Italy

Urodynamic Analysis of Voiding Symptoms in Female Patients
Ji Lu, China

The Clinical Significance of Bladder Contractility Index in Treating BPH
Ji Lu, China

Testis Lymphoma and Spermatic Cord Liposarcoma: A Unique Coexistence
Ricardo Leao, Portugal
READ-BY-TITLE ABSTRACTS

The Assessment of Transurethral Injection of Botulinum Toxin-A Effect on BPH Refractory to Current Medical Treatment in Poor Surgical Candidates
Ali Hamidi Madani, Iran

Percutaneous Nephrolithotomy in Children by Using Adult Size Instruments: 3 Years' Experience
Robab Maghsoudi, Iran

Outcomes of Percutaneous Nephrolithotomy (PCNL) in Patients with Chronic Renal Insufficiency
Robab Maghsoudi, Iran

Comparison of Outcomes of Single-Tract Percutaneous Nephrolithotomy (PCNL) with Multi-Tract PCNL in Patients with Staghorn Calculi
Robab Maghsoudi, Iran

Early and Late Levels of Prostate Specific Antigen and Testosterone After Renal Transplant
Reza Mahdavi Zafarghandi, Iran

The Role of Transurethral Resection of Prostate in Detecting Prostate Cancer in Patients with Previously Negative Biopsy, Elevated PSA Levels and Positive Lower Urinary Tract Symptoms
Reza Mahdavi Zafarghandi, Iran

Vigen Malkhasyan, Russia

Vigen Malkhasyan, Russia

A Novel Method to Diagnosticate Vasculogenic Erectile Dysfunction by Harmonic Analysis of Penile Bioimpedance
Tigran Markosyan, Russia

Evaluation of Pleural Injuries after Intercostal Access in Percutaneous Nephrostolithotomy
Behkam Rezaei Mehr, Iran

Micturition EMG in the Diagnosis of Recurrent UTIs of Young Women
Silvia Meier-Drioli, Austria

Upper Urinary Tract Transitional Cell Carcinoma: Location Is not Correlated with Prognosis
Bogomir Milojevic, Serbia

Value of Urine Interleukins 8, 6, 5 and 4 Levels at Patients with Bladder Carcinoma in Diagnosis and Prognosis of the Illness
Radovan Milosevic, Serbia

Simple Lumbar Ectopia of Left Kidney with Normal Rotation and Real Stone: A Case Report
Nasser Mogharabian, Iran

Successful Transplantation of a Split Crossed Fused Lump Type Ectopic Kidney into Two Patients with ESRD
Nasser Mogharabian, Iran

Synchronous Contralateral Adrenal Metastasis in a Patient with Renal Cell Carcinoma: A Case Report
Nasser Mogharabian, Iran

The Comparison between Two Groups of Patients Under Operation and Lithotripsy Due to UT Stones from the Aspect of Epidemiologic Parameters During Years 2003-2006 Admitted at Urology Department of I.R Hospital
Nasser Mogharabian, Iran

Microfluidic Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic Microrna Signatures in Sera of Prostate Cancer Patients
Felix Moltzahn, Switzerland
Efficacy of Intraurethral Mitomycin C Hydrogel in Prevention from Anterior Urethral Stricture Recurrence After Internal Urethrotomy
Mahmoudreza Moradi, Iran

Adolescent Varicocele: Long-Term Outcome After Inguinal Varicocelectomy with Loupe Magnification
Essam Moursy, Egypt

Spinal Anesthesia and Intercostal Access for Percutaneous Nephrolithotomy
Seyed Habibollah Mousavi-Bahar, Iran

Analysis of Detrusor Activity According to Type of Cerebrovascular Accidents
Woong Na, South Korea

The Influence of Urine Cytology on Patient Care
Anmar Nassir, Saudi Arabia

Single Center Deflux Experience
Durwood Neal, USA

237 Shotgun Pellets Cause Erectile Dysfunction without Other Urological Injury
Hemant Nemade, United Kingdom

Antibiotics without Prescription: A Recipe for Resistance
Elie Nemr, Lebanon

Mass Screening of Prostate Cancer in Vietnam: Current Status and Our Opinions
Tien De Nguyen, Vietnam

Therapeutic Efficacy of Bipolar Radio Frequency Thermal Treatment for Patients with Chronic Prostatitis
Joonhwa Noh, South Korea

The Distribution of Non-Malignant Conditions in Patients Referred for Prostate Biopsy
Alireza Nouri, Iran

Testicular Fine Needle Aspiration versus Testicular Open Biopsy: Comparable Sperm Retrieval Rate in Selected Patients
Mohammad Reza Nowroozi, Iran

A Novel Method with Soft Coagulation in Partial Nephrectomy
Atsuhiko Ochi, Japan

Evaluation of Urgency-Like Symptom Using Questionnaires in Benign Prostatic Hyperplasia Patients
Hitoshi Oh-Oka, Japan

Isolation Sites and Antimicrobial Agent Susceptibility of A. baumannii in My Hospital
Hitoshi Oh-Oka, Japan

The Effects of Diosmin-Hesperidin on Testicular Damage Induced by Varicocele in an Experimental Rat Varicocele Model
Taylan Oksay, Turkey

A New Experimental Model of Benign Prostate Hyperplasia in the Ventral Prostate of Wistar Rats by Testosterone Undecanoate
Taylan Oksay, Turkey

Evaluation of the Ischemia Reperfusion Injury Level by Johnson Tubular Biopsy Score (JTBS) and Apoptosis in the Experimental Model of Testis Torsion
Taylan Oksay, Turkey

Meta-Analysis of Impact of Circumcision and Vitamin D on Occurrence of Prostate Cancer: Could They Act by Suppressing Anaerobes Colonising Areas of Prostatic Proliferative Inflammatory Atrophy
Tim Oliver, United Kingdom

Transureteroureterostomy: The “Ugly Duckling” in Ureteral Repair?
Robert Oomen, The Netherlands
New Surgical Mentorship, “Hand Holding Teaching Technique” for Shortening the Learning Curve of HoLEP
Chang Soo Park, South Korea

The Relationship Between Metabolic Syndrome and Prostate Volume in Men Under 50 in Korea
Kyung Seo Park, Korea, South

Clinical Importance of the Microscopic Focus of Prostate Cancer on a Single Sample of a Trans-Rectal 8-Core Biopsy
Giandomenico Passavanti, Italy

Large Obstructed Upper Ureteric Calculi Laparoscopy vs. URS
Prashant Pattnaik, India

Management of Urinary Calculi in Patients with Urinary Diversions
Prashant Pattnaik, India

Clinical Study of Holmium Laser Vaporization of Prostate
Prashant Pattnaik, India

PCNL in Modified Supine Position
Prashant Pattnaik, India

Retrograde Ureterorenoscopy and Endopyelotomy in Patients with UPJ Obstruction
Prashant Pattnaik, India

Optimizing Use of Antibiotics in Endourology: A Study Based on Population Based Bacterial Surveillance for Limiting Antibiotic Resistance in India
Prashant Pattnaik, India

Lower Calyceal Calculi: SWL vs. PNL/URS
Prashant Pattnaik, India

Management of Symptomatic Small Renal Calculi Unsuitable for ESWL
Prashant Pattnaik, India
Fractal Analysis of Uroflow Curves
Petros Pavlopooulos, Greece

Sonographic and Clinical Features of Simple Intratesticular Cysts
Petros Pavlopooulos, Greece

Simultaneous Nephron-Sparing Surgery and Caesarian Section for the Treatment of Renal Cell Carcinoma in Pregnancy
Ambrosi Pertia, Georgia

Nephron-Sparing Surgery for the Treatment of Renal Cell Carcinoma Between 4 and 7 cm in Greatest Dimension
Ambrosi Pertia, Georgia

An Approach to Microcarcinoma in Extended Transrectal Prostate Biopsy
Bogdan Nicolae Pietricica, Spain

Bladder Outlet Obstruction (BOO) After BPH Surgery: Our Experience Using Holmium Laser
Francesco Pisanti, Italy

Treatment of Uretero-Pelvic Stones: Laser Ureteroscopic Lithotripsy and ESWL
Francesco Pisanti, Italy

Narrow Banding Image (NBI) Technology to Improve Bladder Neoplasm Detection Rate During TURBt
Francesco Pisanti, Italy

Our Experience in Novel Method of Photodynamic Therapy for Superficial Bladder Cancer
Alexei Plekhanov, Russia

Dyslipidemia In Kidney Transplantation Recipients: Evaluation of Risk Factors
Gholamreza Pourmand, Iran

Augmentation of Chimerism by Donor Bone Marrow Cells Infusion in Kidney Allograft Recipients
Gholamreza Pourmand, Iran

Exraperitoneal Orthotopic Radical Cystoprostatectomy Approach Can Improve Postoperative Morbidity
Gholamreza Pourmand, Iran

Is Anti Thymocyte Globulin Therapy Considered a Risk Factor for Post Kidney Transplantation Cytomegalovirus Infection?
Gholamreza Pourmand, Iran

Modified Cut-off Point of Total Prostate-Specific Antigen and Free-to-Total Prostate-Specific Antigen Ratio for Detecting Prostate Cancer: Sensitivity and Specificity Evaluation
Gholamreza Pourmand, Iran

Prognostic Significance of Her-2/neu Overexpression in Primary Urothelial Carcinoma of the Bladder: A Comparative Analysis
Gholamreza Pourmand, Iran

Prospective Evaluation of Serum Triglyceride Concentration and Prostate Cancer Risk in a Multicenter Study
Gholamreza Pourmand, Iran

Serum Calcium as a Protective Marker Against Prostate Cancer: Role of Associated Factors
Gholamreza Pourmand, Iran

Serum Uric Acid as a Risk Predictor for Erectile Dysfunction Severity
Gholamreza Pourmand, Iran

Testosterone Administration Effects on Sexual Function in Aging Males With Symptoms of Late-Onset Hypogonadism and Normal or Subnormal Testosterone Level: a Comparative Analysis
Gholamreza Pourmand, Iran

Is There a Relation Between Post Kidney Transplantation Antithymocyte Globuline Therapy and Wound Healing Disturbance?
Gholamreza Pourmand, Iran
READ-BY-TITLE ABSTRACTS

Sandwiched Tunnel: A Novel Antireflux Ureterointestinal Pouch Anastamosis Approach with Easier Endourologic Access
Gholamreza Pourmand, Iran

Management of Bosniak Category III Renal Cysts
Xiaojian Qin, China

Strategies of Ureteral Stenting Under Cystoscope in Patients with Gynecological Cancers
Xiaojian Qin, China

CD276 in Clear Cell Renal Cell Carcinoma: Potential Role in the Development of Tumor-Specific, Vascular-Targeted Therapies and Its Evaluation
Xiaojian Qin, China

Regular Follow-Up Is Warranted in Simple Renal Cysts
Xiaojian Qin, China

Number of Tracts or Stone Size? Which One Influences Outcome of PCNL for Staghorn Renal Stone?
Mohammad H Radfar, Iran

Acupuncture Versus Standard Therapy for Overactive Bladder Using Tolterodine in Overactive Bladder Patients. Effects on Symptom Scores and Bladder Diary Parameters
Harrina Rahardjo, Indonesia

Transureteral Ureterolithotripsy of Ureteral Calculi: Which Is Best, Pneumatic or Holmium Laser Technique?
Mohamad Reza Razaghi, Iran

Diode Laser Vaporization of the Prostate in Comparison with Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Preliminary Results of a Randomized Clinical Trial
Mohamad Reza Razaghi, Iran

Renal Transplantation in a Woman with History of Ovarian Tumor
Nouri Rebai, Tunisia

PSA: The “Milestone” in Urology
Apostolos Rempelakos, Greece

From Empiricism to Laparoscopy: The History of Hernia
Apostolos Rempelakos, Greece

Unilateral Versus Bilateral Tined Lead Stimulation in Patient’s Selection for Sacral Nerve Stimulation: Preliminary Results
Patrick Richard, Canada

The DEFI-Study-Dosimetry in Endourologic Fluoroscopic Interventions: Risk of Radiation Exposure for Endourologic Patients
Manuel Ritter, Germany

Is There a Difference in the Perception of Pain with Flexible Cystoscopy Between Men and Women and Different Ages?
Simon Robinson, UK

Incontinence in the Insane
Simon Robinson, UK

Fertility and Race
Simon Robinson, UK

Twenty-Five Years of Research on Stone-Free and Stone-Prone Population Groups: What Has Been Learned?
Allen Rodgers, South Africa

Preventive Use of Bisphosphonates Against Bone Demineralization Promotes Adjuvant Anti-Neoplastic Effect on High-Risk Prostate Cancer Patients
Paulo Rodrigues, Brazil
Benign Prostatic Hyperplasia in Association with Latent Prostate Cancer After the Chernobyl accident in the Ukraine
Alina Romanenko, Ukraine

Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis
Antonio Romao, Portugal

Laparoscopy in the Management of Large Upper Ureteric Stones
Mamdouh Roshdy, Egypt

Expression of Transforming Growth Factor Beta-1 Protein and Its Receptor in Tissues of Patients with Bladder Cancer Associated or Not with Schistosomiasis
Mamdouh Roshdy, Egypt

TGF-ß1 Pathway as Biological Marker of Schistosomal and Non-Schistosomal Bladder Carcinoma
Mamdouh Roshdy, Egypt

Evaluation of Charlson Comorbidity Index and Radical Cystectomy Outcomes
Ismail Saad, Egypt

The Association Between Bladder Cancer and a Single Nucleotide Polymorphism (Rs2854744) in the Insulin-Like Growth Factor Binding Protein-3 Gene
Mohammad Reza Safarinejad, Iran

Association of Genetic Polymorphism of Glutathione S-Transferase (GSTM1, GSTT1, GSTP1) with Bladder Cancer Susceptibility in the Iranian Population
Mohammad Reza Safarinejad, Iran

The Effect of Coenzyme Q10 Supplementation on Pregnancy Rate in Infertile Men with Idiopathic Oligoastenoteratozoospermia: An Open Label Prospective Study
Mohammad Reza Safarinejad, Iran

Relationship of Insulin-Like Growth Factor (IGF) Binding Protein-3 (IGFBP-3) Gene Polymorphism with the Susceptibility to Development of Prostate Cancer and Influence on Serum Levels of IGF-I, and IGFBP-3
Mohammad Reza Safarinejad, Iran

Glutathione S-Transferase Gene Polymorphisms (GSTM1, GSTT1, GSTP1) and Prostate Cancer: A Case-Control Study in Tehran, Iran
Mohammad Reza Safarinejad, Iran

Relationship Between Premature Ejaculation and Genetic Polymorphisms of the Dopamine Transporter Gene (SLC6A3)
Mohammad Reza Safarinejad, Iran

Relationship Between Genetic Polymorphisms of Methyleneetetrahydrofolate Reductase (C677T, A1298C, and G1793A) as Risk Factors for Idiopathic Male Infertility
Mohammad Reza Safarinejad, Iran

Association of Polymorphisms in the Estrogen Receptors Alpha and Beta (ESR1, ESR2) with the Occurrence of Male Infertility and Semen Parameters
Mohammad Reza Safarinejad, Iran

Association of the (TAAAA)N Repeat and Asp327Asn Polymorphisms in the Sex Hormone-Binding Globulin (SHBG) Gene with Idiopathic Male Infertility and Relation to Serum SHBG Concentrations
Mohammad Reza Safarinejad, Iran

Effect of Pentoxifylline on Semen Parameters, Reproductive Hormones and Seminal Plasma Antioxidant Capacity in Men with Idiopathic Infertility: A Randomized Double-Blind Placebo-Controlled Study
Mohammad Reza Safarinejad, Iran
Association of the T-786C, G894T and 4a/4b Polymorphisms of the Endothelial Nitric Oxide Synthase Gene with Vasculogenic Erectile Dysfunction in Iranian Subjects
Mohammad Reza Safarinejad, Iran

Safety and Efficacy of Coenzyme Q10 Supplementation in Early Chronic Peyronie's Disease: A Double-Blind, Placebo-Controlled Randomized Study
Mohammad Reza Safarinejad, Iran

Medium-Term Results of Female Pelvic Floor Reconstruction with Synthetic Meshes: A Clinical Comparison of the Efficacy, the Operating Time and Complications: Our 5-Year Experience
Ioannis Salmas, Greece

Comparison of Efficacy and Safety of Minimally Invasive Synthetic Suburethral Sling Operations for Stress Urinary Incontinence in Women
Ioannis Salmas, Greece

Initial Experience with Fluorescence In Situ Hybridization (FISH) for Detection of Urothelial Carcinoma of the Bladder
Iliya Saltirov, Bulgaria

Endothelial Nitric Oxide Synthase Gene Polymorphism and Risk of Prostate Cancer in Iranian Patients
Mohammad Sam Zadeh, Iran

Intracytoplasmic Morphologically Selected Sperm Injection, IMSI in the Management of Refractory Infertile Couples
Wael Sameh, Egypt

Extracorporeal Shock Wave Therapy (ESWT) Using the Storz Duolith ESWT System to Treat Patients with Peyronie's Disease (PD)
Rafael Sanchez-Salas, France

Initial Experience with Tachosil® in Penile Prosthetic Surgery
Rafael Sanchez-Salas, France

Long-Term Oncologic Outcomes of Patients Treated with High Intensity Focused Ultrasound for Localized Prostate Cancer
Rafael Sanchez-Salas, France

Robotic Prostatectomy Positive Margins Learning Curve
Rafael Sanchez-Salas, France

Pioneering Institution Mid- and Long-Term Outcomes of Laparoscopic Radical Prostatectomy
Rafael Sanchez-Salas, France

Early Outcomes of LESS Nephrectomy Experience
Rafael Sanchez-Salas, France

Laparoscopic Radical Cystectomy and Neoadjuvant Chemotherapy in Invasive Bladder Carcinoma
Rafael Sanchez-Salas, France

Predictors of Complete Nerve Sparing During Robot Assisted Radical Prostatectomy
Oscar Schatloff, USA

Surgeon’s Intent of Nerve Sparing and Residual Nerve Tissue on Prostatectomy Specimens
Oscar Schatloff, USA

Right Robot Assisted Ureteral Reimplantation with Psoas Hitch
Oscar Schatloff, USA

The Combination of Retroperitoneoscopic and Open Surgery for Partial Nephrectomy: A Minimal-Invasive Technique for Challenging Renal Tumors
Meike Schneider, Germany
Comparison Between Transobturator Vaginal Tape Inside Out and Single Incision Sling System in the Treatment of Female Stress Urinary Incontinence: Prospective Randomized Study
Joon Hyung Seo, South Korea

Comparison of the Crede Maneuver to the Visualization Technique for Tensioning Single Incision Slings
Scott Serels, USA

Is Laparoscopic Re-evaluation Justified After Previously Failed Open Exploration for Undescended Testis?
Pejman Shadpour, Iran

Management of Arteriogenic Erectile Dysfunction (ED)
Ali Shamsa, Iran

Preliminary Results of the Mini Sling Vaginal Tape (Ophira) in the Treatment of Stress Urinary Incontinence in Two Hospitals at Tehran City
Farzaneh Sharifiaghdas, Iran

Can Lymphovascular and Perineural Invasion Determine the Treatment after Radical Cystectomy?
Yi-Jun Shen, China

Clinical Outcome of Sunitinib Is Associated with Appearance of Hypothyroidism as Adverse Events in Patients with Metastatic Renal Cell Carcinoma in Asian Cohort
Ryoichi Shiroki, Japan

Complications in Laparoscopic Transperitoneal Radical Nephrectomy
Dimitar Shishkov, Bulgaria

Correlation Between Bladder Wall Thickness and Urodynamic Findings in Patients with Spinal Cord Injury
Jose Silva, Brazil

A Novel Risk Stratification System Developed for Transperineal Template Prostate Mapping To Aid Categorisation Intermediate and High Risk Prostate Cancer
Lucy Simmons, United Kingdom

Visuospatial Representation and Risk Categorization of Individual Cancer Foci on Three-Dimensional Template Guided Prostate Mapping (TPM) Biopsies
Paras Singh, United Kingdom

High Prevalence of Systemic Acidosis in Stone Formers Is Not Due To Lactose Intolerance
Shrawan Kumar Singh, India

Molecular Basis of Aberrant Expression and Activity of Alkaline Phosphate in Renal Cell Carcinoma
Shrawan Kumar Singh, India

Uretero-Vaginal Fistula: Results of Laparoscopic Repair at Cho Ray Hospital
Tran Sinh, Vietnam

Iatrogenic Vesico-Vaginal Fistula Repair: Laparoscopic and Early Intervention at Cho Ray Hospital
Tran Sinh, Vietnam

Does Using the Hypogastric Artery in Kidney Transplantation Cause a Curved Penis?
Tran Sinh, Vietnam

Injection of Bupivacaine Decreases Epidural Meperidine Requirements After Urologic Surgery
Saied Soleymani, Iran

Muscular Paralysis and Ventilatory Failure Caused by Hyperkalemia
Saied Soleymani, Iran

Predictive Factors Influencing Failure of ESWL in Treating Patients with Ureteral Stone
Phil Hyun Song, South Korea
READ-BY-TITLE ABSTRACTS

Anchor Tissue Retrieval Bag for Robot-Assisted Laparoscopic Prostatectomy (RALP)
Kurt Strom, USA

180W GreenLight XPS: Laser Photoselective Vaporization of the Prostate (PVP) for Symptomatic Benign Prostatic Hyperplasia (BPH)
Kurt Strom, USA

Retrograde Radical Extraperitoneal Cystectomy vs Trans Peritoneal Technique
Cristian Surcel, Romania

The Impact of Bladder Tumors on the Evolution of Upper Urinary Tract Tumors
Cristian Surcel, Romania

The Possibility of Access to the Kidneys from the Posterior Axillary Line in Supine Position
Ali Tabibi, Iran

We Thought It Was Benign, But It’s Snot!
Sergiy Tadtayev, United Kingdom

Urology Registrar of the Week Rota: Does It Improve Continuity of Care?
Sergiy Tadtayev, United Kingdom

Comparing PSA and Free PSA Serum Levels in Fresh and Frozen Blood Samples
Rahim Taghavi, Iran

The Effect of Acupuncture on Relieving Pain Following Inguinal Surgeries
Rahim Taghavi, Iran

Marginal Cadaveric Pediatric Donors and Adult Recipients
Rahim Taghavi, Iran

The Effects of Late Urological Complications on Graft Survival After Kidney Transplantation in Living and Cadaveric Donor
Rahim Taghavi, Iran

Management of Pediatric Post Traumatic Obliterative Stricture Urethra: Our Experience
Rajeev Puthenveetil Thekumpadam, India

Management of Adolescent Renal Tumor: Our Experience
Rajeev Puthenveetil Thekumpadam, India

Management of Giant Adrenal Cysts: Our Experience
Rajeev Puthenveetil Thekumpadam, India

Giant Spermatocytic Seminoma: A Case Report
Rajeev Puthenveetil Thekumpadam, India

Laparoscopic Assisted Percutaneous Nephrolithotomy (PCNL) in Ectopic Pelvic Kidney
Rajeev Puthenveetil Thekumpadam, India

Recording History: The Living Witness Program
Peter Thompson, UK

Is There a Difference in Quality of Life for Patients Undergoing Urinary Diversion for Benign Versus Malignant Conditions of the Urinary Tract? A 20–Year Single Centre Retrospective Cohort Study
Ali Thwaini, UK

Vaginal Reconstruction with Ileum and Uterus-Neovaginal Anastomosis in Patient with Variant of Rokitansy Syndrome
Massimiliano Timpano, Italy

Microsurgical “Testis Sparing” Surgery for Nonpalpable Hypoechoic Testicular Lesions
Massimiliano Timpano, Italy
Sperm Retrieval by Micro-TESE in Patients with Klinefelter Syndrome
Massimiliano Timpano, Italy

Uropathogenic E. coli Infection Leads to DNA Hypermethylation in Uroepithelial Cells: Consequences for UTI Recurrence Risk?
Cornelia Toelg, Canada

Screening and Identification of Renal Cancer Specific Peptide from A Phage Display Peptide Library
Xiangan Tu, China

Effect of eIF-4E Inhibition on Heparanase mRNA and Protein Expression In Bladder Cancer
Xiangan Tu, China

Comparison of Local Anaesthetic Effects of Lidocaine with Tramadol and the Effect of Child Anxiety on Pain Level in Circumcision Procedure
Altug Tuncel, Turkey

Combined Modality Treatment for Prostate Cancer Patients
Albertas Ulys, Lithuania

Effect of a New Potassium Channel Opener on Clitoral and Vaginal Blood Flow in Spinalized Rats
Khaleeq Ur Rehman, Pakistan

Upper Urinary Tract Urothelial Carcinoma in End-Stage Kidney Disease
Tomas Urge, Czech Republic

The Role of TRPA1 in the Bladder Cooling Reflex in a Urethane Anaesthetized and Spinal Cord Injury Rat Model
Pieter Uvin, Belgium

Changes in Histological Pattern Post-Urethroplasty Using Small Intestinal Submucosa in Rabbits with Injured Urethra
Gustavo Villoldo, Argentina

Is It Necessary To Screen the Prostate Before TRUS Guided Biopsy?
Daohu Wang, China

Comparing the Efficacy of Biofeedback Therapy in Premature Ejaculation
Hongxiang Wang, China

Feasibility Analysis of Carrying Out Group Sensate Focus Exercise in ED Patients in Shanghai Region
Hongxiang Wang, China

IIELT as an Assessment Criterion of Symptoms and Effects of the Type Illa Prostatitis Patient: A Feasibility Study
Hongxiang Wang, China

Preliminary Investigation of the Effect of Seminal Plasma Leptin in Promoting Apoptosis of Sperm and Its Possible Paths
Hongxiang Wang, China

The Role of Integrated Fertility Evaluation in the Diagnosis and Treatment of Male Infertility
Hongxiang Wang, China

Pharmaco-Induced Erections for Penile Color-Duplex Ultrasound: Oral Phosphodiesterase Type 5 Inhibitors or Intracavernosal Injection?
Hongxiang Wang, China

Effect of Acute Tadalafil on Sperm Motility and Acrosome Reaction: Studies Both In Vitro and Vivo
Hongxiang Wang, China

Oral Tadalafil Administration Plus Low Dose Vasodilator Injection: A Novel Approach of Erection Induction for Penile Color-Duplex Ultrasound
Hongxiang Wang, China

Preliminarily Studies on the Teaching Reform of Sex and Reproductive Health for College Students
Hongxiang Wang, China
READ-BY-TITLE ABSTRACTS

Retroperitoneoscopic Partial Adrenalectomy for Aldosteronoma: Clinical Experiences with 163 Cases
Xiaojing Wang, China

Retroperitoneoscopic Surgery for Adrenal Lesions Close to Vena Cava
Xiaojing Wang, China

Diagnosis and Treatment of Malignant Pheochromocytoma: Report of 45 Cases
Xiaojing Wang, China

Minimally Invasive Treatment for Ligation of Ectopic Ureter
Xiaojing Wang, China

Retroperitoneoscopic Surgery for Pelvi-Ureteric Junction Obstruction (Crossing Vessels)
Xiaojing Wang, China

Laparoscopic Surgery for Adrenal Metastasis
Xiaojing Wang, China

Retroperitoneal Laparoscopic Adrenalectomy for Adrenal Microtumors: The Ruijin Clinical Experience in 108 Procedures
Xiaojing Wang, China

The Fabrication and Properties of Co-polymer Poly(lactic-co-glycolic acid) Ureteral Stent By Electrospinning
Xiaojing Wang, China

Renal Access by Urologist Versus Sonographer During Percutaneous Nephrolithotomy
Yanbo Wang, China

Which Factors May Affect Urinary Leakage Following Ultrasound-Guided Percutaneous Nephrolithotomy?
Yanbo Wang, China

Evaluation of Prostate-Bladder Angle Measured by MRI in the Diagnosis of Benign Prostate Obstruction
Chun-Xiao Wei, China

Elevated and/or Rising PSA in Presence of Negative Biopsy: Cancer, Inflammation, or Watchful Waiting
Mohamed Wishahi, Egypt

Elevated and/or Rising PSA in Presence of Negative Biopsies: Justifications for Total Androgen Blockade
Mohamed Wishahi, Egypt

Laparoendoscopic Single Site Retroperitoneal Lymph Node Dissection: The Initial Experience
Abai Xu, China

Laparoendoscopic Single Site Extraperitoneal Radical Prostatectomy: Initial Chinese Experience
Abai Xu, China

Laparoendoscopic Single Site Assisted Transsexual Surgery for Male Pseudohermaphroditism: 2 Case Reports
Abai Xu, China

Efficacy of Microsurgical Subinguinal Approach Technique
Kohei Yamaguchi, Japan

Five-Year Reports on Outcomes of Radical Retropubic Prostatectomy
Aliasghar Yarmohamadi, Iran

Salvage Genitourinary Fistula Repair: Our Experience
Aliasghar Yarmohamadi, Iran

Efficacy of Desmopressin and Celecoxib in Treatment of Nocturia Caused by Benign Prostatic Hyperplasia: Comparative Study
Aliasghar Yarmohamadi, Iran

Prospective Randomized Double Blinded Study on Transurethral Bipolar Resection Plus Vaporization (The Hybrid Technique) Versus Resection Only in Treatment of Benign Prostate Hyperplasia
Sidney Yip, Hong Kong
READ-BY-TITLE ABSTRACTS

Effectiveness of a Immediate Mitomycin C Instillation in Patients With Non-Muscle Invasive Bladder Cancer Receiving Periodical Mitomycin C Instillation
Kwon Young Kee, South Korea

Analysis of A/G Polymorphism of ARE-I Region on PSA Gene in Iranian Patients with Prostate Cancer
Mohammad Sam Zadeh, Iran

Enterocystoplasty and Ureterocystoplasty Before Renal Transplantation: A Comparison with the Control Group
Reza Mahdavi Zafarghandi, Iran

The Effect of Post Renal Transplant Extensive Ureteral Stricture on Patient and Graft Survival
Reza Mahdavi Zafarghandi, Iran

Early and Late Levels of Prostate Specific Antigen and Testosterone After Renal Transplant
Reza Mahdavi Zafarghandi, Iran

Comparing Extracorporeal Shock Wave Lithotripsy and Transureteral Lithotripsy for Treatment of Ureteral Calculi: A Prospective Study
Reza Mahdavi Zafarghandi, Iran

Successful Ambulatory Microsurgical Testicular Sperm Extraction (microTESE) in a Community Setting
Scott Zeitlin, USA

Improving the Efficacy of Sorafenib by Transarterial Embolization in Metastatic Renal Cell Carcinoma with Unresectable Primary Tumor: Preliminary Results from a Chinese Center
Hai-Liang Zhang, China

Combination of Chlortetracycline Hydrochloride Ointment and Urea Cream in Treating Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Metastatic Renal Cell Carcinoma
Hai-Liang Zhang, China

Retroperitoneoscopic Partial Nephrectomy versus Open Partial Nephrectomy for Small Renal Tumors: Results of a Retrospective Trial of Chinese Patients
Long Zhang, China

Retroperitoneoscopic Right Nephrectomy for Living Donor Kidney Transplant
H. L. Zhou, China

Narrow-Band Imaging Flexible Cystoscopy in the Detection of Clinically Unconfirmed Positive Urine Cytology
Yiping Zhu, China

Is Leaving Expansion Place for Suture in Anastomosis of Vessel Safe and Helpful for Prevention of Stenosis?
Afshar Zomorrodi, Iran

U-Stitch for Evert and Control of Bleeding in the Anastomosing Renal Vein Is Safe and Helpful
Afshar Zomorrodi, Iran

24-Hour Heart Rate Variability Parameters in Patients with Lower Urinary Tract Symptoms: A Preliminary Study
Orhan Unal Zorba, Turkey

Transvaginal NOTES Nephrectomy in a Series of 42 Cases: Stepwise Transition from Hybrid to Pure NOTES
Xiaofeng Zou, China

Transvaginal NOTES-Assisted Laparoscopic Adrenalectomy: First Clinical Experience
Xiaofeng Zou, China

Pure Transvaginal Natural Orifice Transluminal Endoscopic Surgery (NOTES) for Nephrectomy: Report of 5 Cases
Xiaofeng Zou, China
Pure Transvaginal Natural Orifice Transluminal Endoscopic Surgery (NOTES) for Unroofing of Renal Cyst: Report of 4 Cases
Xiaofeng Zou, China

A Novel Approach for Embryonic Natural Orifice Transumbilical Endoscopic Surgery Using Conventional Laparoscopic Instruments in Urology
Xiaofeng Zou, China

Application of Embryonic Natural Orifice Transumbilical Endoscopic Surgery in Urology: A Report of 103 Cases
Xiaofeng Zou, China

Laparoendoscopic Single-Site Surgery for Pyelolithotomy and Ureterolithotomy: Report of 24 Cases
Xiaofeng Zou, China

Two-Trocar Transumbilical Laparoscopic Surgery for High Ligation of Spermatic Vein: Report of 14 Cases
Xiaofeng Zou, China
## INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbass</td>
<td>Yasser</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Abbou</td>
<td>Claude C.</td>
<td>PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abd Alazeem</td>
<td>Mohamed</td>
<td>MP-03.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Abdel Aziz</td>
<td>Mohamed</td>
<td>UP-01.135, UP-03.064</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abdel Rahman</td>
<td>Abdalla</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Abdelbaky</td>
<td>Tarek</td>
<td>MP-11.09, MP-15.09, UP-01.132</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abdul Razack</td>
<td>Azad Hassan</td>
<td>UP-01.017</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Abol-Enein</td>
<td>Hassan</td>
<td>PL02, PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abol-Enine</td>
<td>Hassan</td>
<td>PL02, PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abol-Enein</td>
<td>Hassan</td>
<td>PL02, PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abomelha</td>
<td>Mohammed</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Abrahamsson</td>
<td>Per-Anders</td>
<td>EAU, PL01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Abrams</td>
<td>Paul</td>
<td>PL03, PP04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>AbouGhosh</td>
<td>Zeid</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Adomaitis</td>
<td>Robertas</td>
<td>UP-02.102</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Agarwal</td>
<td>Vikas</td>
<td>MP-05.06, UP-01.099, UP-03.070, VID-06.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ahmadia AsrBadr</td>
<td>Yadhollah</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ahmadnia</td>
<td>Hassan</td>
<td>UP-01.110</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ahmed</td>
<td>Irfan</td>
<td>UP-01.057</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ahn</td>
<td>Hanjong</td>
<td>WUOF1</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Akaza</td>
<td>Hideyuki</td>
<td>PP08, UP-02.227, WUOF1</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Akman</td>
<td>R. Yavuz</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Akpioriye</td>
<td>Leslie</td>
<td>UP-02.003</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Al Amery</td>
<td>Hayder Ismael</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Albers</td>
<td>Peter</td>
<td>PP03, WUOF3, WUOF8</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Albertsen</td>
<td>Peter</td>
<td>PL01, PP08, WUOF2</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Alefelder</td>
<td>Joachim</td>
<td>UP-03.072</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Alei</td>
<td>Giovanni</td>
<td>MP-07.19, MP-07.19, RBT, UP-03.042, UP-03.055</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ali</td>
<td>Ahmed A.A.</td>
<td>MP-11.06</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Allen</td>
<td>Darrell</td>
<td>UP-03.066</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Alloussi</td>
<td>Saladin</td>
<td>UP-03.207</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Almonacid Grunert</td>
<td>Jorge Hugo</td>
<td>MP-02.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Alnajjar</td>
<td>Hussain</td>
<td>MP-15.01, MP-15.02, UP-02.215, UP-02.216 UP-03.007</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Amano</td>
<td>Hiroyuki</td>
<td>UP-02.103</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Amini</td>
<td>Erfan</td>
<td>MP-07.13, UP-03.060</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Amjadi</td>
<td>Mohsen</td>
<td>MP-10.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Anai</td>
<td>Satoshi</td>
<td>MP-03.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Andersson</td>
<td>Karl-Erik</td>
<td>PP01, PP09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Andreou</td>
<td>Matei</td>
<td>MP-14.02, UP-01.002</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Andrich</td>
<td>Daniela</td>
<td>PP10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Andriole</td>
<td>Gerald</td>
<td>ICUD1, ICUD2, PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Andrusco</td>
<td>Alexander</td>
<td>MP-03.07, MP-03.08, MP-03.09UP-03.176</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Angermeier</td>
<td>Kenneth</td>
<td>GURS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Annerstedt</td>
<td>Magnus</td>
<td>IC12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Aoki</td>
<td>Yoshihaka</td>
<td>MP-11.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Aoyagi</td>
<td>Teiichiro</td>
<td>UP-01.068</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
## INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arab</td>
<td>Davood</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Arda</td>
<td>Ersan</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Argirovic</td>
<td>Djordje</td>
<td>MP-15.20, UP-03.112</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Arjanayagam</td>
<td>Ranjan</td>
<td>UP-03.108</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Arichi</td>
<td>Naoko</td>
<td>MP-06.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Arnonson</td>
<td>William</td>
<td>ICUD2</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Arrabal-Polo</td>
<td>Miguel Angel</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Artibani</td>
<td>Walter</td>
<td>EAU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Asgari</td>
<td>Seyed Alaeddin</td>
<td>RBT, MP-15.11, UP-02.039, UP-03.008, UP-03.063</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Assem</td>
<td>Akram</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Aydur</td>
<td>Emin</td>
<td>RBT, UP-01.069, UP-01.070, UP-02.011, UP-03.129 UP-03.161 UP-03.192 UP-03.196</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Azinhais</td>
<td>Paulo</td>
<td>UP-01.028, UP-01.046, UP-01.158, UP-01.198 UP-03.094</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Babjuk</td>
<td>Marek</td>
<td>PP13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bach</td>
<td>Christian</td>
<td>UP-02.047, UP-02.104</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bachmann</td>
<td>Alexander</td>
<td>IC07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Badawi</td>
<td>Hisham</td>
<td>PAUSA</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bancevic</td>
<td>Vladimir</td>
<td>POD-01.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bapat</td>
<td>Shivadeo</td>
<td>RBT, UP-01.111, UP-03.015, UP-03.073, UP-03.130</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Barbaghi</td>
<td>Guido</td>
<td>PP10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bardan</td>
<td>Razvan</td>
<td>MP-09.04, UP-02.196</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Bargão</td>
<td>Pedro</td>
<td>VID-03.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Barnes</td>
<td>Richard</td>
<td>PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Barod</td>
<td>Ravi</td>
<td>UP-03.025</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Basic</td>
<td>Dragoslav</td>
<td>MP-06.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Basiri</td>
<td>Abbas</td>
<td>UP-03.067, VID-01.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Basson</td>
<td>Jacques</td>
<td>UP-02.065</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Baston</td>
<td>Catalin</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Batra</td>
<td>Vikram</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Baydilli</td>
<td>Numan</td>
<td>MP-02.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Beck</td>
<td>Christian</td>
<td>UP-02.013</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bedhe</td>
<td>Jens</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Beels</td>
<td>Elodie</td>
<td>UP-03.139, UP-03.140, UP-03.141</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Beier</td>
<td>Jörn</td>
<td>VID-03.05, VID-07.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Beisland</td>
<td>Christian</td>
<td>UP-01.185</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bhandarkar</td>
<td>Ajay</td>
<td>MP-01.09, POD-04.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bhattach</td>
<td>Amit</td>
<td>RBT, VID-04.01, VID-08.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bhuayan</td>
<td>Mohammed</td>
<td>MP-01.02, UP-02.048</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bjerkudlh Johansen</td>
<td>Truls E.</td>
<td>IC14</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Black</td>
<td>Peter</td>
<td>WUOFF6</td>
<td>Medical Advisory Board, Grant Funding (July 2011-present): GenomeDx</td>
</tr>
<tr>
<td>Black</td>
<td>Peter</td>
<td>MP-08.12</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Blasco</td>
<td>Francisco Jose</td>
<td>UP-02.230</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bolenz</td>
<td>Christian</td>
<td>POD-01.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Bonkat</td>
<td>Gernot</td>
<td>UP-01.012</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Botoca</td>
<td>Mircea Radu</td>
<td>MP-04.20, MP-10.05, UP-02.032</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Boulalas</td>
<td>Ioannis</td>
<td>UP-01.018</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Bozzini</td>
<td>Giorgio</td>
<td>MP-04.04, UP-03.113, UP-03.142</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brancato</td>
<td>Tommaso</td>
<td>UP-01.187</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Branchereau</td>
<td>Julien</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Brandao</td>
<td>Luis</td>
<td>VID-02.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brandes</td>
<td>Steven</td>
<td>GURS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brausi</td>
<td>Maurizio</td>
<td>MP-02.09, POD-06.01, PL02, RBT, UP-02.131, UP-02.178</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brenner</td>
<td>Walburgis</td>
<td>MP-02.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Breza</td>
<td>Jan</td>
<td>PP12, RBT, UP-01.114, UP-03.037</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Briel</td>
<td>Christoph</td>
<td>UP-03.178</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brime Menéndez</td>
<td>Ricardo</td>
<td>MP-07.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Brookman-May</td>
<td>Sabine</td>
<td>MP-02.110, MP-02.11, UP-01.150</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Broul</td>
<td>Marek</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Bubeck</td>
<td>Juergen R.</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Bucuras</td>
<td>Viorel</td>
<td>UP-02.012, UP-02.197</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Budäus</td>
<td>Lars</td>
<td>MP-13.01, POD-03.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Bultitude</td>
<td>Matthew</td>
<td>PL04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Bumbu</td>
<td>Gheorghe</td>
<td>UP-01.071</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Burks</td>
<td>Frank</td>
<td>GURS, MP-12.12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Busto Martin</td>
<td>Luis</td>
<td>MP-13.15, UP-02.198, UP-02.199, UP-02.200</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Caballero Gine</td>
<td>Jose Maria</td>
<td>VID-03.06</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cabrera Meiras</td>
<td>Fernando</td>
<td>UP-01.188</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cadilha</td>
<td>Jose</td>
<td>UP-02.105</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Caione</td>
<td>Paolo</td>
<td>ESPU, PP02, ST04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cakir</td>
<td>Omer Onur</td>
<td>MP-01.03, MP-13.18</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cano Garcia</td>
<td>Maria Del Carmen</td>
<td>UP-01.151</td>
<td>Registration: Astellas</td>
</tr>
<tr>
<td>Carmel</td>
<td>Michel</td>
<td>UP-01.157</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Carmona</td>
<td>Lina Maria</td>
<td>MP-05.04, MP-16.13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Carroll</td>
<td>Peter R.</td>
<td>ICU02, PL04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Casado Varela</td>
<td>Javier</td>
<td>UP-02.080, UP-02.182</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cash</td>
<td>Hannes</td>
<td>UP-01.112, UP-03.026</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Castelo</td>
<td>David</td>
<td>UP-02.049, UP-02.150</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Castillo</td>
<td>Octavio</td>
<td>PP06, PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Casu</td>
<td>Cristian Vasile</td>
<td>UP-01.040, UP-02.062, UP-02.063, UP-02.151</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Çek</td>
<td>Mete</td>
<td>PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Celada Luis</td>
<td>Guillermo</td>
<td>UP-02.079</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cepeda Delgado</td>
<td>Marcos</td>
<td>MP-01.12, VID-09.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Chandrasekar</td>
<td>Ponnambalam</td>
<td>POD-04.02, UP-02.231</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Charalampos</td>
<td>Stavros</td>
<td>IC02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chauhan</td>
<td>Sanket</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Cheadgy</td>
<td>Edmund</td>
<td>UP-01.008</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chen</td>
<td>Shiu-Sheng</td>
<td>UP-01.130, UP-02.106</td>
<td>Nothing to Disclose</td>
</tr>
</tbody>
</table>
INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen</td>
<td>Wen-Chi</td>
<td>UP-02.226, UP-03.061</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chen</td>
<td>Yan</td>
<td>UP-03.179</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cheng</td>
<td>Cheung Hing</td>
<td>MP-12.13, UP-02.107</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cheng</td>
<td>Christopher</td>
<td>PP01, PP08, WUOF8</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Chew</td>
<td>Ben</td>
<td>SUS</td>
<td>Consultant: Boston Scientific, Cook Medical, Percutaneous Systems, Poly-Med Inc.</td>
</tr>
<tr>
<td>Chigogidze</td>
<td>Teimuraz</td>
<td>RBT, UP-02.201</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chihara</td>
<td>Yoshitomo</td>
<td>MP-04.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chikako</td>
<td>Nishihara</td>
<td>UP-01.022</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chira</td>
<td>Ionut Dumitru</td>
<td>UP-03.074</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cho</td>
<td>Chak Lam</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Cho</td>
<td>Deae Yeon</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Cho</td>
<td>Deok Hyun</td>
<td>MP-09.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cho</td>
<td>In Rae</td>
<td>UP-01.171</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cho</td>
<td>In-Chang</td>
<td>MP-16.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Cho</td>
<td>Jeong Man</td>
<td>UP-01.007, UP-03.085</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Choi</td>
<td>Woo Suk</td>
<td>MP-09.10, UP-02.015, UP-03.197</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Chovelidze</td>
<td>Shalva</td>
<td>UP-01.131</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chuen</td>
<td>Chi Kit</td>
<td>MP-02.14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Chun</td>
<td>Felix</td>
<td>MP-16.12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ciuta</td>
<td>Catalin</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Claassen</td>
<td>Frederik</td>
<td>RBT, MP-08.05, MP-11.04, UP-01.175</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Claici</td>
<td>Dorin</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Coleman</td>
<td>Jonathan A.</td>
<td>IC01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Coloby</td>
<td>Patrick</td>
<td>PL02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Comploj</td>
<td>Evi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Cozzi</td>
<td>Paul</td>
<td>POD-07.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Cruz</td>
<td>Francisco</td>
<td>PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Da Costa</td>
<td>Walter</td>
<td>UP-01.142, UP-01.189, UP-01.190</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dabees</td>
<td>Khaled</td>
<td>PAUSA</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dahlien</td>
<td>Ruland</td>
<td>MP-12.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dahm</td>
<td>Philipp</td>
<td>IC03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Dakkak</td>
<td>Youssef</td>
<td>MP-01.13, RBT, UP-02.202</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Darabi Mahboub</td>
<td>Mohammad Reza</td>
<td>MP-01.14, UP-03.092</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Davis</td>
<td>John</td>
<td>UP-03.116, WUOF3</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Davits</td>
<td>Robert</td>
<td>MP-13.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>De Baets</td>
<td>Karen</td>
<td>MP-12.03, UP-03.016</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>De La Rosa Kehrmann</td>
<td>Federico</td>
<td>MP-06.13, MP-06.14</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>de La Rosette</td>
<td>Jean</td>
<td>IC13, PP13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>De Ridder</td>
<td>Dirk</td>
<td>IC02, PP04, PP16, ST01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>De Stefanis</td>
<td>Paolo</td>
<td>RBT, VID-02.10, VID-08.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dean</td>
<td>John</td>
<td>ISSM</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Deger</td>
<td>Serdar</td>
<td>IC07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>D’Elia</td>
<td>Gianluca</td>
<td>VID-01.02, VID-01.03, VID-01.04, VID-01.05, VID-03.01, VID-09.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Delmas</td>
<td>Vincent</td>
<td>ST01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Demidko</td>
<td>Yuri</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Desai</td>
<td>Mahesh R.</td>
<td>PL04, PP07, PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Desai</td>
<td>Mihir Mahesh</td>
<td>PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>DeVries</td>
<td>Catherine R.</td>
<td>IC01, MP-11.05, PAUSA</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Dickinson</td>
<td>Louise</td>
<td>MP-03.10, MP-13.03, UP-02.153</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Djajadiningrat</td>
<td>Rosa</td>
<td>MP-15.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Djordjevic</td>
<td>Miroslav</td>
<td>IC06, VID-08.02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Djozic</td>
<td>Jasenko</td>
<td>UP-01.191</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dobruch</td>
<td>Jakub</td>
<td>MP-13.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dockray</td>
<td>Judith</td>
<td>MP-15.12, UP-02.016, UP-03.114</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dogra</td>
<td>Pn</td>
<td>VID-02.08, VID-07.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Donatucci</td>
<td>Craig F.</td>
<td>IC08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Drake</td>
<td>Marcus</td>
<td>MP-05.01, PP09, ST03</td>
<td>Research, Advisory Board, Speaker (2010-2011): Allergan, Astellas, Pfizer, Advisory Board, Speaker (2010-2011): Ferring</td>
</tr>
<tr>
<td>Drasa</td>
<td>Kim</td>
<td>MP-09.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Droller</td>
<td>Michael J.</td>
<td>WUOF6</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dusek</td>
<td>Pavel</td>
<td>UP-01.047</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Dymov</td>
<td>Alim</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ebel Ebinger</td>
<td>Luis</td>
<td>MP-15.21</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mundorff</td>
<td>Nicole</td>
<td>IC07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Eisenberger</td>
<td>Mario</td>
<td>ICUD1</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Eissa</td>
<td>Mohamed</td>
<td>PAUSA, PP02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ekwueme Elbendary</td>
<td>Kingsley</td>
<td>UP-02.108, UP-02.109</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Elnady</td>
<td>Mohamed</td>
<td>MP-09.06</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>El-Feel</td>
<td>Ahmed</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>El-Ghoneimi</td>
<td>Alaa</td>
<td>ESPU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Elhilali</td>
<td>Mostafa M.</td>
<td>PL03</td>
<td>Advisor: Astellas, GSK, Pfizer, Lumenis</td>
</tr>
<tr>
<td>Elatti</td>
<td>Riyad</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Elmussareh</td>
<td>Muhammad</td>
<td>MP-02.12, UP-01.154</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Eenii</td>
<td>Suzy</td>
<td>PP16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Eftrfai</td>
<td>Alaa</td>
<td>UP-01.097</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Elseweifi</td>
<td>Aref</td>
<td>VID-08.03, VID-08.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Emberton</td>
<td>Mark</td>
<td>IC09, PP01, WUOF3</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Endo</td>
<td>Fumiyasu</td>
<td>UP-02.228</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Engel</td>
<td>Oliver</td>
<td>MP-12.04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Epplen</td>
<td>Robin</td>
<td>POD-02.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Erkan</td>
<td>Erkan</td>
<td>MP-01.06, UP-01.029, UP-01.128, UP-02.110, UP-03.075</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Esen</td>
<td>Tarik</td>
<td>PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Evans</td>
<td>Christopher</td>
<td>WUOF4</td>
<td>Speaker (2011): Amgen, Centocor</td>
</tr>
<tr>
<td>Eylert</td>
<td>Maiko</td>
<td>MP-04.11</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Fangerau</td>
<td>Heiner</td>
<td>HISTORY</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Faraji Shovey</td>
<td>Mehdi</td>
<td>UP-03.047</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Farshi Haghro</td>
<td>Alireza</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>---------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Figueiredo</td>
<td>Luis</td>
<td>MP-07.17, RBT, UP-01.136</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Filipas</td>
<td>Dragana</td>
<td>ST04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Filipovic</td>
<td>Zoran</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Finelli</td>
<td>Antonio</td>
<td>WUOF5</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fisch</td>
<td>Margit</td>
<td>GURS, ESPU, PP02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fischer</td>
<td>M.A.</td>
<td>RBT, UP-01.137</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Fischereder</td>
<td>Katja</td>
<td>UP-01.072, UP-03.180</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fitzpatrick</td>
<td>John M.</td>
<td>PL03, PL04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fleshner</td>
<td>Neil</td>
<td>WUOF1</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fletcher</td>
<td>Sophie</td>
<td>PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fradet</td>
<td>Vincent</td>
<td>POD-07.07, UP-02.084, UP-02.184, UP-02.229</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fradet</td>
<td>Yves</td>
<td>PP13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Frees</td>
<td>Sebastian</td>
<td>MP-02.13</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Friedersdorff</td>
<td>Frank</td>
<td>MP-06.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fu</td>
<td>Qiang</td>
<td>PP10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Fujimoto</td>
<td>Kiyohide</td>
<td>POD-05.02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Fujimoto</td>
<td>Naohiro</td>
<td>UP-02.154</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Fukatsu</td>
<td>Akitoshi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Fukumoto</td>
<td>Kazuhiro</td>
<td>UP-02.004</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Fuller</td>
<td>Florian</td>
<td>VID-02.09</td>
<td>Financial Interest (2011): Karl Storz Endoskope</td>
</tr>
<tr>
<td>Fumey</td>
<td>Julien</td>
<td>MP-06.04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Furuse</td>
<td>Hiroshi</td>
<td>UP-03.143</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Gadelmoula</td>
<td>Mohamed</td>
<td>MP-10.06, UP-01.143</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Galal</td>
<td>Ehab</td>
<td>UP-03.065</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Galante Romo</td>
<td>Isabel</td>
<td>POD-01.02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Gamal</td>
<td>Wael</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ganda</td>
<td>Oumarou S.</td>
<td>PP16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gandaglia</td>
<td>Giorgio</td>
<td>UP-03.198</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ganeswaran</td>
<td>Dinesh</td>
<td>UP-02.111, UP-02.203</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ganpule</td>
<td>Arvind</td>
<td>MP-06.06, MP-06.07, MP-11.01, UP-01.194, UP-02.084 VID-04.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Garcia-Rojo</td>
<td>Dario</td>
<td>UP-01.073, UP-01.176, UP-03.132, VID-09.04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Garcia-Segui</td>
<td>Alejandro</td>
<td>VID-02.03, VID-06.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Garde</td>
<td>Hector</td>
<td>UP-01.041</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Gardiner</td>
<td>Robert F.</td>
<td>WUOF3</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gaston</td>
<td>Richard</td>
<td>PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Geavlete</td>
<td>Bogdan</td>
<td>POD-05.03, POD-04.04, POD-05.08, UP-02.071 VID-09.07</td>
<td>Speaker (2009-2010): General Electric Healthcare Speaker (2010-2011): Olympus</td>
</tr>
<tr>
<td>Geavlete</td>
<td>Petrisor A.</td>
<td>MP-01.18, MP-01.20, PP11, UP-03.080</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Geiges</td>
<td>Gitz</td>
<td>UP-02.064</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gelman</td>
<td>Joel</td>
<td>GURS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gentile</td>
<td>Barbara C.</td>
<td>MP-10.09, MP-10.10, MP-10.11, MP-13.10 POD-01.06, UP-01.074, UP-02.024, UP-02.034 UP-02.128, UP-02.130, UP-02.132, UP-03.088 UP-03.208</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ghicavii</td>
<td>Vitalii</td>
<td>MP-09.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Goel</td>
<td>Apul</td>
<td>UP-03.019</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Golab</td>
<td>Adam</td>
<td>UP-01.100</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Golubtsova</td>
<td>Elena</td>
<td>UP-02.155</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gomez Illanes</td>
<td>Reynaldo</td>
<td>PP10, PP14, UP-03.121, UP-03.123, UP-03.124</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gontero</td>
<td>Paolo</td>
<td>MP-04.13, UP-01.066, UP-03.052</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gonzalez</td>
<td>Christopher</td>
<td>GURS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gorgal-Carvalho</td>
<td>Tiago</td>
<td>MP-05.07, UP-01.195, UP-02.001</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Gormley</td>
<td>E. Ann</td>
<td>PP09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Govind</td>
<td>Hari</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Goyal</td>
<td>Arvind</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Grimsley</td>
<td>Samuel</td>
<td>MP-04.12, UP-02.112</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Gross</td>
<td>Andreas</td>
<td>PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gudbrandsdottir</td>
<td>Gigia</td>
<td>UP-01.140, UP-01.141</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gueye</td>
<td>Serigne</td>
<td>IC01, PAUSA, PP16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Guidoni</td>
<td>Luiz Renato Montez</td>
<td>UP-03.006</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Guix</td>
<td>Benjamin</td>
<td>POD-07.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gupta</td>
<td>Manu</td>
<td>POD-04.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Guspanov</td>
<td>Renat</td>
<td>MP-13.16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gutshci</td>
<td>Thomas</td>
<td>UP-01.155</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Gutue</td>
<td>Cristian Stefan</td>
<td>UP-02.029, UP-03.059</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Haab</td>
<td>Francois</td>
<td>UP-02.014</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hadaschik</td>
<td>Boris</td>
<td>POD-02.02, UP-02.085</td>
<td>Advisor (2010-2011): MedCom; Advisor (2011): Janssen-Cilag, Sanofi-Aventis, Teva</td>
</tr>
<tr>
<td>Hadj Slimen</td>
<td>Mourad</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Haertiln</td>
<td>Ulrich</td>
<td>UP-01.013</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Haga</td>
<td>Kazunori</td>
<td>UP-03.076</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hakim</td>
<td>Lukman</td>
<td>UP-03.077</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Halawa Gonzalez</td>
<td>Omar Bilal</td>
<td>UP-03.093</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ham</td>
<td>Won Sik</td>
<td>MP-09.12</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hamann</td>
<td>Claudius</td>
<td>UP-02.115, UP-02.116</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hamdoune</td>
<td>Abdelaziz</td>
<td>RBT, UP-03.133</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hamid</td>
<td>Agus Rizal</td>
<td>UP-02.086</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hamidi Madani</td>
<td>Ali</td>
<td>UP-02.204</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hammoud</td>
<td>Khaled Mursi</td>
<td>MP-01.01, MP-11.12, UP-01.059, UP-01.075</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hampel</td>
<td>Christian</td>
<td>PP04, PP09, ST01, ST03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hara</td>
<td>Noboru</td>
<td>UP-02.185</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Haraguchi</td>
<td>Takahiro</td>
<td>UP-02.017</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Harimoto</td>
<td>Kouji</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Harza</td>
<td>Mihai Christian</td>
<td>MP-06.03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hasanzad</td>
<td>Mandana</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Hassani</td>
<td>Altaf</td>
<td>MESOT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hassani</td>
<td>Mohammed</td>
<td>UP-01.153</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hatiboglu</td>
<td>Gencay</td>
<td>UP-01.144, UP-02.205</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hattori</td>
<td>Kazunori</td>
<td>MP-04.19</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hauschild</td>
<td>Eveline</td>
<td>UP-02.089</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hautmann</td>
<td>Richard E.</td>
<td>IC10, PL02, PP06, WUOF7</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hashiu</td>
<td>Isae</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Hayami</td>
<td>Shinsuke</td>
<td>UP-02.019</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Heidenreich</td>
<td>Axel</td>
<td>PP03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Heinrich</td>
<td>Elmar</td>
<td>MP-13.05, UP-02.087</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Heinzelbecker</td>
<td>Julia</td>
<td>UP-02.117</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hekal</td>
<td>Ihab</td>
<td>MP-13.17, RBT, UP-02.206, UP-02.118, UP-02.119</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hemal</td>
<td>Ashok K.</td>
<td>IC05, IC12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Heo</td>
<td>Jung Moon</td>
<td>UP-02.033</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hernando Arteche</td>
<td>Alberto</td>
<td>MP-03.11, UP-02.120</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Herr</td>
<td>Harry</td>
<td>PL02, PP03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Herrmann</td>
<td>Edwin</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Heyns</td>
<td>Chris F.</td>
<td>MP-15.13, PP05, RBT, UP-02.005, UP-02.006, UP-03.118</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hilton</td>
<td>Paul</td>
<td>PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hiniev</td>
<td>Alexander</td>
<td>MP-15.15, UP-02.066, UP-03.017, UP-03.144</td>
<td>Company Speaker Honorarium (2011); Eli Lilly; Trial Participation (2010-2011); Hexal AG, Innovacell Biotechnologie; Travel Grant (2010); Bayer Schering Pharma; Travel Grant (2011): Astellas, Eli Lilly, Pfizer</td>
</tr>
<tr>
<td>Hinotsu</td>
<td>Shiro</td>
<td>MP-16.14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hirano</td>
<td>Yasuhiro</td>
<td>MP-04.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ho</td>
<td>Christopher Chee Kong</td>
<td>UP-02.121</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hohenfellner</td>
<td>Markus</td>
<td>PP12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hollowell</td>
<td>Jean</td>
<td>PP02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Holm</td>
<td>Henriette Veiby</td>
<td>UP-03.181</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Honda</td>
<td>Satoshi</td>
<td>UP-03.162</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hong</td>
<td>Sung Kyu</td>
<td>MP-16.16, UP-02.083</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Horie</td>
<td>Shigeo</td>
<td>WUOF1</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Horiuchi</td>
<td>Kohei</td>
<td>UP-02.007</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Horwich</td>
<td>Alan</td>
<td>PP03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hsu</td>
<td>Chao-Yu</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Huang</td>
<td>Chien-Ming</td>
<td>RBT, UP-03.086</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hubert</td>
<td>Jacques</td>
<td>IC05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Höbner</td>
<td>Wilhelm A.</td>
<td>ST01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hudak</td>
<td>Steven</td>
<td>MP-12.15</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Hung</td>
<td>Shun-Fa</td>
<td>RBT, UP-03.048</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Hussein</td>
<td>Alayman</td>
<td>MP-07.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Iatsyna</td>
<td>Oleksandr</td>
<td>POD-01.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ichikawa</td>
<td>Takaharu</td>
<td>UP-02.020</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Igawa</td>
<td>Tsukasa</td>
<td>UP-02.157</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ignjatovic</td>
<td>Ivan</td>
<td>VID-02.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Izuka</td>
<td>Jumpei</td>
<td>UP-01.156</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ikeda</td>
<td>Hiroshi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ilievski</td>
<td>Aleksandar</td>
<td>UP-03.010</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Inokuchi</td>
<td>Junichi</td>
<td>UP-03.146</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ishikawa</td>
<td>Akira</td>
<td>UP-02.072</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ishimura</td>
<td>Takeshi</td>
<td>MP-06.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ishiura</td>
<td>Yoshiuki</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ishizuka</td>
<td>Osamu</td>
<td>UP-01.009</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Isotalo</td>
<td>Taina</td>
<td>SUS</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Issa</td>
<td>Rami</td>
<td>POD-05.01, POD-06.02, UP-01.098, UP-02.158 UP-02.159, UP-02.232, UP-03.119, VID-07.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ito</td>
<td>Kazuto</td>
<td>UP-02.122</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Itoh</td>
<td>Naoki</td>
<td>UP-03.199</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ivanauskas</td>
<td>Andrius</td>
<td>UP-02.161</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Iwata</td>
<td>Tsuyoshi</td>
<td>MP-13.08</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Izaki</td>
<td>Hirofumi</td>
<td>UP-01.003</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Izquierdo Morejón</td>
<td>Emilio</td>
<td>RBT, UP-03.011</td>
<td>Speaker (2011): GlaxoSmithKline; Registration (2011): Astellas</td>
</tr>
<tr>
<td>Izumi</td>
<td>Kazuyoshi</td>
<td>MP-07.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jacqmin</td>
<td>Didier</td>
<td>EAU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jäger</td>
<td>Wolfgang</td>
<td>PP13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jalil</td>
<td>Rozh</td>
<td>UP-02.038</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Janetschek</td>
<td>Günter</td>
<td>PP07, PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jankowski</td>
<td>Thomas</td>
<td>MP-14.03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jardin</td>
<td>Alain</td>
<td>HISTORY</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jarolim</td>
<td>Ladislav</td>
<td>UP-02.056</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jefferies</td>
<td>Edward</td>
<td>POD-03.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jeong</td>
<td>Min Su</td>
<td>MP-05.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jeremic</td>
<td>Dimitrije</td>
<td>MP-15.16</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jewett</td>
<td>Michael A. S</td>
<td>PP03, PP12, WUOF5</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jha</td>
<td>Akhileshvar</td>
<td>MP-11.08</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jimenez-Pacheco</td>
<td>Antonio</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Jindal</td>
<td>Ashish</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Jo</td>
<td>Jung Ki</td>
<td>MP-03.14, MP-07.11, UP-01.211</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jones</td>
<td>J. Stephen</td>
<td>IC03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Joniau</td>
<td>Steven</td>
<td>RBT, POD-03.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jordan</td>
<td>Gerald H</td>
<td>PL01, SUS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Jundi</td>
<td>Omar</td>
<td>MP-14.04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Jung</td>
<td>Seung Il</td>
<td>UP-03.145</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Junior Barthelemy</td>
<td>MekemeMekeme</td>
<td>MP-03.17, RBT, UP-01.076</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Junker</td>
<td>Kerstin</td>
<td>DGU, UP-01.172</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kaisary</td>
<td>Amir</td>
<td>UP-02.162, UP-02.163</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
## INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kajioka</td>
<td>Shunichi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kalpinskiy</td>
<td>Alexey</td>
<td>UP-01.196, UP-02.044</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kamal</td>
<td>Mohammed</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kamal Gheith</td>
<td>Mohamed</td>
<td>UP-03.029</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kang</td>
<td>Taek Won</td>
<td>UP-02.088</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kapoor</td>
<td>Anil</td>
<td>WUOF5</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kaptan</td>
<td>Hulagu</td>
<td>UP-03.183</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Karami</td>
<td>Hosein</td>
<td>UP-03.209, UP-03.210, VID-06.04 VID-06.05, VID-09.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Karavitakis</td>
<td>Markos</td>
<td>UP-02.164</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Karunyam</td>
<td>Bheena</td>
<td>UP-02.052</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kassouf</td>
<td>Wassim</td>
<td>IC11, UP-03.117</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kato</td>
<td>Masashi</td>
<td>UP-01.197</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kato</td>
<td>Yuji</td>
<td>MP-01.16</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Katshiro</td>
<td>Fukuta</td>
<td>UP-02.067</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kawamura</td>
<td>Kenji</td>
<td>UP-02.018</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kawamura</td>
<td>Sadafumi</td>
<td>MP-03.13</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kawanishi</td>
<td>Yasuo</td>
<td>MP-07.10</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Keil</td>
<td>Christian</td>
<td>MP-01.10</td>
<td>Consultant, Advisory Board Member (2010-2011): EMS Medical S.A.</td>
</tr>
<tr>
<td>Keil</td>
<td>Christopher</td>
<td>MP-01.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Khalaf</td>
<td>Ismail</td>
<td>PL04, PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Khanna</td>
<td>Sudhir</td>
<td>MP-08.09, MP-08.10, RBT UP-03.012</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Khazael</td>
<td>Dinyar</td>
<td>RBT, UP-03.095</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Khormani</td>
<td>Mohannad Hatef</td>
<td>UP-03.158</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Khoury</td>
<td>Antoine E.</td>
<td>ESPU, PP02, ST04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kiel</td>
<td>Anne</td>
<td>UP-01.048</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kikugawa</td>
<td>Tadahiko</td>
<td>UP-01.019</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Byung Hoon</td>
<td>UP-01.037, UP-01.180, UP-02.147</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Hong Sup</td>
<td>MP-08.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Ju Sung</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kim</td>
<td>Kikyung</td>
<td>UP-03.078</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Sang Deuk</td>
<td>UP-01.060</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>So Joong</td>
<td>UP-03.147</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kim</td>
<td>Tae Hyo</td>
<td>RBT, MP-14.05, MP-14.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Tae Nam</td>
<td>UP-02.021</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kim</td>
<td>Taek Sang</td>
<td>MP-04.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kim</td>
<td>Won Tae</td>
<td>UP-02.208</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kimura</td>
<td>Kyoosuke</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kingo</td>
<td>Pernille Skjold</td>
<td>UP-03.096</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kitahara</td>
<td>Satoshi</td>
<td>UP-02.209</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kitta</td>
<td>Takeya</td>
<td>UP-01.081, UP-02.008</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Klecka</td>
<td>Jiri</td>
<td>MP-16.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Klingler</td>
<td>Christoph H.</td>
<td>PP07</td>
<td>Advisory: Coloplast and Allergan; Educational services: Ferring Pharmaceuticals; Advisory and Educational services: Astellas</td>
</tr>
<tr>
<td>Klitz</td>
<td>Laurence</td>
<td>PL01, POD-03.04, PP01, WUOF1-8</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kluth</td>
<td>Luis Alex</td>
<td>MP-12.16, MP-12.17, POD-04.03 UP-03.134</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Knöchel-Clarke</td>
<td>Ruth</td>
<td>PL02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Knüpfer</td>
<td>Stephanie</td>
<td>UP-03.169</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Koc</td>
<td>Gokhan</td>
<td>MP-08.01, MP-10.19, MP-10.20, UP-01.115 UP-01.116, UP-02.210, UP-02.211, UP-03.110</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kodaira</td>
<td>Kiichiro</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kodama</td>
<td>Ronald</td>
<td>GURS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kojovic</td>
<td>Vladimir</td>
<td>MP-07.20, UP-03.056</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Köhler</td>
<td>Heinz</td>
<td>ICSSUFU, PP09, ST03</td>
<td>International Advisory Board: Astellas (2011)</td>
</tr>
<tr>
<td>Kondo</td>
<td>Fukuji</td>
<td>UP-03.120</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Konety</td>
<td>Badrinath</td>
<td>IC03, WUOF7</td>
<td>Speaker: Amgen (2011); Consultant: Spectrum Pharm (2011)</td>
</tr>
<tr>
<td>Konstantinidis</td>
<td>Charalampos</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kozal</td>
<td>Sebastien</td>
<td>MP-12.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kral</td>
<td>Xaver</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Kratzik</td>
<td>Christian</td>
<td>UP-02.212</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Krishnamurthi</td>
<td>Venkatesh</td>
<td>MP-06.10, MP-06.11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kronenberg</td>
<td>Peter</td>
<td>RBT, UP-01.049</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kubota</td>
<td>Yasuaki</td>
<td>UP-02.123</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kukreja</td>
<td>Rajesh</td>
<td>MP-10.07, UP-03.099</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kulaksizoglou</td>
<td>Haluk</td>
<td>UP-01.014, UP-03.122, UP-03.170, UP-03.184</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kulchavenya</td>
<td>Ekaterina</td>
<td>ISSM, MP-08.13, RBT, UP-01.117, UP-01.118 UP-01.119, UP-03.049, UP-03.050</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kulkarni</td>
<td>Jagdeesh</td>
<td>MP-13.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kulkarni</td>
<td>Ravindra</td>
<td>SS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kulkarni</td>
<td>Sanjay</td>
<td>PP10, UP-03.097, UP-03.097</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kumar</td>
<td>Pardeep</td>
<td>POD-06.03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kumar</td>
<td>Santosh</td>
<td>RBT, UP-01.061, UP-03.013, UP-03.148</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kumar</td>
<td>Vivekanand</td>
<td>MP-16.15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kuo</td>
<td>Tricia</td>
<td>UP-02.213</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kuratsukuri</td>
<td>Katsuyuki</td>
<td>UP-02.214</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kuroda</td>
<td>Isao</td>
<td>RBT, UP-02.165</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Kusuhara</td>
<td>Yoshito</td>
<td>UP-03.043</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Kutzenberger</td>
<td>Johannes</td>
<td>UP-03.212</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Labanaris</td>
<td>Apostolos P.</td>
<td>RBT, MP-03.12, UP-02.144, UP-02.145, UP-02.189 UP-03.157</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lückgren</td>
<td>Göran</td>
<td>ESPU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Laguna</td>
<td>Pilar</td>
<td>PP07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lahoz Garcia</td>
<td>Clara</td>
<td>MP-07.14, MP-08.07, MP-08.08 UP-03.083, UP-03.084</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lambert</td>
<td>Sarah</td>
<td>PP02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>Lammers</td>
<td>Rianne Janna Marie</td>
<td>POD-05.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lang</td>
<td>Christoph</td>
<td>MP-05.08, UP-03.163</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lange</td>
<td>Dirk</td>
<td>MP-01.17, MP-01.19, UP-03.062 UP-03.100</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lange</td>
<td>Paul</td>
<td>ICUD1, PP03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Leao</td>
<td>Ricardo</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Leclair</td>
<td>Marc David</td>
<td>ESPL, PP02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lee</td>
<td>Changho</td>
<td>POD-03.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lee</td>
<td>Frank</td>
<td>PL03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lee</td>
<td>Hyung-Lae</td>
<td>UP-02.186, UP-03.211</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lee</td>
<td>Joong Shik</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Lee</td>
<td>Kwang Soo</td>
<td>UP-03.068, UP-03.091</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lee</td>
<td>Sang-Cheol</td>
<td>MP-01.11</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lee</td>
<td>Yong Seong</td>
<td>UP-03.159</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Leitão</td>
<td>Tito</td>
<td>UP-02.124, UP-03.185</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lemack</td>
<td>Gary</td>
<td>ICSSUFU</td>
<td>Speaker, Consultant (2 years): Pfizer; Speaker (2 years): Astellas; Clinical Trial, Consultant (2 years): Allergan; Clinical Trial (2 years): Contura</td>
</tr>
<tr>
<td>Lerner</td>
<td>Seth P.</td>
<td>POD-05.06, PP13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Levakov</td>
<td>Ivan</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Leyten</td>
<td>Gisele</td>
<td>MP-16.09</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Leyton</td>
<td>Rodrigo</td>
<td>IC02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lezrek</td>
<td>Mohammed</td>
<td>RBT, UP-02.046, VID-06.06, VID-06.07, VID-06.08 VID-08.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Li</td>
<td>Aihua</td>
<td>UP-03.079, VID-06.02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lim</td>
<td>Ju Hyun</td>
<td>MP-04.10, UP-02.100</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Lopes</td>
<td>Ivo</td>
<td>POD-02.05, UP-02.125, UP-02.193 UP-03.101</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lopes</td>
<td>Tiago</td>
<td>UP-03.200</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lu</td>
<td>Ji</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Lu</td>
<td>Shing-Hwa</td>
<td>MP-05.09, UP-01.015</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Lynch</td>
<td>William J.</td>
<td>PP01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Madersbacher</td>
<td>Helmut</td>
<td>PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Maeda</td>
<td>Yoshiko</td>
<td>UP-02.040</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Maghsoudi</td>
<td>Robab</td>
<td>UP-02.053, UP-03.087, UP-03.102</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mahdavi Zafarghandi</td>
<td>Reza</td>
<td>MP-06.12, MP-10.12, RBT, UP-03.030, UP-03.031</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Maitra</td>
<td>Neil</td>
<td>UP-02.022</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Makanjuola</td>
<td>Jonathan Kehinde</td>
<td>UP-03.125, UP-03.135</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Maki</td>
<td>Yoshio</td>
<td>UP-01.101</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Malik</td>
<td>Manar</td>
<td>UP-03.126</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mansson</td>
<td>Wiking</td>
<td>PL02, UP-03.160</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Marberger</td>
<td>Michael</td>
<td>PL03, PP01, PP12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Markovsky</td>
<td>Oliver</td>
<td>UP-02.126</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Marri</td>
<td>Rajendran</td>
<td>UP-01.085</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Marshall</td>
<td>Daniel</td>
<td>UP-02.127</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Martenstein</td>
<td>Christian</td>
<td>UP-03.193</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
### INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martins</td>
<td>Francisco</td>
<td>IC06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Maruschke</td>
<td>Matthias</td>
<td>UP-01.146</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Masri</td>
<td>Marwan</td>
<td>MESOT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Matin</td>
<td>Sarena</td>
<td>IC05, WUOF8</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Matsuyama</td>
<td>Hideyasu</td>
<td>UP-01.062</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mattiolli</td>
<td>Stefano</td>
<td>MP-09.14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mayr</td>
<td>Roman</td>
<td>MP-04.08, UP-01.042</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>McBean</td>
<td>Alexander</td>
<td>UP-02.041</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>McCammon</td>
<td>Kurt</td>
<td>GURS, IC02, PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>McDonald</td>
<td>Jean</td>
<td>PAUSA</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mehralivand</td>
<td>Sheriff</td>
<td>UP-01.200</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mendoza-Valdes</td>
<td>Arturo</td>
<td>PL02, PP08, WUOF1</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Merlini</td>
<td>Emilio</td>
<td>ESPU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mhiri</td>
<td>Nabil</td>
<td>MP-02.04, MP-06.20, MP-06.21, MP-08.02, MP-02.050, MP-02.113, MP-02.114, MP-03.027, MP-03.090, MP-03.156</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mian</td>
<td>Badar</td>
<td>POD-02.03, UP-01.020</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Michailov</td>
<td>Michael Ch.</td>
<td>UP-03.127</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Michel</td>
<td>Maurice-Stephan</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mikami</td>
<td>Kazuya</td>
<td>UP-01.045</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Miller</td>
<td>Kim</td>
<td>MP-16.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Min</td>
<td>Seung Ki</td>
<td>MP-08.15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Min</td>
<td>Seung Ki</td>
<td>UP-02.009</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Minagawa</td>
<td>Shingo</td>
<td>UP-02.023</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Minato</td>
<td>Akinori</td>
<td>UP-02.070</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Minciu</td>
<td>Radu</td>
<td>UP-02.082, UP-02.183</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mitsui</td>
<td>Yozo</td>
<td>MP-03.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Miura</td>
<td>Takeshi</td>
<td>MP-03.18</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Miyagawa</td>
<td>Tomoaki</td>
<td>UP-02.133</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Miyaji</td>
<td>Yoshiyuki</td>
<td>UP-01.159</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mitzusawa</td>
<td>Hiroya</td>
<td>UP-02.187</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mkonny</td>
<td>Charles</td>
<td>UP-03.020</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mogharabian</td>
<td>Nasser</td>
<td>RBT, UP-03.103</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mohanty</td>
<td>Nayan</td>
<td>MP-07.15, MP-09.15, UP-01.050</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Molimard</td>
<td>Benoit</td>
<td>POD-02.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Moll</td>
<td>Friedrich H.</td>
<td>HISTORY</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Montorsi</td>
<td>Francesco</td>
<td>IC04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Montoya-Chinchilla</td>
<td>Raul</td>
<td>UP-03.128</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Moradi</td>
<td>Mahmoudreza</td>
<td>MP-12.01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Moreira</td>
<td>Pedro</td>
<td>UP-01.133</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Morey</td>
<td>Allen</td>
<td>GURS, IC06, PP10</td>
<td>Speaker, Consultant: American Medical Systems (2010-2011); Speaker: GlaxoSmithKline (2010-2011)</td>
</tr>
<tr>
<td>Morgia</td>
<td>Giuseppe</td>
<td>UP-01.039, UP-02.081</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Morizane</td>
<td>Shuichi</td>
<td>UP-03.151</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mortensen</td>
<td>Martin Merck</td>
<td>MP-16.10</td>
<td>Nothing to Disclose</td>
</tr>
</tbody>
</table>
# INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morton</td>
<td>Ronald</td>
<td>POD-03.06, UP-02.076</td>
<td>GTX, Inc. (2007-2011)</td>
</tr>
<tr>
<td>Moudouni</td>
<td>Said Mohammed</td>
<td>POD-06.04, UP-02.137</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mousavi-Bahar</td>
<td>Seyed Habibollah</td>
<td>MP-01.21</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Moussa</td>
<td>Fathy</td>
<td>UP-03.038, UP-03.039</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Mukhtar</td>
<td>Saheel</td>
<td>POD-01.07, UP-01.051, UP-01.052</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Müller</td>
<td>Georg</td>
<td>MP-08.16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Müller</td>
<td>Stefan C.</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Multescu</td>
<td>Razvan</td>
<td>MP-10.13, UP-03.104, UP-03.105 VID-05.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Mundy</td>
<td>Anthony</td>
<td>PP04, PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Murai</td>
<td>Tetsuo</td>
<td>UP-02.035</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Muschter</td>
<td>Rolf</td>
<td>EAU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Naber</td>
<td>Kurt</td>
<td>PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nagao</td>
<td>Kazuhiro</td>
<td>MP-06.16</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nakajima</td>
<td>Fumio</td>
<td>MP-09.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nakamura</td>
<td>Nobuyuki</td>
<td>UP-01.102</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nakamura</td>
<td>Terukazu</td>
<td>UP-03.111</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nakano</td>
<td>Yuzo</td>
<td>UP-01.123</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nakatsuji</td>
<td>Hiroyoshi</td>
<td>UP-01.021</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nam</td>
<td>Jong Kil</td>
<td>UP-02.054, UP-03.152</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nanya</td>
<td>Masumori</td>
<td>UP-03.202</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nasu</td>
<td>Yoshitsugu</td>
<td>MP-08.17</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nativ</td>
<td>Ofer</td>
<td>SUS</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nayar</td>
<td>Christian</td>
<td>UP-03.021</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Neal</td>
<td>Durwood</td>
<td>MP-12.18, RBT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Negro</td>
<td>Carlo Luigi Augusto</td>
<td>MP-05.13, MP-06.17, SUS, UP-01.010, UP-01.064 UP-02.026, UP-03.057 UP-03.165</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Neisius</td>
<td>Andreas</td>
<td>MP-09.16</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nemade</td>
<td>Hemant</td>
<td>POD-06.07, RBT, UP-01.086, UP-01.087, UP-01.089 UP-01.203 UP-01.208, UP-02.055</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nestler</td>
<td>Sebastian</td>
<td>UP-01.160</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Neymeyer</td>
<td>Joerg</td>
<td>MP-01.05, UP-01.082, UP-01.103 VID-05.08, VID-05.09</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Neyra Lee-Eng</td>
<td>Godofredo</td>
<td>UP-02.192</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ng</td>
<td>Ada</td>
<td>MP-10.14, UP-01.104</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ng</td>
<td>Keng Lim</td>
<td>UP-02.190, UP-03.194</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nguyen Phuc Cam</td>
<td>Hoang</td>
<td>UP-01.161, UP-03.106</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nicholas</td>
<td>Rebecca</td>
<td>UP-01.105</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nickel</td>
<td>J. Curtis</td>
<td>IC14, MP-08.18</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nijman</td>
<td>Rien</td>
<td>ESPU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nikic</td>
<td>Predrag</td>
<td>UP-02.036</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nishiyama</td>
<td>Toru</td>
<td>UP-01.106</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nita</td>
<td>Gheorghie</td>
<td>MP-05.14, UP-01.202</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nikolaiyev</td>
<td>Kairat</td>
<td>UP-01.065</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Noguchi</td>
<td>Mitsuru</td>
<td>UP-03.172</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Noh</td>
<td>Choong-Hee</td>
<td>MP-08.22, MP-09.03, UP-02.031</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
## INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noh</td>
<td>Joonhwa</td>
<td>RBT, UP-02.042</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nomikos</td>
<td>Michael</td>
<td>MP-10.15, MP-10.16</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Noon</td>
<td>Aidan</td>
<td>UP-03.186</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nouri</td>
<td>Alireza</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Nowroozi</td>
<td>Mohammad Reza</td>
<td>UP-01.134</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nozawa</td>
<td>Masahiro</td>
<td>UP-01.201</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nyarangi-Dix</td>
<td>Joanne</td>
<td>UP-03.187</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Nygard</td>
<td>Yngve</td>
<td>UP-02.217</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Nyushko</td>
<td>Kirill</td>
<td>MP-16.11, UP-02.148</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Obara</td>
<td>Kenji</td>
<td>MP-11.10</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Obi</td>
<td>Anselm Okwudili</td>
<td>UP-02.233</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ochi</td>
<td>Atsuhioko</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ogawa</td>
<td>Osamu</td>
<td>PP04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Obara</td>
<td>Teruyuki</td>
<td>UP-01.016</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ohbatake</td>
<td>Aya</td>
<td>UP-03.206</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ohira</td>
<td>Shin</td>
<td>MP-03.19, UP-01.107</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Oh-Oka</td>
<td>Hitoshi</td>
<td>RBT, MP-09.17, UP-01.124, UP-03.213</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Okamura</td>
<td>Takehiko</td>
<td>MP-04.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Okorie</td>
<td>Chukwudi</td>
<td>MP-15.17, MP-15.18</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Olapade-Olaopa</td>
<td>E.Oluwabunmi</td>
<td>PAUSA</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Olbert</td>
<td>Peter</td>
<td>DGU</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Oliver</td>
<td>Tim</td>
<td>RBT, UP-03.115</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Onita</td>
<td>Toru</td>
<td>UP-02.073</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Oomen</td>
<td>Robert</td>
<td>MP-07.21, RBT</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Orsolya</td>
<td>Martha</td>
<td>MP-08.14, MP-11.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ota</td>
<td>Tomonori</td>
<td>UP-01.207</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Ozok</td>
<td>Hakki Ugur</td>
<td>UP-01.033</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Öztekin</td>
<td>Çetin Volkan</td>
<td>UP-02.191</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Pacheco-Figueiredo</td>
<td>Luis</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Paehernik</td>
<td>Sascha</td>
<td>UP-01.173, UP-02.156</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Paick</td>
<td>Sung Hyun</td>
<td>UP-03.153</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Pal</td>
<td>Raj</td>
<td>UP-02.027, UP-02.028, UP-02.166</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Palou</td>
<td>Joan</td>
<td>IC12, PL02, POD-01.08, RBT, UP-01.067, UP-01.147, UP-03.154, UP-03.155, VID-07.05, VID-08.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pandey</td>
<td>Abhishek</td>
<td>MP-12.06, UP-03.022</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pannek</td>
<td>Juergen</td>
<td>PP14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Panopoulos</td>
<td>Ioannis</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Pansadoro</td>
<td>Vito</td>
<td>PL02, ST06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Park</td>
<td>Chang Myon</td>
<td>MP-16.22, RBT, UP-02.237, UP-03.054</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Park</td>
<td>Jae Shin</td>
<td>MP-11.11, POD-04.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Park</td>
<td>Joon Jae</td>
<td>UP-03.058</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Park</td>
<td>Kyung Seo</td>
<td>RBT, MP-08.03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Park</td>
<td>Seung Chol</td>
<td>MP-08.19, UP-02.074</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Passavanti</td>
<td>Giandomenico</td>
<td>RBT, UP-01.125</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Pastore</td>
<td>Antonio Luigi</td>
<td>MP-03.20, UP-01.023, UP-02.218, UP-03.173</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>

BERLIN SIU 2011
# INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patankar</td>
<td>Suresh</td>
<td>POD-04.05, POD-06.05, UP-02.002, UP-03.018, UP-03.023</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Patel</td>
<td>Anup</td>
<td>PP11</td>
<td>Travel Remuneration: EAU Research Foundation</td>
</tr>
<tr>
<td>Patrascoiu</td>
<td>Titus</td>
<td>MP-12.11</td>
<td>Speaker: Astellas, AstraZeneca</td>
</tr>
<tr>
<td>Pattnaik</td>
<td>Prashant</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Pejic</td>
<td>Tomislav</td>
<td>UP-02.010, VID-05.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Peña González</td>
<td>Juan Antonio</td>
<td>VID-05.02, VID-05.03, VID-05.04, VID-07.03, VID-07.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Persu</td>
<td>Cristian</td>
<td>UP-03.166, UP-03.214</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pertia</td>
<td>Ambrosi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Perugia</td>
<td>Giacomo</td>
<td>UP-01.108</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Petri</td>
<td>Eckhard</td>
<td>PP09, ST03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Pfalzgraf</td>
<td>Daniel</td>
<td>UP-03.136</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Picozzi</td>
<td>Stefano</td>
<td>MP-01.07, MP-04.14, POD-01.09, UP-02.091, UP-02.134</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pietricica</td>
<td>Bogdan Nicolae</td>
<td>RBT, UP-02.135</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Pisanti</td>
<td>Francesco</td>
<td>MP-05.10, MP-05.11, MP-05.12, RBT, UP-01.063, UP-02.025, UP-02.129, VID-02.01, VID-02.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Polascik</td>
<td>Thomas</td>
<td>IC09, PP01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pompeo</td>
<td>Antonio Carlos Lima</td>
<td>PP06</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Popenechii</td>
<td>Ionel Valentin</td>
<td>MP-05.15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Popov</td>
<td>Elenko</td>
<td>UP-03.137</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Porru</td>
<td>Daniele</td>
<td>UP-01.077</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Poulsen</td>
<td>Mads Hvid</td>
<td>MP-16.17</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pourmand</td>
<td>Gholamreza</td>
<td>MP-04.03, MP-06.18, MP-07.08, POD-01.03, RBT UP-02.219, UP-02.220, UP-02.094, UP-02.095 UP-03.033, UP-03.034, UP-03.046</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Preminger</td>
<td>Glenn</td>
<td>IC13, PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Price</td>
<td>Thomas</td>
<td>UP-02.069</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pricop</td>
<td>Catalin</td>
<td>UP-03.053</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Protzel</td>
<td>Chris</td>
<td>MP-06.19, MP-15.05, MP-15.06, UP-03.203</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Pruthi</td>
<td>Raj S.</td>
<td>PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Psikhakev</td>
<td>Akhmed</td>
<td>MP-08.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Puglisi</td>
<td>Marco</td>
<td>VID-01.06, VID-09.05</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Qayyum</td>
<td>Tahir</td>
<td>UP-01.053</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Rabii</td>
<td>Redouane</td>
<td>PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Radavoi</td>
<td>George Daniel</td>
<td>MP-03.21, UP-01.005, UP-01.177</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Radfar</td>
<td>Mohammad</td>
<td>UP-03.107</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Radmayr</td>
<td>Christian</td>
<td>ESPU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rafiq</td>
<td>Muhammad</td>
<td>UP-01.058</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rajpal</td>
<td>Sanjay</td>
<td>MP-08.20, UP-01.088</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ramsay</td>
<td>J. W. A.</td>
<td>PP03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rao</td>
<td>Pradeep</td>
<td>MP-05.16, PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rasheed Taha</td>
<td>Mohamed</td>
<td>UP-01.083</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rassweiler</td>
<td>Jens J.</td>
<td>PP07, PP15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rawlinson</td>
<td>Alexander</td>
<td>UP-01.054</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>-------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Razaghi</td>
<td>Mohamad Reza</td>
<td>MP-09.18, UP-03.081</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rebai</td>
<td>Nouri</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Recker</td>
<td>Franz</td>
<td>WUOF2</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Reich</td>
<td>Oliver</td>
<td>PL03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Reiss</td>
<td>Philip</td>
<td>MP-12.19</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rempelakos</td>
<td>Apostolos</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Rempelakos</td>
<td>Apostolos</td>
<td>UP-01.090, UP-01.091, UP-01.092, UP-01.093 UP-01.094, UP-03.040</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rendon</td>
<td>Ricardo</td>
<td>UP-01.181, UP-01.193, UP-03.150</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Resende</td>
<td>Alexandre</td>
<td>UP-01.078</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Rezaei Mehr</td>
<td>Behkam</td>
<td>MP-10.17</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Riedl</td>
<td>Markus</td>
<td>UP-01.204</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Riggs</td>
<td>Stephen</td>
<td>ICU02, PP03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Robertson</td>
<td>Cary</td>
<td>POD-07.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Robinson</td>
<td>Simon</td>
<td>RBT, MP-03.22, MP-13.11, UP-02.167</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Roder</td>
<td>M. Andreas</td>
<td>MP-16.18, UP-02.075, UP-02.168, UP-02.221</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Rodriguez</td>
<td>Alejandro</td>
<td>MP-14.08</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Roehrborn</td>
<td>Claus G.</td>
<td>MP-05.18, MP-05.17, MP-13.12 MP-13.13, PL03, POD-04.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rogers</td>
<td>Craig</td>
<td>IC05, MP-14.10, MP-14.11, MP-14.12, MP-14.13 POD-06.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Romics</td>
<td>Imre</td>
<td>PP13, UP-01.095</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Roobol</td>
<td>Monique</td>
<td>IC03, ICU01, UP-02.136, WUOF2</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Roos</td>
<td>Frederik</td>
<td>UP-01.148</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Rouse</td>
<td>Paul</td>
<td>VID-04.04, VID-04.05, VID-08.09 Laparoscopic Video Fellowship (2010-2011): Kings College Hospital/Ethicon</td>
<td></td>
</tr>
<tr>
<td>Rovner</td>
<td>Eric</td>
<td>ICSSUFU</td>
<td>Consultant, Course Faculty (2009-present); American Medical Systems; Consultant, Study Investigator (2009-present); Allergan, Johnson and Johnson, Tengion; Consultant, Study Investigator, Speaker, Symposium (2009-present); Pfizer, Astellas; Study Investigator (2009-present): Contura</td>
</tr>
<tr>
<td>Rowland</td>
<td>Randall G.</td>
<td>PP06</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Saad</td>
<td>Fred</td>
<td>WUOF4</td>
<td>Consultant, Research (present): Amgen, Janssen, Novartis, Sanofi-Aventis</td>
</tr>
<tr>
<td>Sabnis</td>
<td>Ravindra</td>
<td>MP-01.15, VID-04.03, MP-06.08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sadeghi-Nejad</td>
<td>Hossein</td>
<td>IC08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Saeed</td>
<td>Bassam</td>
<td>MESOT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Safarinejad</td>
<td>Mohammad Reza</td>
<td>MP-07.01, MP-07.02, MP-07.03, MP-07.05 MP-07.07, MP-07.12, UP-01.024, UP-01.025 UP-01.138, UP-02.092, UP-02.093, UP-03.041</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sakano</td>
<td>Shigeru</td>
<td>UP-01.174</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Sakuyama</td>
<td>Gaku</td>
<td>MP-09.01</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Salem</td>
<td>Braiek</td>
<td>UP-03.009</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Salm</td>
<td>Silvia</td>
<td>UP-03.174</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Salmas</td>
<td>Ioannis</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Saitrov</td>
<td>Iliya</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Salvitti</td>
<td>Mariarita</td>
<td>UP-01.004, UP-01.032, UP-01.199, UP-03.164</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
### INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sam Zadeh</td>
<td>Mohammad</td>
<td>RBT, UP-02.096, RBT, MP-04.06, MP-12.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sameh</td>
<td>Wael</td>
<td>UP-01.162, UP-03.215</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sampson</td>
<td>Natalie</td>
<td>DGU</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Sanda</td>
<td>Martin G.</td>
<td>PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sangar</td>
<td>Vijay</td>
<td>PL02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Santamaria</td>
<td>Nerea Felip</td>
<td>VID-09.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Santucci</td>
<td>Richard A.</td>
<td>GURS, PP10</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Sarkar</td>
<td>Somita</td>
<td>UP-01.152, UP-01.163, UP-01.192, UP-03.089</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sasaki</td>
<td>Takeshi</td>
<td>MP-16.03</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Sato</td>
<td>Fuminori</td>
<td>MP-03.02, UP-01.055</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Scardino</td>
<td>Peter T.</td>
<td>PL01, PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Scarpia</td>
<td>Roberto Mario</td>
<td>PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schaefer</td>
<td>Werner</td>
<td>ICSSUFU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schalken</td>
<td>Jack</td>
<td>ICUD2</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schatloff</td>
<td>Oscar</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Schmid</td>
<td>Marianne</td>
<td>UP-01.164</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schmadermaier</td>
<td>Martin</td>
<td>UP-01.121, UP-01.122, UP-02.090</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schnalke</td>
<td>Thomas</td>
<td>HISTORY</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schoensee</td>
<td>Bernhard</td>
<td>MP-05.19</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schostak</td>
<td>Martin</td>
<td>UP-02.169</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Schröder</td>
<td>Fritz</td>
<td>EAU, PL01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Schwab</td>
<td>Thomas</td>
<td>WUOF5</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Segaran</td>
<td>Surayne</td>
<td>UP-02.222, UP-02.138</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Segawa</td>
<td>Takehiko</td>
<td>UP-01.043</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Seki</td>
<td>Toshimori</td>
<td>MP-14.09</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Sesterhenn</td>
<td>Isabell</td>
<td>UP-02.170, UP-02.194, UP-02.195</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Seth</td>
<td>Amlesh</td>
<td>MP-10.08, MP-12.08, MP-14.07, UP-01.034, VID-03.07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shabsigh</td>
<td>Ahmad</td>
<td>PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shadpour</td>
<td>Pejman</td>
<td>MP-11.13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shah</td>
<td>Taimur</td>
<td>MP-15.19, UP-02.223</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Shalaby</td>
<td>Mahmoud</td>
<td>UP-03.024</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shamsa</td>
<td>Ali</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Shariat</td>
<td>Shahrok F.</td>
<td>IC11, POD-05.04, POD-05.05, UP-01.120, UP-02.160, WUOF6</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shariflagdas</td>
<td>Farzaneh</td>
<td>UP-01.079</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sharlip</td>
<td>Ira D.</td>
<td>IC01, IC08, PP05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sharma</td>
<td>Deen</td>
<td>MP-16.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shiga</td>
<td>Yoshiyuki</td>
<td>UP-02.236</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shim</td>
<td>Sung Ryoul</td>
<td>UP-02.037</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Shin</td>
<td>Hong Seok</td>
<td>MP-05.20</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Shiroki</td>
<td>Ryoichi</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Shishkov</td>
<td>Dimitar</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Shore</td>
<td>Neal</td>
<td>UP-02.068</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
# INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shoskes</td>
<td>Daniel</td>
<td>PP05</td>
<td>Advisor: Farr Laboratories (ongoing); Financial Interest: Triurol (ongoing)</td>
</tr>
<tr>
<td>Siemens</td>
<td>D. Robert</td>
<td>WUOF4</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Siemer</td>
<td>Stefan</td>
<td>MP-04.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Siemer</td>
<td>Stefan</td>
<td>PP06, UP-02.149</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sievert</td>
<td>Karl-Dietrich</td>
<td>UP-03.171</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sim</td>
<td>Allen</td>
<td>POD-02.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Simforoosh</td>
<td>Nasser</td>
<td>IC07, MESOT, PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Simmons</td>
<td>Lucy</td>
<td>MP-03.15, MP-03.16, RBT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Simpson</td>
<td>Helen</td>
<td>MP-05.21, MP-16.05, MP-16.19, UP-02.139</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Singh</td>
<td>Harvinder</td>
<td>MP-09.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Singh</td>
<td>Iqbal</td>
<td>UP-01.035, UP-03.071</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Singh</td>
<td>Paras</td>
<td>MP-13.19, RBT</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Singh</td>
<td>Santosh Kumar</td>
<td>MP-01.22, UP-02.140</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Singla</td>
<td>Ajay</td>
<td>IC02, PP09</td>
<td>Consultant and Speaker: American Medical Systems (5 years)</td>
</tr>
<tr>
<td>Sinn</td>
<td>Tran</td>
<td>RBT, UP-03.028, UP-03.035, VID-08.01</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Skakkebaek</td>
<td>Niels E.</td>
<td>PP03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Skobejko-Wlodarska</td>
<td>Lidia</td>
<td>MP-11.15, UP-03.002</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Smoliski</td>
<td>Michal</td>
<td>MP-03.23</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Soebadi</td>
<td>Doddy Mus比亚迪</td>
<td>UP-03.044</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Soleymani</td>
<td>Saied</td>
<td>MP-04.15, RBT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Soloway</td>
<td>Mark S.</td>
<td>MP-13.06, MP-13.07, PLO2, POD-07.03, POD-07.04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sorg</td>
<td>Rüdiger</td>
<td>MP-02.08, UP-01.149</td>
<td>Yes</td>
</tr>
<tr>
<td>Sotelo</td>
<td>Rene</td>
<td>PP07, PP11, PP15, VID-01.07, VID-02.06, VID-03.02, VID-03.03, VID-04.06, VID-04.07, VID-05.01, VID-05.06, VID-06.09, VID-07.07, VID-07.08, VID-07.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Souza Escandon</td>
<td>Alejandro</td>
<td>MP-04.21</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Soydan</td>
<td>Hasan</td>
<td>UP-01.129, UP-03.201, UP-03.051</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Spahn</td>
<td>Martin</td>
<td>MP-03.03, POD-07.02, UP-02.077</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Spahovic</td>
<td>Hajrudin</td>
<td>MP-01.08, UP-01.001, UP-02.171</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Spiess</td>
<td>Philippe E.</td>
<td>MP-16.21</td>
<td>Advisory Board Member (2010-present): COLD Registry</td>
</tr>
<tr>
<td>Spiess</td>
<td>Philippe E.</td>
<td>MP-15.08, UP-01.205</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Stanca</td>
<td>Vasile Dan</td>
<td>UP-02.030, UP-03.003</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Staskin</td>
<td>David</td>
<td>UP-03.204</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Steffens</td>
<td>Joachim</td>
<td>MP-12.09</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Stein</td>
<td>Raimund</td>
<td>ESPU, PP02, ST04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Steinsvik</td>
<td>E. Andreas Svabo</td>
<td>MP-07.16</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Stenzl</td>
<td>Arnulf</td>
<td>PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sternberg</td>
<td>Cora</td>
<td>PL02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Stöckle</td>
<td>Michael</td>
<td>PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Strbavy</td>
<td>Miroslav</td>
<td>UP-02.173</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Strope</td>
<td>Seth A.</td>
<td>ICUD2</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Studer</td>
<td>Urs E.</td>
<td>IC10, PL02, PP06, WUOF4, WUOF7</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sugimoto</td>
<td>Morito</td>
<td>UP-01.165, UP-01.166</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sul</td>
<td>Chong Koo</td>
<td>UP-02.097, UP-03.167, UP-02.174</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sun</td>
<td>Fu-Kang</td>
<td>UP-01.006</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Sun</td>
<td>Yinghao</td>
<td>PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Surcel</td>
<td>Cristian</td>
<td>UP-01.111, UP-01.038, UP-01.080, UP-01.182 UP-01.183, UP-01.184, UP-03.131, UP-03.177</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Suzuki</td>
<td>Kuri</td>
<td>UP-03.004</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Tabibi</td>
<td>Ali</td>
<td>UP-01.109</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tadtayev</td>
<td>Sergiy</td>
<td>RBT, UP-02.141</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Taghavi</td>
<td>Rahim</td>
<td>MP-06.15, UP-02.188, UP-03.032, UP-03.014</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tahmazopoulos</td>
<td>Anastasios</td>
<td>MP-12.10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Takagi</td>
<td>Toshio</td>
<td>UP-01.167, UP-01.168, UP-01.169, UP-01.206</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Takemura</td>
<td>Masahiko</td>
<td>MP-02.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Takenaka</td>
<td>Toichi</td>
<td>PL01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Takezawa</td>
<td>Yutaka</td>
<td>MP-02.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tan</td>
<td>Yeh Hong</td>
<td>MP-14.14, MP-14.15, UP-02.057</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tanabe</td>
<td>Kazunari</td>
<td>IC07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tanaka</td>
<td>Nobumichi</td>
<td>MP-16.20</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tanaka</td>
<td>Toshiaki</td>
<td>UP-01.178</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Taneja</td>
<td>Samir</td>
<td>ICU01, PP12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tanguay</td>
<td>Simon</td>
<td>PP12</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Teloken</td>
<td>Claudio</td>
<td>ISSM</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Teves</td>
<td>Frederico</td>
<td>MP-15.07</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Tewari</td>
<td>Ashutosh</td>
<td>IC04, ST02</td>
<td>Sponsored Research: Astellas (2011), Pfizer (2008-2011), NIH/NCI (Present), Prostate Cancer Foundation (Present); Director: Global Prostate Cancer Research Foundation (Present)</td>
</tr>
<tr>
<td>Thakare</td>
<td>Niyukta</td>
<td>UP-01.126, UP-03.188, UP-03.189, UP-03.216</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Thekumpadam</td>
<td>Rajeev Puthenveetil</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Theodosiou</td>
<td>Alexandros</td>
<td>UP-01.139</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Thomas</td>
<td>Christian</td>
<td>MP-03.04, UP-02.098</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Thompson</td>
<td>Peter</td>
<td>ICU01, RBT</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Thüroff</td>
<td>Joachim W.</td>
<td>PL01, PL02, PL04, PP12, ST02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Thüroff</td>
<td>Stefan</td>
<td>MP-16.02, UP-02.142, UP-02.175, UP-02.176 UP-02.224</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Thwaini</td>
<td>Ali</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Tilki</td>
<td>Derya</td>
<td>UP-01.036, WUOF3</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Timpano</td>
<td>Massimiliano</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Tolley</td>
<td>David</td>
<td>PP11</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tombal</td>
<td>Bertrand</td>
<td>EAU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tonshal</td>
<td>Sanjeev</td>
<td>MP-10.18</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Touma</td>
<td>Naji</td>
<td>MP-02.15</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Trachtenberg</td>
<td>John</td>
<td>PP01, WUOF4</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Traxer</td>
<td>Olivier</td>
<td>IC13</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Trigo Rocha</td>
<td>Flavio</td>
<td>UP-03.168</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Trigo Rocha</td>
<td>Flavio</td>
<td>VID-02.05</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Trip</td>
<td>Evelien</td>
<td>MP-15.04</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Tsuchiyama</td>
<td>Katsuki</td>
<td>UP-03.205</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tsugaya</td>
<td>Masayuki</td>
<td>UP-03.190</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Tuerk</td>
<td>Ingolf</td>
<td>PP07</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tulic</td>
<td>Cane</td>
<td>UP-01.145</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Tunn</td>
<td>Ralf</td>
<td>ICSSUFU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Uchida</td>
<td>Toyoaki</td>
<td>MP-13.14</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Uemura</td>
<td>Hirotsugu</td>
<td>WUOF1</td>
<td>Advisor (2011): Astellas, Ono Pharm; Speaker (2009-2011): Bayer, Pfizer, Novartis, Takeda; Research Grant (2009): AstraZeneca</td>
</tr>
<tr>
<td>Uesugi</td>
<td>Tatsuya</td>
<td>UP-02.143</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ulys</td>
<td>Albertas</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Uno</td>
<td>Hiromi</td>
<td>POD-02.08</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Unteregger</td>
<td>Gerhard</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Urakami</td>
<td>Shinji</td>
<td>UP-02.177</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Urgé</td>
<td>Tomas</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Valiquette</td>
<td>Luc</td>
<td>PL03, PL04</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Vallo</td>
<td>Stefan</td>
<td>UP-01.026</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Van Den Heuvel</td>
<td>Suzanne</td>
<td>POD-07.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Der Merwe</td>
<td>Andre</td>
<td>IC07, UP-03.138</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Der Merwe</td>
<td>Jacobus</td>
<td>MP-12.14, MP-15.14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Herpen</td>
<td>Catharina</td>
<td>UP-02.152</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Kerrebroeck</td>
<td>Philip</td>
<td>MP-05.03</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Oort</td>
<td>Inge</td>
<td>WUOF3</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Van Poppel</td>
<td>Hendrik</td>
<td>EAU, PP08, PP12, WUOF5</td>
<td>Member of Advisory Board: Antigenics, AstraZeneca, Wyeth, Bayer, Cougar Biotechnology, Janssen-Cilag, Dendreon, OncoMethylome, Bristol-Myers; Expert in the Field: Astellas; Consultant: Ferring, Amgen, Ipsen</td>
</tr>
<tr>
<td>Varshney</td>
<td>Anil Kumar</td>
<td>MP-05.22, MP-05.23</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Vasavada</td>
<td>Sandip</td>
<td>ICSSUFU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Vaz</td>
<td>Igor</td>
<td>PP10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Venderbos</td>
<td>Lionne</td>
<td>POD-02.09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Veneziano</td>
<td>Domenico</td>
<td>VID-04.08</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Villa</td>
<td>Luca</td>
<td>MP-02.02</td>
<td>Study Sponsor: Recordati</td>
</tr>
<tr>
<td>Villers</td>
<td>Arnauld</td>
<td>PP01, PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Vojinov</td>
<td>Sasa</td>
<td>UP-03.045</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Volkmer</td>
<td>Bjoern</td>
<td>IC10</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wadhwa</td>
<td>Karan</td>
<td>UP-01.056</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wagenlehner</td>
<td>Florian</td>
<td>DGU, IC14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Waldinger</td>
<td>Marcel D.</td>
<td>IC08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Walz</td>
<td>Peter</td>
<td>DGU</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wang</td>
<td>Hongxiang</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Ward</td>
<td>John F.</td>
<td>IC09</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Watanabe</td>
<td>Atsuko</td>
<td>UP-03.005</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Presentation Code</td>
<td>Disclosure</td>
</tr>
<tr>
<td>---------------</td>
<td>------------</td>
<td>-------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Watya</td>
<td>Stephen</td>
<td>IC01</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Weber</td>
<td>H. Matthias</td>
<td>UP-01.096</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wei</td>
<td>An</td>
<td>MP-14.16, UP-02.058, UP-02.059</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Weidner</td>
<td>Wolfgang</td>
<td>DGM, EAU, IC14</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Weiss</td>
<td>Robert</td>
<td>MP-04.16</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wiegel</td>
<td>Thomas</td>
<td>PL01, PP08</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wiklund</td>
<td>Peter</td>
<td>ICO4, IC12, PP06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wilder</td>
<td>Jennifer</td>
<td>UP-02.179</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Williams</td>
<td>Kevin</td>
<td>UP-02.225</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Witt</td>
<td>Timothy J.</td>
<td></td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Wirth</td>
<td>Manfred P.</td>
<td>DGM, ICUD1, ICUD2, MP-04.17, MP-04.18, MP-10.04 MP-13.20, MP-13.21, PL01, UP-03.001</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wischnack</td>
<td>Mee-Na Nina</td>
<td>UP-01.127</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wishahi</td>
<td>Mohamed</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Wortel</td>
<td>Ruud C.</td>
<td>UP-03.069</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wozniak</td>
<td>Pavo</td>
<td>UP-01.044</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wu</td>
<td>Chun-Te</td>
<td>UP-01.027</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wu</td>
<td>Wei-Che</td>
<td>MP-10.02</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Wuestle</td>
<td>Melanie</td>
<td>MP-09.13</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Wullich</td>
<td>Bernd</td>
<td>DGM</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Wyndaele</td>
<td>Jean Jacques</td>
<td>MP-05.02</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Xu</td>
<td>Abai</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Yachia</td>
<td>Daniel</td>
<td>SUS</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yamada</td>
<td>Daisuke</td>
<td>UP-02.146</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yamaguchi</td>
<td>Kohei</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Yamamoto</td>
<td>Hidekazu</td>
<td>UP-02.234, UP-02.078</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yamamoto</td>
<td>Yasuyo</td>
<td>UP-03.191</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yao</td>
<td>Akihisa</td>
<td>UP-02.180</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yarmohamadi</td>
<td>Aliasghar</td>
<td>RBT, UP-01.084, UP-02.181</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yasuda</td>
<td>Kenji</td>
<td>UP-02.099</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yeboah</td>
<td>Edward Donkor</td>
<td>MP-09.11</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yesilli</td>
<td>Cetin</td>
<td>MP-14.01, UP-03.082</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yokomizo</td>
<td>Akira</td>
<td>UP-01.179</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yokoyama</td>
<td>Teruhiho</td>
<td>UP-08.21, UP-03.195</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Yoon</td>
<td>Jong Hyun</td>
<td>MP-08.11</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yoon</td>
<td>Sang Min</td>
<td>UP-03.175</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Young Kee</td>
<td>Kwon</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Yu</td>
<td>Cheong</td>
<td>UP-01.031</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Yuh</td>
<td>Bertram</td>
<td>UP-01.209, UP-02.235, UP-02.060</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Zakri</td>
<td>Rhana</td>
<td>UP-01.210, UP-02.051, UP-03.149</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Zalesky</td>
<td>Miroslav</td>
<td>UP-02.061</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Zarrabi</td>
<td>Amir</td>
<td>PP05, UP-02.207</td>
<td>Nothing to Disclose</td>
</tr>
<tr>
<td>Zeitlin</td>
<td>Scott</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Zengerling</td>
<td>Friedemann</td>
<td>DGM</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>
# INDEX OF PRESENTERS AND DISCLOSURES

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Presentation Code</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang</td>
<td>Hai-Liang</td>
<td>RBT</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Zhong</td>
<td>Shan</td>
<td>UP-02.101</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ziaran</td>
<td>Stanislav</td>
<td>MP-16.06</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Ziesel</td>
<td>Christopher</td>
<td>MP-11.16, UP-02.043</td>
<td>Not Received at Press Time</td>
</tr>
<tr>
<td>Zomorrodi</td>
<td>Afshar</td>
<td>RBT, UP-03.036</td>
<td>Not Received at Press Time</td>
</tr>
</tbody>
</table>